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Abstract 
Cystic fibrosis is a lethal autosomal recessive disease, caused by a defect of the cystic 
fibrosis transmembrane conductance regulator (CFTR), which is characterised by lung 
disease. However, medical advances mean the survival age is increasing and, as such, 
various non-pulmonary co-morbidities are modulating quality and longevity of life. For 
instance, cystic fibrosis-related diabetes is the most common non-respiratory consequence 
of cystic fibrosis, which is associated with poorer lung disease and vascular dysfunction. 
Furthermore, endothelial perturbation is observed in people with cystic fibrosis without 
dysglycaemia and may modulate aerobic exercise dysfunction. Therefore, it was 
hypothesised that cystic fibrosis-related dysglycaemia would impair aerobic exercise and 
ventilatory function, which would be associated with microvascular endothelial 
dysfunction and oxidative stress. 
Data within this thesis demonstrated, for the first time, that the determination of maximal 
oxygen uptake was safe, valid and feasible amongst children, adolescents and adults with 
mild to severe lung disease. When utilising this protocol, it was also revealed that maximal 
aerobic fitness was impaired in people with cystic fibrosis-related diabetes compared to 
their age- and sex-matched counterparts with cystic fibrosis and normal glucose tolerance. 
Ventilation-perfusion mismatches were also observed in a 3rd of adults with cystic fibrosis, 
irrespective of their glycaemic status. Cell culture studies demonstrated that CFTR 
regulated inflammation, oxidative stress and cell signalling in the human lung 
microvasculature, which ultimately promoted optimal actin cytoskeleton formation and 
cell alignment in response to flow. Therefore, a loss of CFTR function could cause lung 
microvascular perturbation and ventilation-perfusion mismatches in vivo. Oxidative stress 
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in cystic fibrosis is an important pathophysiological mechanism for these observations; 
furthermore, it was observed that biomarkers of oxidative stress were elevated in people 
with clinically-stable cystic fibrosis. 
Together, these data provide promising rationale to study redox-based therapeutics in 
models of cystic fibrosis-related lung disease, dysglycaemia and endothelial dysfunction.  
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Page 3 of 300 
 
Chapter 1 
 
General Introduction 
1.1. Cystic Fibrosis 
In 1938, a report in the American Journal of Diseases of Children analysed the autopsies of 
49 infants with ‘cystic fibrosis (CF) of the pancreas’ (8). From this, cases were classified into 
3 groups with different outcomes: 1) 5 infants with intestinal obstruction that caused death 
within the 1st week of life; 2) 19 infants with respiratory tract infection that caused death 
before 6 months, of which 13 were nutritionally insufficient; and, 3) 25 infants with 
respiratory tract infection that caused death before the age of 14 y, many of which 
presented with symptoms resembling coeliac disease (8). From this preliminary 
identification of CF as a disease, the median survival age of infants with this condition was 
only a few months until the 1950s, mainly due to meconium ileus and pancreatic 
insufficiency (PI) (114). 
In the 80 years since these seminal findings of Dorothy H. Andersen (8), medical advances 
mean that CF is no longer considered a paediatric disease. Indeed, the CF Foundation 2017 
Annual Data Report observed that 53.8% of people with CF in the United States of America 
(USA) are 18 y or older (60.4% of people with CF in the United Kingdom (UK) are currently 
16 y or older (530)), compared to only 29.8% in 1987 when the CF Foundation’s records 
began (532). In developed countries, such as the UK (45.1 y of age) and the USA (43.6 y of 
age), the median survival age has reached the 5th decade of life (530, 532). Various 
breakthroughs have contributed towards these clinically significant improvements in life 
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expectancy. Firstly, newborn genetic screening has reduced the median age of diagnosis to 
only 3 months (532); meaning that infants with CF have earlier access to specialist 
multidisciplinary teams, airway clearance, aggressive treatment of respiratory infections 
and nutritional therapeutics (152). Furthermore, the continued advances in precision 
medicine and gene therapy in CF means that the survival age will continue to increase (391). 
In the 21st century, the most common cause of death in people with CF is cardiorespiratory 
failure as a consequence of progressive lung disease due to bacterial colonisation 
(accounting for 62.9% of deaths in 2017, of which 16.1% were transplant related) (532). 
However, various non-pulmonary co-morbidities are also becoming increasingly prevalent 
and are having a greater bearing upon quality and longevity of life of people with CF, as the 
clinical management of pulmonary manifestations continues to improve within CF clinics 
(Table 1.1).  
Table 1.1. The top 10 complications of CF in the UK in 2016. 
Complication Prevalence (%) 
 Paediatric Adult Overall 
CF-related diabetes (CFRD) 3.6 30.5 25.4 
Osteopenia 1.1 22.2 13.8 
Liver disease 7.5 17.8 13.7 
Asthma 11.4 14.9 13.5 
Gastroesophageal reflux disease  4.6 16.1 11.5 
Raised liver enzymes 6.1 12.4 9.9 
Sinus disease 1.6 15.2 9.8 
Haemoptysis 0.9 11.3 7.2 
Allergic bronchopulmonary aspergillosis 3.8 8.6 6.7 
Arthropathy 0.5 8.6 5.4 
This data were extracted from the UK CF Trust 2017 Annual Data Report (530). 
The severity of complications experienced in CF are dictated by a variety of environmental 
(67, 440), socioeconomic (376, 383) and genetic factors (45). For example, people with CF 
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of a low economic status are likely to experience greater lung and nutritional disease 
throughout adolescence, partially due to an increased exposure to environmental tobacco 
smoke (383). Furthermore, since the cause of CF is a genetic mutation of the CF 
transmembrane conductance regulator (CFTR) gene, the severity of disease can, at least in 
part, be attributed to the degree of CFTR protein deficiency and/or dysfunction. 
1.1.1. CFTR and modifier genes 
The CFTR protein was first described in the summer of 1948, where a heatwave in New 
York meant there was an influx of dehydrated infants attending accident and emergency 
departments (128, 129). It was noted that many of these infants had CF and presented with 
elevated sweat chloride (Cl-) and sodium (Na+) concentrations, independent of pancreatic 
and pulmonary disease, which persisted after the heat wave subsided (128, 129). It is now 
understood that elevated sweat Cl- and Na+ concentrations are a result of the CFTR protein 
being present in the apical and basolateral membrane of cells lining the sweat duct, where 
it is critical for the reabsorption of secreted Cl- – a process driven by Na+ absorption through 
Na+ channels present in the apical membrane (447, 543). To date, evaluating the 
concentration of Cl- in the sweat following pilocarpine iontophoresis remains the 
mainstream in vivo measurement and diagnostic tool of CFTR dysfunction (a sweat [Cl-] of 
≥ 60 mmol·L-1 is indicative of CF) (302, 366), and is also an important outcome 
measurement for the clinical trials of ground-breaking CFTR modulator therapies (262). 
The CFTR protein is a cyclic adenosine monophosphate (cAMP)-dependent Cl- channel, 
which is primarily present on the apical membrane of epithelial cells of the respiratory 
system, pancreas and gastrointestinal tract (152). Approximately 77% of total CFTR protein 
resides in the cell cytoplasm, 19% spanning the cell membrane and 4% in an extracellular 
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loop (476). CFTR is an adenosine triphosphate (ATP)-binding cassette (ABC) transporter, 
which consists of two membrane spanning domains (MSD), two nucleotide binding 
domains (NBD), and a centrally regulatory (R) domain (476). Phosphorylation of the R 
domain, which is modulated by cAMP-dependent protein kinase A, initiates the binding of 
ATP to NBD1 (for partial CFTR opening) and NBD2 (for prolonged CFTR opening) for Cl- and, 
in some cases, bicarbonate (HCO3-), glutathione (GSH), thiocyanate (SCN-) and ATP 
conductance (308, 309, 476). Hydrolysis of the bound ATP subsequently initiates closure of 
the channel (351, 543). CFTR also regulates ion transport through various other means 
(275, 543), including: inhibition of the amiloride sensitive epithelial Na+ channels (ENaC) 
(497), volume-regulated anion channels (VRAC) (546) and endogenous calcium (Ca2+)-
activated Cl- channels (CaCC) (558), activating the outwardly rectifying Cl- channel (ORCC) 
(178), sensitising potassium (K+) channels to sulfonylurea compounds (330), and regulating 
intracellular vesicle transport (506). 
Figure 1.1. An overview of normal CFTR function versus class I-VI CFTR mutations that are associated with the 
development of CF. This figure was extracted from Boyle & De Boeck (56). 
General introduction 
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In 1985, Knowlton et al. (279) reported a genetic defect of CFTR on the long arm of 
chromosome 7. Further study identified a common mutation, whereby a deletion of 3 base 
pairs resulted in the omission of a phenylalanine residue at the amino acid position 508 
(428). This mutation, p.Phe508del, interferes with the biogenesis and maturation of CFTR 
in the endoplasmic reticulum and Golgi apparatus (see Figure 1.1). Deoxyribonucleic acid 
(DNA) diagnosis of CF, in particular genetic screening for the common p.Phe508del 
mutation, was a breakthrough in the medical management of CF (269). In 2017, the 
p.Phe508del genotype (present in 85.7% of people with CF in the USA (532)) was the most 
common of > 2,000 CFTR mutations that have been identified thus far (532). Due to the 
increasing number of identified CFTR mutations (532), genotypes of CF are often classified 
into 5-6 distinct groups (30) (Figure 1.1). Importantly, CFTR function, and therefore sweat 
[Cl-] concentrations and disease severity, differ between classes of genetic mutation. Class 
I-III genotypes often elicit a sweat [Cl-] of up to 100 mmolL−1 and are considered to be more 
severe (532); whereas, residual CFTR function in class IV-VI mutations may contribute to 
lower sweat [Cl-] and a less severe clinical phenotype (532). However, clinical phenotypes 
of newly diagnosed individuals cannot be predicted by genotyping alone.  
Sweat [Cl-] within classifications of CFTR mutation are heterogeneous; whereby, 
considerable overlap in CFTR dysfunction between people with class I-III mutations (median 
[95% confidence intervals; 95% CI] sweat [Cl-]: 102.0 [79.0-128.0] mmolL−1) and class IV-V 
mutations (median [95% CI] sweat [Cl-]: 71.0 [27.0-113.0] mmolL−1) are present (532). Such 
variance is partially due to the aforementioned environmental (67, 440) and socioeconomic 
(376, 383) factors. For instance, cigarette smoke extract reduces CFTR function in human 
lung bronchial epithelial cells (288). Furthermore, a host of ‘modifier genes’ have been 
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reported to modulate various pathologies that commonly contribute to clinical phenotypes 
(45, 107, 180, 204, 278, 559). Notably, such modifier genes are also likely to disrupt 
inflammatory- and redox-homeostasis, which may subsequently exacerbate lung disease 
and dysglycaemia (Table 1.2).  
Table 1.2. A list of the most commonly studied modifier genes that influence lung disease and dysglycaemia 
prior 2015. The pathophysiological pathways and phenotypical consequences of the modifier gene are also 
reported. 
Gene Pathway Phenotype Reference 
TGFB1 Inflammation Lung disease (16, 60, 100, 140, 573) 
IL8 Inflammation Lung disease (100, 227) 
IL10 Inflammation Lung disease (16, 64, 140) 
TNFA Inflammation Lung disease (64, 140, 236) 
MBL2 Immunity Lung disease (81)1 
DEFB1 Immunity Lung disease (106, 512, 544) 
AGER Immunity Lung disease (41, 99, 293) 
SLC6A14 Ion transport Lung disease (304, 501) 
SLC26A9 Ion transport Dysglycaemia (140, 304, 501) 
SLC9A3 Ion transport Lung disease (137, 304, 501) 
SLC8A3 Ion transport Lung disease (573) 
GSTP1 Redox Lung disease (140, 163, 167, 236) 
GSTM1 Redox Lung disease (163, 167, 236) 
nNOS Redox Lung disease (194, 195, 513) 
eNOS Redox Lung disease (196) 
CDKAL1 tRNA processing Dysglycaemia (43) 
CDKN2A Cytokine signalling Dysglycaemia (43) 
CDKN2B Cytokine signalling Dysglycaemia (43) 
IGF2BP2 IGF regulation Dysglycaemia (43) 
IGF, insulin-like growth factor; tRNA, Transfer ribonucleic acid. 1 a systematic review of relevant literature. 
These data were extracted from Bombieri et al. (45). 
1.1.2. CF-related lung disease 
Lung disease in CF is characterised by mucus obstruction and bacterial colonisation of the 
airway, neutrophil-dominated inflammation, and progressive bronchiectasis (494). This 
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pathology leads to respiratory failure and, ultimately, remains the most common cause of 
premature death in this population (530, 532). In cases of severe and irreversible 
bronchiectasis, bi-lateral subsequential lung transplantation is a therapeutic option but not 
always possible (356).  
The underlying pathophysiology of CF lung disease is caused by a loss of CFTR function in 
the airway epithelium. Animal models of CF suggest that a narrowing of the large airways 
(333), in addition to abnormalities of submucosal glands and smooth muscle, may be 
present at birth (494). These observations are somewhat supported by autopsy data 
whereby a narrowed trachea (333), which is associated with poorer lung function and 
increased infection susceptibility (166), was observed in infants with CF (< 2 weeks old) 
compared to healthy controls (333, 496). Additionally, the genesis of CF lung disease may 
also be attributed to abnormalities in airway surface liquid (ASL) volume and composition 
in the small airways (470, 494). After birth (≥ 2 weeks), a loss of CFTR function in both the 
small and large airways increases the susceptibility of the lung to bacterial colonisation, 
due to a more acidic ASL and impaired mucociliary clearance (494) (Figure 1.2). 
The human airway relies upon mucus clearance to trap and transport potentially 
pathogenic bacteria from the lower airways to the mouth (277). Whilst it may not be 
present at birth (494), lowered Cl- secretion and hyper-reabsorption of Na+ by the lung 
epithelium causes impaired mucociliary clearance and dehydration of the ASL (51) (Figure 
1.2). In addition to this, CFTR abnormalities reduce HCO3- secretion in the lung epithelium 
(309), which leads to a reduced submucosal gland and ASL pH (2, 484) and, ultimately, 
contributes to the reduced bacterial killing properties that characterise the CF lung (401). 
Whilst the origin of lung disease in CF is debated (324, 331), a multi-faceted 
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pathophysiology within the lung means people with CF are susceptible to repeated and 
enduring respiratory tract infections (152).  
 
Figure 1.2. The mechanisms in which CFTR dysfunction leads to progressive lung injury in models of CF. This 
figure is adapted from Elborn (152).  
Early in life colonisation of Staphylococcus aureus is reported to affect 30.7% of children 
and adolescents with CF (< 16 y) (530). Throughout adolescence and into adulthood, 
chronic (prevalence of 44.2%) or intermittent (prevalence of 12.6%) isolates of 
Pseudomonas aeruginosa become the most common pathogen in the sputum of people 
with CF (530). Other bacteria (e.g. Burkholderia cepacia complexes) significantly increase 
mortality risk (157), and the antibiotic resistant non-tuberculous mycobacteria complexes 
(e.g. Mycobacterium abscessus) reduce the efficacy of lung transplantation (143, 184). 
Virulence factors of these pathogens directly contribute to damage of the CF airway (182); 
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furthermore, host defence mechanisms in response to bacterial colonisation exacerbate 
the inflammatory response associated with the loss of CFTR and various modifier genes 
(367).  
The causes of the pro-inflammatory microenvironment of the CF airway is debated (152, 
367). A body of evidence suggests that inflammation may precede bacterial colonisation in 
the CF lung (367). This notion is somewhat supported by the observations of increased 
neutrophil count, neutrophil elastase activity and interleukin (IL)-8 in the bronchoalveolar 
lavage fluid of infants (n = 7; mean age: 6 months), without evidence of exposure to 
bacteria, fungus and/or viruses (272). The loss of epithelial CFTR function is associated with 
reduced nuclear factor erythroid-derived-like 2 (Nrf2) and increased nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-κB) activities (398, 557, 589), which are 
important transcriptional factors that modulate inflammatory and redox homeostasis (311, 
365). Lowered activity of Nrf2 in human tracheal epithelial cells resulted in elevated steady 
state intracellular hydrogen peroxide (H2O2) production that subsequently causes elevated 
concentrations of IL-6 and IL-8 (86). Whereas, NF-κB is a central transcriptional promoter 
of inflammation (367), which contributes to a sterile pro-inflammatory state through 
increased IL-8 expression (345, 557), and may also play a pivotal role in initiating the 
neutrophil-dominated inflammatory response to a bacterial challenge (130). 
Once pathogens invade the airways of infants with CF, lung disease ensues and is 
characterised by chronic and disproportionate neutrophil recruitment (152). In healthy 
humans, neutrophils have a pivotal role in host defence through secreting antimicrobial 
peptides, promoting phagocytosis and the release of DNA-rich neutrophil extracellular 
traps (367). However, in the CF lung, neutrophils accumulate due to increased expression 
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of chemoattractants (e.g. IL-8 and high-mobility group box-1; HMGB1), which also further 
activate NF-κB in a cyclic fashion (367). The importance of neutrophils in the pathology of 
CF-related lung disease is emphasised by the observations that neutrophil elastase activity 
(≥ 200 ng·mL-1), measured at 3 months of age, is associated with a > 3-fold greater risk of 
bronchiectasis from up to 3 y of age (480). Furthermore, the clearance of apoptotic 
neutrophils is suppressed due to abnormalities in mucociliary clearance and limited 
macrophage phagocytosis (310). Because of this, neutrophils in the airways of people with 
CF often undergo necrosis that leads to the release of reactive oxygen species (ROS) (588). 
At normal physiological levels, ROS and reactive nitrogen species (RNS) are important 
physiological signalling molecules that modulate cellular adaptation, function and 
communication (209). Conversely, exacerbations of lung disease (291), infection (247), 
inflammation (299) and hypoxaemia (580) cause deleterious levels of these free radicals to 
accumulate. Under such circumstances in healthy tissues, activation of Nrf2 would enhance 
antioxidant defence mechanisms through increasing the protein levels of glutathione 
reductase (GR), glutathione peroxidase (GPx)-1, peroxiredoxin-1, sulphiredoxin, 
thiroedoxin reductase and γ-glutamylcysteine synthetase (209). This ultimately leads to the 
increased tissue content of the major antioxidant that neutralises ROS/RNS; GSH (215). 
However, inadequate activity of Nrf2 in the CF lung (398, 589), a genetic predisposition to 
reduced GSH synthesis (140, 163, 167, 236) (Table 1.2), and a loss of CFTR-mediated GSH 
and SCN- trafficking (308, 309) leads to an inadequate antioxidant defence system 
becoming overwhelmed by ROS, and ultimately, results in cytotoxic oxidative modifications 
of lipids, proteins and DNA (291, 588). Whilst the clinical relevance of oxidative stress in 
the pathophysiology of CF lung disease remains uncertain (209),  systematic evidence from 
19 randomised controlled trials (n = 924 children and adults with CF) demonstrating that 
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antioxidant therapy improves lung function supports the rationale to conduct further 
research in this area (92). 
The treatment of lung disease is central to the clinical management of CF (138, 482). Anti-
inflammatory drugs, airway clearance techniques, inhaled, oral and intravenous antibiotics, 
and preventing respiratory exacerbations are the corner-stones of lung therapeutics (152). 
Furthermore, new CFTR modulator therapies are being increasingly used in a clinical setting 
(391). Most recently, a combination of Elexacaftor with Tezacaftor and Ivacaftor 
(Trikaftor™) has been shown to restore CFTR function (sweat [Cl-]: -41.6 to -45.9 mmol·L-1 
vs. Tezacaftor-Ivacaftor treatment) and results in significant improvements in lung function 
(forced expiratory volume in 1 s, FEV1: +10.0 to +13.8 percentage points vs. Tezacaftor-
Ivacaftor treatment) in patients with one or two p.Phe508del alleles and mild to very severe 
CF lung disease (222, 335). 
1.1.3. CF-related dysglycaemia 
CF-related dysglycaemia originates from normal glucose tolerance (NGT), to impaired 
glucose tolerance (IGT) and, ultimately, the development of CFRD (347). CFRD is the most 
common non-respiratory consequence of CF affecting 30.5% of adults in the UK (Table 1.1) 
(530), but is suggested to be present in 40-50% of adults in the USA (349). Of particular 
clinical importance, is that the development of CFRD is associated with a greater decline in 
lung function (298), worsened nutritional status (280) and poorer prognosis (349). Despite 
the recognised clinical importance of CFRD (61, 325, 343, 347, 349), the complex 
pathophysiology of CF-related dysglycaemia is not fully understood. 
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Figure 1.3. The complex mechanisms in which CFTR dysfunction leads to the development of CFRD. Solid 
arrows represent causative associations; whereas, the dotted line represents treatments to address 
inflammation. This figure was adapted from Kayani et al. (259). 
Exocrine PI is observed in 85% of adults with CF (568), particularly in those with severe 
genotypes and is a key factor in the initiation of CF-related dysglycaemia (259). In utero and 
early in life (< 42 weeks), destruction of pancreatic tissues are attributed to reduced CFTR-
mediated HCO3- trafficking, which causes viscous and sticky mucous to accumulate within 
the CF pancreas (240, 417). Such mucous, which is rich in protein residues (286), obstructs 
the exocrine ducts and the accumulation of zymogens ultimately leads to the destruction 
of pancreatic tissues (259, 523). In particular, islet destruction causes a reduced count of 
α-cells and β-cells (259, 343); both of which contribute to glucose intolerance (Figure 1.3). 
↓ Inflammation
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The destruction of pancreatic tissue is, in part, associated with inflammation and oxidative 
stress that originates from CF-lung disease (373). Furthermore, CF-related dysglycaemia is 
associated with greater levels of lipid peroxidation in children (374), and an intrinsic CFTR 
defect within islet cells may render them more susceptible to such oxidative damage (375). 
CFTR is expressed in both glucagon-producing α-cells and insulin-producing β-cells (48), and 
causes an islet-intrinsic defect in anion, antioxidant and ATP trafficking (281). β-cells of 
pancreatic islets are the only cells to produce and release insulin in response to glucose-
regulated membrane depolarisation; a process mediated by the voltage-gated Ca2+ 
channels and ATP-sensitive K+ channels (KATP) (340). However, CFTR dysfunction causes a 
higher intracellular [Cl-], resulting in a hyperpolarised potential (40). Consequently, a 
greater glucose stimulus is required for KATP-mediated depolarisation and vesicle insulin 
trafficking, due to an impaired anion efflux (206). In α-cells, reduced insulin production and 
an intrinsic loss of CFTR increases glucagon secretion through the reduced activation of KATP 
(234). More recently, White and colleagues (566) have demonstrated that CFTR is 
expressed in < 1% of in situ β-cells of healthy pancreatic tissue; therefore, reduced insulin 
secretion in CF may be primarily a consequence of exocrine PI. This is further supported by 
observations that pancreatic replacement therapies improve glycaemic control in 
adolescents with CF (n = 14; 13.1 ± 2.7 y; FEV1, 92.4 ± 11.8% predicted), through 
normalising incretin secretion (394). 
Given these pathophysiological mechanisms, it is commonly accepted that the onset of CF-
related dysglycaemia throughout adolescence is driven by reduced insulin secretion (259). 
However, as the CF population reaches the third decade of life, fluctuations in both lung 
disease (117) and insulin sensitivity (52) contribute to dysglycaemia. Indeed, observations 
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from a 10 y follow-up study suggest that the progressive, age-related developments of 
insulin resistance during the 4th and 5th decade of life becomes the predominant 
mechanism of CF-related dysglycaemia (98). The underlying cause of insulin resistance in 
CF is unknown. However, potential mechanisms include (98): chronic and systemic 
inflammation/oxidative stress (260); the development of a sedentary lifestyle and age-
related decrements in exercise tolerance (474) - a notion supported by the observation that 
structured exercise training improved the insulin sensitivity of adults with CF (n = 8; 31.9 
[range: 24-41] y; FEV1, 70.5.4 [range: 14.9-32.8]% predicted) (34); the high calorie and high 
fat diet typically recommended for people with CF (527), which is also associated with 
excessive carbohydrate intakes that contribute to glucose excursions (336); and, whilst 
body mass index is often low in people with CF, there is a tendency for abdominal fat 
accumulation (85) and the prevalence of obesity in cohorts with CF is increasing (212). 
A considerable challenge in the management of CFRD is detecting and diagnosing 
abnormalities at the onset of dysglycaemia. Traditional screening modalities for diabetes 
mellitus, such as oral glucose tolerance testing (OGTT) and glycated haemoglobin (HbA1c) 
assessments, are somewhat inappropriate, as dysglycaemia-induced lung damage occurs 
in people who do not meet such diagnostic criteria (556). Furthermore, registry data has 
demonstrated that the earlier detection of CFRD is associated with a slower decline in lung 
function, highlighting the importance of frequent and appropriate screening techniques in 
this population (174). Novel digital technologies, such as continuous glucose monitoring 
(CGM), are gaining increased attention in CF centres and may better for the earlier 
detection of dysglycaemia-initiated lung injury (298). Whilst the clinical uptake of CGM has 
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grown over the last decade (44), including CF clinics (53), such technology is currently 
limited due to a lack of cut-off criteria for CGM-derived diagnoses (53, 266).  
The first line of therapy for CFRD is insulin (259, 266), primarily due to the early 
manifestation of insulin deficiency and, as a secondary benefit, to provide nutritional 
support through its anabolic properties (382). The treatment of lung disease in CF is 
paramount, however, it results in a considerable treatment burden (451, 452). 
Consequently, adherence to complex and demanding insulin regimens is generally poor in 
people with CF (266, 350). Furthermore, preventing respiratory exacerbations is essential 
as they are associated with the development of dysglycaemia, even in people with CF and 
NGT (364). Lifestyle modifications such as exercise training (34) and the avoidance of sugary 
confection (266) are recommended, whilst improving adherence to pancreatic enzyme 
replacement therapies are also likely to reduce glucose excursions (289). 
1.2. The Vascular Endothelium 
The endothelium acts as a selective semi-permeable barrier between tissues and the blood 
stream, and is essential for regulating vascular tension, fluid and molecular transport, 
immune cell trafficking, and promoting angiogenesis (73). Of particular interest to the 
present thesis is the role of the endothelium in regulating vascular tone and the response 
to shear stress. 
1.2.1. Endothelial regulation of vascular tone 
The endothelium regulates vascular tone through a host of endothelial-dependant dilatory 
and constrictor pathways. Mechanical (e.g. shear stress), chemical (e.g. acetylcholine; Ach) 
and hormonal (e.g. insulin and oestrogen) stimuli cause endothelial-mediated dilation of 
the blood vessels, through increasing the production of nitric oxide (NO), prostaglandins 
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(in particular, prostacyclin; PGI2) and endothelium-derived hyperpolarisation factors 
(EDHF). Conversely, the major endothelium-derived vasoconstrictors are the endothelin 
(ET) family.  
Figure 1.4. Mechanisms for endothelial-dependent vasodilation in response to mechanical (e.g. shear stress) 
or chemical (Ach or bradykinin; BK) stimulus. K+ efflux and Ca2+ influx initiates a chain of events whereby: 1) 
arachidonic acid (AA) is a substrate for cyclooxygenase (COX)-derived PGI2 production and cytochrome P450 
monooxygenase (CYP450)-derived EDHF production, which initiates smooth muscle relaxation through 
cAMP-, K+ channel- or Na+/K+-ATPase-dependant hyperpolarisation, and 2) L-arginine (L-Arg) is a substrate for 
NO synthase (NOS)-mediated NO production, which initiates smooth muscle relaxation through cyclic 
guanosine monophosphate (cGMP)-dependant hyperpolarisation. This figure was extracted from Durand et 
al. (144). AC, adenyl cyclase; EET, epoxyeicosatrienoic acids; GC, guanylyl cyclase; GTP, guanosine 
triphosphate; PLC, phospholipase C. 
NO is the smallest known signalling molecule and is a potent vasodilator (344). NO 
produced within the endothelium regulates vascular tone through activating soluble GC, 
which upregulates cGMP and ultimately leads to smooth muscle relaxation (144) (Figure 
1.4). Furthermore, endothelial NO plays a regulatory role in other physiological functions, 
such as: inhibition of platelet aggregation and adhesion; inhibition of leucocyte adhesion 
and inflammation; possessing antioxidant properties; inhibition of smooth muscle cell 
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proliferation; and, stimulation of angiogenesis (73, 171, 186). In the endothelium, NO is 
produced through endothelial NOS (eNOS), which is activated by calmodulin as a result of 
increased intracellular Ca2+ or enzyme phosphorylation (144, 171) (Figure 1.4). 
Furthermore, inducible NOS (iNOS) is also expressed in the endothelium, albeit to a lesser 
extent, in the presence of bacterial lipopolysaccharides or cytokines (170). Regardless of 
the NOS isoform, NO is produced with L-arg as the substrate, in addition to the co-
substrates of molecular oxygen (O2) and nicotinamide adenine dinucleotide phosphate 
(NADPH) (171). Furthermore, the co-factors flavin adenine dinucleotide (FAD), flavin 
mononucleotide (FMN), and tetrahydrobiopterin (BH4) must also be present (171). 
Furthermore, the dietary nitrate-nitrite-NO pathway, which is upregulated under 
circumstances of hypoxaemia and acidosis, also contributes to the endothelial NO pool 
(257). 
In the healthy endothelium, a vasodilator and inhibitor of platelet activation, PGI2, is 
available in abundance, however its role in regulating vascular tone is secondary to NO 
(160), especially during adulthood (593). Indeed, whilst venous blood flow in the volar 
forearm of healthy adults (n = 38; 21.3 ± 2.5 y) was reduced in response to aspirin (i.e. a 
COX inhibitor), increases in acetylcholine-induced endothelial-dependent vasodilation 
were not supressed with the co-administration of aspirin (141). Notably, in circumstances 
of eNOS uncoupling and/or reduced NO bioavailability, an increased production of PGI2 
may act as a compensatory mechanism to maintain vascular tone (500, 505). PGI2 is 
produced from AA by the COX enzyme and, subsequently, results in cAMP-dependent 
smooth muscle relaxation (144) (Figure 1.4). COX-1 and COX-2 isoforms are constitutively 
expressed in endothelial cells and are both upregulated in response to shear stress (139); 
whereas, COX-2 is also upregulated in response to ROS and inflammation (271) (Figure 1.4).  
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Residual dilation of the vessel following inhibition of pathways that produce NO and PGI2 
are due to the remaining EDHF that are released from endothelial cells (73). EDHF initiates 
hyperpolarisation and relaxation of vascular smooth muscle through activating Na+/K+-
ATPases and inwardly rectifying K+ channels (148). Numerous EDHF are documented and 
have varying physiological importance depending on the species, vessel location and vessel 
size (144). EDHF include, but may not be limited to, H2O2, K+, CYP450 metabolites, 
lipoxygenase products, C-type natriuretic peptide, and electrical coupling through 
myoendothelial gap junctions (144, 148, 161).  
In addition to the various vasodilators, negative regulation (vasoconstriction) is also 
required to achieve optimal vascular tone. The most prominent vasoconstrictor, which acts 
through pro-inflammatory and a pro-oxidant pathways, is the ET family that contains 3 
isoforms: ET-1, ET-2 and ET-3 (73). In the endothelium, ET-1 peptide content is regulated 
by the expression of the End1 gene, which can be upregulated by a number of factors, 
including: angiotensin-II; transforming growth factor-β; thrombin; Bk; hypoxaemia; and 
low-density lipoproteins (231). Conversely, chronic shear stress and NO generation 
downregulates the expression of ET-1 (231). It is important to note, however, that a 
maintenance of vascular tone is reliant upon a number of endothelial-dependent and 
independent mechanisms that can become dysregulated by disease. 
A variety of enzymes within the vessel wall produce ROS at low physiological levels, 
including: NADPH oxidases (NOX), xanthine oxidase (XO) and mitochondrial respiratory 
chain enzymes (355). However, pathological stimuli (e.g. cigarette smoking, diabetes 
mellitus, hypertension and hypercholesterolaemia) mean these enzymes produce ROS, 
particularly superoxide radicals (O₂̇‾), at cytotoxic levels (355). In circumstances of a pro-
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oxidant state, BH4 is oxidised by O₂̇‾ to form 7,8-dihydrobiopterin (BH₂), L-arg stores are 
depleted and the NOS binding site for BH4 and L-arg undergo oxidative modifications (104, 
171). These factors are associated with eNOS uncoupling, which is characterised by a 
further production of O₂̇‾ rather than NO (105). The presence of both coupled and 
uncoupled eNOS within the endothelium means O₂̇‾ readily oxidises NO, forming 
peroxynitrite (ONOO‾). Increased levels of ONOO‾ are associated with a reduced NO 
bioavailability (303) and limited endothelial-dependent vasodilation (78).  
In addition to eNOS uncoupling, COX-2 expression is upregulated in response to ROS and 
inflammation (462) and, subsequently, co-oxidises NADPH that contributes to the 
exacerbated generation of O₂̇‾ (508). Under conditions of eNOS uncoupling and COX-2 
overexpression, the endothelial antioxidant defence mechanisms, in particular superoxide 
dismutase (SOD), catalyse the dismutation of O₂̇‾ into H2O2 (148). However, elevated levels 
of hydroperoxides initiate a positive-feedback loop that further activates COX-1 and COX-
2 (508). Furthermore, COX complexes and their products (including prostaglandins, 
isoprostanes and PGI2) also act as endothelial-dependant constrictors, particularly in 
circumstances of: abnormal Ca2+ handling; increased levels of ROS/RNS; increased PGI2 
synthase expression; exacerbated release of thromboxane A2 and prostaglandin H2 (160).  
1.2.2. Endothelial regulation in response to shear stress 
The in vivo endothelium is constantly exposed to a frictional force generated by blood flow, 
which is quantified by determining the power of flow required to move 1 g of mass at a 
rate of 1 cm per second (i.e. dynescm2). The venous system in vivo is reported to be 
exposed to 1-6 dynescm2 of shear stress, whereas the arterial vascular system in vivo 
experiences ~10-fold higher forces (10-70 dynescm2) (317). In the pulmonary artery, shear 
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stress may be reduced in comparison to systemic arterial values (20 dynes·cm2 vs. up to 70 
dynes·cm2, respectively), due to the reduced blood pressure of the pulmonary circulation 
(507). The degree of shear stress experienced by the vessel is determined by 3 factors: 
blood viscosity, blood flow and vessel radius (27). Therefore, the endothelium constantly 
adapts in response to changes in blood flow by regulating vascular tone and blood viscosity 
(89). 
Forces experienced by the endothelium are detected by a network of mechanoreceptors 
that drive the process of mechanotransduction, which is defined as the conversion of 
physical forces into intracellular biochemical signalling (89). A plethora of 
mechanoreceptors exist in endothelial cells, including: gap-junction proteins (e.g. occludin 
and vascular endothelial-cadherin; VE-cadherin), receptor kinases (e.g. vascular endothelial 
growth factor [VEGF] receptor 2; VEGFR2), integrins, focal adhesions, G-proteins, G-
protein-coupled receptors (GPCR), ion channels and glycocalyx (205). Such 
mechanoreceptors act through a variety of physiological pathways; however, re-
organisation of the actin cytoskeleton in the endothelial cell is considered the first 
responder to shear stress (312). 
The cytoskeleton comprises an F-actin cortical rim, cytosolic stress fibres and the 
membrane skeleton (312). When in vitro endothelial cells are acutely exposed to shear 
stress (a time frame of minutes to hours), which is only observed in vivo following 
angiogenesis and occlusion, the actin cytoskeleton is re-organised so that the cells align in 
the direction of flow (27). Notably, reduced alignment in the direction of flow is an in vivo 
(134, 192) and in vitro (111) marker of endothelial dysfunction. Changes in endothelial cell 
alignment is initiated by Ca2+ and integrin signalling (113), and mediated by a re-distribution 
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of integrins and focal adhesions at the most upstream surface of the cell (112, 185). 
Furthermore, the initiation of flow activates several proinflammatory factors, such as 
mitogen-activated protein kinase (MAPK) (306), stress-activated protein kinase (SAPK) 
(379) and NF-κB (342) signalling pathways, which prime the endothelium for chronic 
exposure to flow (27, 89). 
Figure 1.5. The cascade of events in response to chronic shear stress leading to increased expression of Nrf2 
and Krüppel-like factor 2 (KLF2), which protect the cell by increasing its antioxidant, vasodilatory, anti-
inflammatory and antithrombotic properties. This figure was adapted from Chistiakov et al. (89). Akt, RAC-α 
serine/threonine protein kinase; AP-1, activator protein 1; ASS, argininosuccinate synthase; CNP, C-
natriuretic peptide; EPHX1, microsomal epoxide hydrolase 1; Erk5, extracellular protein kinase 5; GCG, c-
glutamylcysteine synthase; GST, glutathione S-transferase, HOX-1, heme oxygenase 1; MEF2, myocyte 
enhancer factor-2; MKK5, mitogen-activated protein kinase kinase 5; NQO1, NAD(P)H quinone 
oxidoreductase 1; p67phox, 67-KDa subunit of NOX2; PAI-1, plasminogen activator inhibitor-1; PAR3, protease-
activated receptor 3; PI3K, phosphatidylinositol-3-kinase; PECAM-1, platelet endothelial cell adhesion 
molecule 1; PKC, protein kinase C; Rac1, Ras-related C3 botulinum toxin substrate 1; SEMA3F, semaphorin-
3F; SQSTM1, sequestosome 1; TF, tissue factor; TIAM1, T-cell lymphoma invasion and metastasis-inducing 
protein 1; TM, thrombo- modulin; t-PA, tissue plasminogen activator; TRX1, thioredoxin 1; VCAM1, vascular 
cell adhesion molecule 1.  
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Applying chronic shear stress to endothelial cells in vitro (a time frame of days to weeks) is 
a more appropriate model for replicating the physiological events that occur in vivo, 
compared to acute shear stress exposures (27). In contrast to an acute exposure to shear 
stress, prolonged exposure to normal laminar flow results in an optimised antioxidant, anti-
inflammatory and antithrombotic protection, which facilitates the maintenance of vascular 
tone and a quiescent phenotype through an increased expression of KLF2 and Nrf2 (27, 89) 
(Figure 1.5). 
KLF2 is a transcriptional regulator that significantly upregulates NOS but limits ET-1 
expression (123), whilst also contributing to a variety of vasoprotective effects (20). These 
include: inhibiting inflammation through negatively regulating NF-κB (307), thus reducing 
both pro-inflammatory cytokines (IL-1β) and adhesion molecules (VCAM-1 and E-selectin) 
(466); inhibiting oxidative stress through the promotion of Nrf2 activity and NQO1 
expression (168); increasing the antithrombotic properties of endothelial cells by 
upregulating thrombomodulin and limiting PAI-1 (307). The mechanotransduction of flow 
results in KLF2 transcription by the activation of the PI3K/Akt pathway, which ultimately 
activates the KLF2 transcriptional factor, MEF2 (89, 123) (Figure 1.5). 
As described in Section 1.1.2., Nrf2 is one of the key antioxidant transcriptional factors that 
promotes the transcription of numerous antioxidant enzymes and, ultimately, increases 
the antioxidant capacity of the cell (209, 215). Chronic flow upregulates the activity of Nrf2 
through activating the mechanotransductory PI3K/Akt and PKC pathways (109). 
Furthermore, flow-mediated initiation of VE-cadherin-PAR3-p67phoxNOX2 increases ROS 
production that upregulates Nrf2 synthesis and activates the antioxidant-response element 
(ARE)-mediated gene transcriptions, such as HO-1 (233). Therefore, flow-initiated 
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improvements in antioxidant, anti-inflammatory and antithrombotic elements of the cell 
are dependent upon the production of ROS (89).  
Disturbed, oscillatory flow is observed in vessels as a result of normal biological branching 
points (27). However, such flow is also associated with atherosclerotic lesions and the 
hypoxia-initiated release of endothelium-derived microparticles (29, 582). Furthermore, 
perturbations in shear stress eradicate the flow-dependant antioxidative and anti-
inflammatory mechanisms (89). Indeed, previous studies have demonstrated that 
oscillatory flow is associated with the activation of pro-inflammatory mediator NF-κB (358), 
increasing adhesion molecule and leukocyte adhesion (83, 475), interfering with 
mechanoreceptors (VE-cadherin) (334), increasing the formation of cytosolic stress fibres 
(520) and increasing ET-1 mRNA, but decreasing NOS mRNA (591). Furthermore, disturbed 
flow initiates the upregulation of XO and NOX that causes a 3-fold increase in O₂̇‾ 
production (329), which causes incidences of oxidative stress and endothelial dysfunction 
(89). 
1.2.3. The implications of CF on vascular endothelial function 
Given that a loss of CFTR is associated with the development of CF-related dysglycaemia, it 
is unsurprising that people with CFRD experience hyperglycaemia-induced vascular 
damage (259). For instance, up to 27% and 52% of people who have been diagnosed with 
established CFRD (≥ 10 y) experience clinically-relevant retinopathy and autonomic 
neuropathy, respectively (9, 460, 541). However, a notable finding is that micro- and 
macrovascular endothelial dysfunction is observed in people with CF without evidence of 
CFRD (411, 430). CFTR-mediated vascular perturbations have also been demonstrated in 
cell culture models in conditions of euglycaemia (65, 121, 408, 518, 519). However, the 
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pathophysiology underpinning CF-related vascular endothelial dysfunction in the absence 
of dysglycaemia is complex and not fully understood. 
Seminal findings by Tousson et al. (519) demonstrated that CFTR is expressed in both 
human lung microvascular endothelial cells (HLMVEC) and human umbilical vein 
endothelial cells (HUVEC), where it facilitates the efflux of Cl- anions. More recently, 
expression of CFTR has been confirmed in human pulmonary artery endothelial cells 
(HPAEC), and a long-term cell culture was developed by extracting cells from an 
extransplanted pulmonary artery of an individual with CF and two p.Phe508del alleles 
(408). Under static cell culture conditions, CF-HPAEC exhibited reduced tight junction 
integrity, demonstrated by reduced transendothelial electrical resistance (518). 
Furthermore, increased corneal endothelial permeability is observed in people with CF 
compared to controls (297) and HUVEC treated with a pharmacological CFTR inhibitor 
(CFTRinh-172) experienced increased endothelial permeability to macromolecules (e.g. 
dextran) (518). Exacerbated endothelial permeability in CF is, to a certain extent, explained 
by a reduced expression of VE-cadherin and p120 catenin following acute shear stress 
(518), internalisation of β-catenin (65), the formation of cytosolic stress fibres (65), and the 
swelling and softening of the glycocalyx (399). 
Increased endothelial permeability is associated with a greater migration of leukocytes, 
which leads to an excessive inflammatory response (121). Pharmacological inhibition of 
CFTR in HUVEC had also been demonstrated to result in a sterile increase of IL-8 (518), 
whilst circulating biomarkers of endothelial perturbation and, indeed, damage were 
positively correlated with plasma cytokine levels (IL-6 and tumour necrosis factor-α; TNF-
α) (432). Pulmonary vascular endothelial dysfunction was reported in 61% of people with 
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end-stage CF lung disease (n = 14; age, 27 ± 4 y; FEV1, 31 ± 2% predicted), and was 
associated with a significantly elevated expression of NF-κB and ET-1 in their arterial tissue 
compared to people with end-stage CF lung disease without endothelial dysfunction (223). 
To further support this, other investigations have also reported elevated ET-1 levels in both 
sputum (80) and plasma (477) samples from children, adolescents and adults with 
moderate to severe CF lung disease. These data suggest that inflammation and 
vasoconstriction may contribute to endothelial dysfunction in CF. 
Rodriguez-Miguelez and colleagues (430) recently reported perturbation of microvascular 
function, measured by laser-Doppler imaging technology, in 16 young adults (22 ± 9 y) who 
were only mildly deconditioned (peak O2 uptake, V̇O2peak: 73 ± 12% predicted) and had mild 
to moderate CF lung disease (FEV1: 75 ± 16% predicted). In this study, it was observed that 
the dilation of the volar forearm microvasculature in response to transdermal 
iontophoresis of Ach and local thermal hyperaemia was significantly lower in people with 
CF versus healthy sex-matched controls (430); therefore, indirectly suggesting COX, EDHF 
and, principally, NO production abnormalities (68, 264, 339, 363). Furthermore, an earlier 
report demonstrated that flow-mediated dilation (FMD) of the brachial artery was 
significantly reduced in children and adolescents with CF who had mild lung disease (FEV1: 
87.7 ± 22.3% predicted) and mild deconditioning (V̇O2peak: 71 ± 14% predicted) compared 
to an age-, height- and body mass index (BMI)-matched healthy control group (411). A 
notable finding of this study was that NO-mediated dilation in response to shear stress was 
significantly reduced in people with CF, despite a normal rate of brachial artery shear stress 
in response to occlusion and reperfusion (411).  
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The pathophysiology of reduced NO-mediated dilation in people with CF has been studied 
in vitro. Inhibition of CFTR in HUVEC resulted in a reduced Akt-mediated NO production in 
response to insulin (518). Reduced concentrations of nasal and exhaled NO (25, 287), as 
well as reduced saliva and sputum concentrations of nitrate and nitrite (120), have been 
reported in people with CF versus controls. Interestingly, when arterial rings from people 
with end-stage CF lung disease and endothelial dysfunction were treated with genistein, 
endothelial-dependant vasodilation was restored (223). Genistein is a CFTR activator (10), 
but also has properties that increase COX-2 dependant PGI2 production (224) and eNOS 
dependant NO production (577). Notably, co-treatment of the aforementioned CF arterial 
rings with the NOS inhibitor, NG-nitro-L-arginine methyl ester, abolished the vasodilatory 
effects of genistein (223). Together, these data suggest that CF-related endothelial 
perturbations are not only a result of inflammation and vasoconstriction, but are also a 
consequence of a reduced NO bioavailability in response to mechanical (occlusion-
reperfusion induced shear stress) and chemical (in this case Ach) stimuli. 
Previous research has demonstrated that acute treatment of CF participants with 
antioxidants (1,000 mg vitamin C, 600 IU vitamin E, and 600 mg α-lipoic acid) (525) or BH4 
(20 mg·kg-1) (248) improved endothelial function measured by FMD, also implicating 
oxidative stress and, subsequently, eNOS uncoupling in CF-related endothelial dysfunction. 
Abnormalities in eNOS regulation in CF may also be exacerbated by a genetic 
polymorphisms of the eNOS gene (196), and may contribute to exercise intolerance (581) 
(see section 1.3.1.1.). Nitrotyrosine concentrations, a biomarker of nitrosative stress by 
RNS, are also reportedly elevated in the exhaled breath condensate (26) and sputum (54) 
of adults with moderate to severe CF lung disease; however, levels in the blood or 
endothelial cells have not been quantified on a case-control basis. To date, the genesis of 
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oxidative stress in the CF endothelium has not yet been studied. Early reports suggest that 
CFTR inhibition in HUVEC is associated with increased ROS production as a consequence of 
MAPK and NF-κB signalling (159). However, future research investigating the sources of 
ROS (XO, NOX or mitochondria) and antioxidant insufficiency (Nrf2 or KLF2) in the CF 
endothelium are warranted and would guide the development of endothelial-targeted 
therapeutics.  
1.3. Aerobic Exercise Function 
Aerobic fitness, measured by V̇O2peak in this case, is an important marker for prognosis in a 
variety of chronic diseases, including heart failure (14), liver disease (37), pulmonary 
hypertension (407), chronic obstructive pulmonary disease (COPD) (228) and, indeed, CF 
(220, 371, 402). Furthermore, both the European CF Society (ECFS) and European 
Respiratory Society (ERS) advocate the annual use of CPET in CF clinics (217, 389). This is 
because exercise capacity, in particular V̇O2peak, is positively correlated with quality of life 
(221) and negatively correlated with the risk of being hospitalised due to a respiratory 
exacerbation (397) in people with CF. The gold-standard assessment of aerobic fitness in 
humans, V̇O2max, describes the maximal rate in which the pulmonary, cardiovascular and 
peripheral systems can uptake, transport and utilise O2, respectively (409) (Figure 1.6). 
Furthermore, a comprehensive assessment of aerobic exercise function is achieved by 
quantifying: the gas exchange threshold (GET; a submaximal parameter of aerobic fitness 
– also known as the anaerobic threshold); the kinetics of V̇O2 (i.e. V̇O2 mean response time); 
and work efficiency (i.e. the functional V̇O2-gain or ∆V̇O2/∆WR) (555). 
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Figure 1.6. An illustration of the relationship between V̇O2 and muscular O2 consumption (Q̇O2). Ambient O2 
is inspired and delivered to the muscle by the lungs and cardiovascular system to produce ATP for skeletal 
muscle stimulation. CO2 is produced as a bi-product of oxidative muscle metabolism (Q̇CO2) and is 
subsequently removed from the muscle and inspired into ambient air, also through the cardiovascular and 
respiratory systems. This figure was extracted from Jones & Poole (252). Creat-PO4, creatine phosphate; f, 
breathing frequency; Pyr-Lac, pyruvate-lactate; SV, stroke volume; VT, tidal volume. 
Whilst cardiopulmonary exercise testing (CPET) provides the gold-standard assessment of 
aerobic exercise function (555), various methodological limitations may limit the utility of 
CPET in a clinical setting. For instance, V̇O2max was historically confirmed when V̇O2 failed 
to increase despite continuing increments in workload – in essence, the occurrence of a 
‘V̇O2 plateau’ (226). However, a V̇O2 plateau is not commonly achieved in paediatric, clinical 
or sedentary populations (115, 133, 434, 453, 564). Therefore, exercise capacity is often 
described by determining V̇O2peak, which is often an artefact of symptom-induced limitation 
as opposed to a true physiological maximum (199). Whilst a recent expert statement on 
behalf of the Cores of Reproducibility in Physiology initiative has advocated exercise testing 
protocols to determine V̇O2max in healthy, athletic and clinical populations (409), various 
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bodies (i.e. the ECFS) have called for future research to investigate the safety and feasibility 
of such protocols in adults with CF and more severe lung disease (218) (see Chapter 3 for 
an overview of the methodological considerations challenging CPET in CF clinics). 
Table 1.3. Gas exchange and ventilation outcomes from CPET reported within the present thesis experimental 
chapters. 
Outcome Abbreviation Description 
Maximal oxygen uptake V̇O2max Physiological maximum aerobic fitness 
Peak oxygen uptake V̇O2peak Symptom-limited peak aerobic fitness 
Gas exchange threshold GET Submaximal aerobic fitness 
Peak work rate Wpeak Symptom-limited marker of exercise 
capacity 
Peak heart rate HRpeak Symptom-limited marker of cardiovascular 
function 
Oxygen pulse O2 pulse A non-invasive estimate of SV 
Arterial oxygen saturation SpO2 Limitation in O2 extraction if significantly 
reduced during or following exercise 
Respiratory exchange ratio RER An indicator of substrate utilisation and 
exercise intensity 
Oxygen uptake gain ∆V̇O2/∆WR A marker of the O2 cost of a given exercise 
intensity 
Breathing reserve V̇E/MVV Ventilatory limitation if V̇E encroaches upon 
MVV 
Ventilatory equivalent of oxygen V̇E/V̇O2peak A marker of ventilatory efficiency for O2 
uptake 
Ventilatory equivalent of carbon dioxide V̇E/V̇CO2peak A marker of ventilatory efficiency for CO2 
extraction 
Ventilatory drive ∆V̇E/∆V̇CO2 A marker of a mismatch between 
ventilatory and perfusion (V̇/Q̇) 
MVV, maximal voluntary ventilation; V̇E, minute ventilation. 
Other outcomes from CPET are becoming more popular in evaluating the effectiveness of 
therapeutic interventions (415), in particular pharmaceutical treatments (147, 455) and 
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lung transplantation (377, 509) in people with CF. Such variables provide information 
regarding exercise capacity, ventilatory function, substrate utilisation, cardiovascular 
function and test quality (Table 1.3). Determining aerobic exercise function using CPET 
therefore provides a useful integrative physiological approach to not only understand the 
maximal capabilities of human physiology; but, also identify pathological limitations and to 
study the compensatory mechanisms of various organs to maintain exercise capacity in 
circumstances of disease. 
1.3.1. Modulators of aerobic exercise function in CF 
Given that CF is a complex multi-system disease, it is troublesome to stratify prognosis by 
determining dysfunction of only a single organ (e.g. the pancreas) (220). Traditionally, 
prognosis is primarily stratified using assessments of lung function by flow-volume loop 
spirometry to derive FEV1 and forced vital capacity (FVC) (270). However, it has been known 
for more than 2 decades that V̇O2peak holds prognostic value in children, adolescents and 
young adults with CF due to its ability to determine dysfunction at a multi-system level 
(371, 402). More recently, a multi-centre trial with a 14 y follow-up period substantiated 
these observations by demonstrating that 4 of the top 5 most important prognostic 
outcomes for people with CF are derived from CPET, when compared to standard clinical 
outcomes, such as lung function, pancreatic status, glycaemic control, infection status, 
nutritional status and demographics (Table 1.4) (220). 
This landmark study by Hebestreit et al. (220) in 2019 confirmed reports that exercise 
capacity, ventilatory limitation and ventilatory efficiency are important factors when 
predicting risk of death and lung transplantation over a 14 y follow-up period in a 
heterogeneous group of children, adolescents and adults with CF (n = 510). People with CF 
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in the highest tertile of aerobic fitness (≥ 82% predicted V̇O2peak) had a 72% lower risk of 
death and 49% lower risk of lung transplantation in the following 10 y from the preliminary 
CPET, compared to those who were in the middle (59-81% predicted V̇O2peak) or lowest (≤ 
58% predicted V̇O2peak) tertile of aerobic fitness (220). Whilst aerobic fitness and ventilatory 
efficiency are important prognostic outcomes in people with CF, the extent of exercise 
limitation is not fully understood. 
Table 1.4. The top 10 most important outcomes to stratify prognosis in people with CF. 
Rank Variable Category 
1 FEV1 as a percentage predicted Lung function 
2 V̇E/V̇O2peak Ventilatory efficiency 
3 V̇E/V̇CO2peak Ventilatory efficiency 
4 V̇E/MVV Ventilatory limitation 
5 V̇O2peak as a percent predicted Exercise capacity 
6 BMI as a z-score Nutritional status 
7 Wpeak as a percent predicted Exercise capacity 
8 Age in y Demographic 
9 Pseudomonas aeruginosa infection Lung disease 
10 Female sex Demographic 
These data were extracted from Hebestreit et al. (220). 
In 1971, Godfrey & Mearns (190) reported that Wpeak was reduced in people with CF (n = 
41; 6-22 y) compared to a previously studied group of healthy children (188). Notably, Wpeak 
was considered normal in those with preserved lung function (FEV1: 85 ± 3% predicted; 
Wpeak: 97 ± 6% predicted), but reductions in exercise capacity were observed in those with 
more pronounced lung disease (FEV1: 49 ± 4% predicted; Wpeak: 69 ± 4% predicted) (190). 
A decade after these seminal findings were published, Hjeltnes et al. (229) observed that 
V̇O2peak was significantly reduced (mean V̇O2peak: 79% predicted) in male adolescents with 
CF (n = 9; 15-17 y) versus 8 age-matched healthy controls; however, considerable variation 
in V̇O2peak was observed in the CF group (40-125% predicted). Notably, a later study in 17 
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adults with CF (25 ± 10 y; 47% female; FEV1, 62 ± 21% predicted) demonstrated a more 
considerable reduction in V̇O2peak (CF: 24.6 ± 6.0 mL·kg-1·min-1 vs. control: 35.5 ± 8.5 mL·kg-
1·min-1) compared to age- and sex-matched healthy controls (469). Whereas, similar V̇O2peak 
(CF: 38.5 ± 7.1 mL·kg-1·min-1 vs. control: 37.9 ± 5.0 mL·kg-1·min-1) values were reported 
between adolescents with CF (n = 18; 61% male; 15.8 ± 6.1 y; FEV1, 71.5 ± 19.5% predicted) 
and their age-matched healthy counterparts (FEV1, 101.0 ± 12.2% predicted) despite 
significant differences in FEV1 (219). Additionally, Wells et al. (561) reported similar V̇O2peak 
(CF: 44.2 ± 10.9 mL·kg-1·min-1 vs. control: 44.7 ± 11.6 mL·kg-1·min-1) between adolescents 
with CF (n = 20; 50% male; 15.1 ± 1.5 y; FEV1, 92.9 ± 12.7% predicted) versus 20 age-, sex- 
and physical activity-matched healthy controls. 
In terms of submaximal measures of aerobic fitness in people with CF, less data are 
available for the GET as there is a lack of consensus regarding the accuracy of this 
measurement in clinical groups (548). For instance, it has been reported that it is only 
possible to determine the GET in 48% of people with CF due to altered breathing patterns 
(514). Nonetheless, several reports have suggested that the GET is similar between people 
with CF (of varying ages and phenotypes) and healthy controls when it is expressed as a 
percentage of V̇O2peak (46, 47, 164, 201, 219, 456, 457), in absolute values (450, 456) and 
at the work rate it was achieved (450). Thin et al. (514) observed that a lowered GET was 
observed in adults with CF (n = 30; 77% male; FEV1 range, 23-118% predicted) versus 18 
healthy controls, and reductions were exacerbated as lung disease worsened (severe CF 
lung disease: 742 ± 281 mL·min-1 vs. moderate CF lung disease: 995 ± 216 mL·min-1 vs. mild 
CF lung disease: 1,202 ± 562 mL·min-1 vs. controls: 1,787 ± 512 mL·min-1). Notably, Stevens 
et al. (492) reported significantly lower GET values when it was expressed relative to body 
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mass (CF: 19 ± 4 mL·kg-1·min-1 vs. control: 26 ± 8 mL·kg-1·min-1), and it also occurred at a 
lower work-rate (CF: 69 ± 32 W vs. control: 102 ± 53 W) in children and adolescents with 
CF (n = 19; 13.4 ± 3.1 y; 9 male; FEV1, 87 ± 21% predicted) compared to 19 age- and sex-
matched healthy controls. Notably, a preoperative GET of ≤ 11 mLkg-1min-1 is a key 
predictor of death by cardiac failure or ischaemia during surgery in elderly patients (378); 
furthermore, expressing GET relative to body mass is a well-established practice in 
preoperative CPET clinics (3). Therefore, more studies investigating the implications of a 
lower GET relative to body mass in populations with CF along the spectrum of disease 
severity are warranted. 
One of the few consistent findings in the growing evidence base, is that exercise capacity 
is seemingly reduced in people with more severe CF lung disease. However, it is unknown 
whether this is solely attributed to a reduced potential for pulmonary O2 uptake, or 
whether more severe CFTR dysfunction in the cardiovascular and peripheral systems also 
contribute to reductions in O2 transport and utilisation. The latter hypothesis is likely, as 
lower V̇O2peak values have been observed in people with CF, even after the statistical 
covariance of age, sex, BMI and FEV1 were removed (450). Together, these data suggest 
that the pathophysiology of aerobic exercise dysfunction in people with CF is complex and 
several modulators of exercise capacity may exist. The following sections of this thesis will 
focus upon the implications of: genotype, lung disease, cardiovascular limitation, muscle 
limitation and dysglycaemia. 
1.3.1.1. Genotype 
The earliest report investigating the association between CFTR genotype and exercise 
capacity demonstrated that there were no significant differences in V̇O2peak between 
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patients who were p.Phe508del homozygous (n = 10; 37.0 ± 10.1 mL·kg-1·min-1), compared 
to those who were p.Phe508del homozygous heterozygous (n = 20; 36.3 ± 12.6 mL·kg-1·min-
1) (258). However, Selvadurai et al. (465) demonstrated that a single p.Phe508del allele in 
addition to a secondary class I/II mutation was associated with a significantly lower relative 
V̇O2peak (class II/I: 29.8 ± 4.2 mL·kg-1·min-1 vs. class II/II: 32.1 ± 4.9 mL·kg-1·min-1 vs. class II/V: 
54.3 ± 6.8 mL·kg-1·min-1) and Wpeak (class II/I: 9.6 ± 1.4 W·kg-1 vs. class II/II: 9.5 ± 1.4 W·kg-1 
vs. class II/V: 11.5 ± 1.5 W·kg-1) compared to people with a single p.Phe508del allele and a 
secondary class III-V mutation (465). Notably, this was independent of age, sex and FEV1 
(percent predicted) as these variables were not significantly different between groups 
(465). More recently, a large (n = 726; 13-22 y; FEV1, 66-91% predicted) multi-centre trial 
across North America, Europe, Australia and Asia investigated the association between 
CFTR genotype and exercise capacity in people with CF (421). In this study, there were no 
significant differences in V̇O2peak (in absolute units, relative to body mass or as a percent 
predicted) amongst CFTR genotype classes once the statistical covariance of age, sex, FEV1, 
BMI and Pseudomonas aeruginosa were removed (421). Interestingly, people with class I-
III genotypes, compared to class IV-V, had a significantly greater V̇E/MVV, but these data 
were not adjusted for FEV1 and BMI (421).  
A genetic predisposition to exercise intolerance may go further than the CFTR genotype 
alone. Over the past 2 decades, more than 200 modifier genes have been identified to 
modulate the fitness and performance of humans (59, 449). A single study has investigated 
the associations between modifier genes and exercise capacity in CF (581). Yvert et al. (581) 
demonstrated that polymorphisms of genes that are related to skeletal muscle mass, 
strength and function are not different between children with CF and healthy controls. 
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However, a polymorphism of the eNOS gene was associated with a reduced V̇O2peak and 
FEV1 in 66 children with CF (53% boys; 9.0 ± 4.0 y) (196, 581). A considerable limitation of 
the aforementioned study was that there were no significant differences in FEV1 (CF: 85.3 
± 28.1% predicted vs. control: 108.9 ± 17.3% predicted), BMI (CF: 17.2 ± 2.8 kg·m2 vs. 
control: 18.3 ± 2.9 kg·m2) or V̇O2peak (CF: 36.0 ± 7.3 mL·kg-1·min-1 vs. control: 38.0 ± 7.4 
mL·kg-1·min-1) between the CF group and their age-matched healthy controls (581). Given 
that various modifier genes contribute to infection susceptibility, inflammation, lung 
disease and dysglycaemia (Table 1.2), more prominent results may be observed in people 
with a more severe CF phenotype.  
1.3.1.2. Lung disease 
Lung function is the most important prognostic outcome in people with CF; however, a 
reduced ventilatory efficiency and a greater ventilatory limitation at peak exercise predicts 
the risk of lung transplantation and death independent of FEV1 (Table 1.4) (220). People 
with moderate to severe CF lung disease have a reduced exercise capacity that is a result 
of lower FEV1 values, whereas excessive ventilation (a greater V̇E/V̇CO2peak and V̇E/MVV) 
becomes the major determinant of exercise intolerance in people with mild to moderate 
CF lung disease (393). This is supported by the observation that annual changes in 
ventilatory parameters from CPET (V̇E/V̇O2peak, V̇E/V̇CO2peak, and ∆V̇E/∆V̇CO2) occur without 
decrements in FEV1 and V̇O2peak (526). 
The ventilatory response to exercise is primary influenced by CO2 production, partial 
pressure of arterial CO2 [PaCO2] and the ventilatory dead space-to-VT ratio (VD/VT) (565). 
When perfusion of CO2 in the lung is compromised, V̇E is increased to maintain PaCO2 and a 
ventilation/perfusion (V̇/Q̇)-mismatch ensues (127, 502). Thus, the ∆V̇E/∆V̇CO2 from CPET 
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is a non-invasive indicator of a V̇/Q̇-mismatch during submaximal exercise (499). During 
exercise, V̇E/V̇CO2peak and ∆V̇E/∆V̇CO2 are generally increased in people with CF irrespective 
of their lung disease classification (127). In line with the Bohr equation (565) (Equation 1.1), 
increases in V̇E/V̇CO2 are determined by a reduced PaCO2 set-point or increased VD/VT: 
. !̇!!̇#$"
 = %&'
	#$)*"	×	,-	.	%&%'/
                Equation 1.1. 
In the earliest reports of ventilatory function during exercise in CF, VD was ≥ 2-fold greater 
and V̇E was increased compared to expected values even in those with a normal FEV1 (9.51 
± 0.72 y; FEV1: 85 ± 3% predicted) (190). Furthermore, a rapid, shallow breathing pattern 
has been reported in children, adolescents and adults with moderate to severe CF lung 
disease (268) which, ultimately, reduces VT (93). A higher VD/VT, in conjunction with an 
increased resting V̇E, is suggestive of an abnormal alveolar dead space (567). Furthermore, 
reductions in FEV1 cause an increased respiratory muscle load and reduced lung compliance 
(214), potentially impairing ventilatory efficiency through exacerbated airway obstruction, 
inflammation and mucus plugging (526). To compensate for a reduced lung compliance, 
people with CF increase breathing frequency to maintain or increase V̇E, but are ultimately 
unable to clear accumulating CO2 and the prevalence of hypercapnia is high (58, 526). 
Children and adolescents with CF have a blunted ventilatory response to hypercapnia 
compared to controls, irrespective of FEV1 (70, 94, 158, 404), however no data are available 
in adults. Furthermore, an increased PaCO2 resulted in an increased alveolar ventilation, but 
not V̇E, in children and adolescents with CF (n = 16; 7-18 y; 63% male) (404). Therefore, an 
increased VD/VT and the resultant dynamic hyperinflation seems to be the driver for 
ventilatory dysfunction in people with CF (127). 
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1.3.1.3. Cardiovascular limitation 
CF-related cardiomyopathy has been recognised as a common non-respiratory 
consequence of CF (290). For instance, 11.2% of children, adolescents and adults with mild 
to very severe CF lung disease (n = 44) experienced a cardiac arrhythmia determined by 
echocardiography during exercise (441). CFTR is expressed in ventricular myocytes of 
humans (554) and other potential pathophysiological contributors to CF-related 
cardiomyopathy include: chronic hypoxaemia, inflammation and myocardial fibrosis (191, 
250, 290). Studies of mice with CFTR knock-out have demonstrated increased myocardial 
contractility that caused progressive myocardial remodelling without established 
pulmonary disease (249). Furthermore, post-mortem investigations of humans with CF 
observed right ventricular hypertrophy and dilatation (442, 490), in addition to epicardial 
and myocardial lymphedema (592). During submaximal exercise, CF-related 
cardiomyopathy is characterised by a blunted increase in SV whereby HR is increased 
compared to healthy controls to maintain cardiac output and O2 delivery (242, 296, 403). 
In people with more severe CF lung disease or during maximal exercise, a blunted SV 
response cannot be compensated for by increasing HR (403, 433) due to an earlier 
occurrence of vagal withdrawal (323). 
In addition to CF-related cardiomyopathy, CFTR is also expressed in the micro- and 
macrovascular endothelial cells (408, 519), and vascular endothelial dysfunction is reported 
even in people with only mild to moderate CF lung disease (411, 430) (see section 1.2.3.). 
Microvascular endothelial dysfunction and vasoconstriction in the lung could contribute to 
the aforementioned V̇/Q̇-mismatch that is increasingly observed in people with CF (400). 
Furthermore, reports of micro- and macrovascular dysfunction in children, adolescents and 
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adults with CF have demonstrated modest positive correlations between endothelial 
function and V̇O2peak (411, 430). Increased ROS production was associated with reduced 
peripheral blood flow during submaximal exercise in people with CF (525). Furthermore, 
antioxidant supplementation (1,000 mg vitamin C, 600 IU vitamin E, and 600 mg α-lipoic 
acid) restores vascular dysfunction in people with CF (525). However, further research is 
required to determine the most appropriate redox-based therapeutics to improve vascular 
endothelial function, especially in circumstances of elevated shear stress, in models of CF. 
1.3.1.4. Muscle limitation 
There is a growing body of evidence to suggest that skeletal muscle dysfunction contributes 
to exercise intolerance in CF (119, 202, 294, 352, 446, 521). Indeed, 16 competitive female 
athletes with CF and preserved lung function (15.0 ± 1.8 y; FEV1, 96 ± 9% predicted; V̇O2peak, 
36.1 ± 6.9 mL·kg[lean body mass] -1·min-1) have a reduced peripheral muscle strength (leg 
strength, CF: 110 ± 26 nM vs. control: 169 ± 32 nM) compared to healthy controls of a 
similar training status (464). Whilst it is clear skeletal muscle dysfunction in CF has an 
important clinical implication (203), it is not clear whether skeletal muscle dysfunction is a 
result of an intrinsic defect (429) or is a secondary consequence of nutritional insufficiency 
(237). 
Studies have used 31Phosphorous-magnetic resonance spectroscopy to investigate 
peripheral skeletal muscle oxidative capacity of people with CF in vivo (122, 561, 563). A 
CF-specific intramuscular oxidative abnormality was evidenced due to reduced resting 
[ATP]  (CF: 7.8 ± 1.2 vs. control: 8.5 ± 1.0) and a delayed post-exercise [phosphocreatine] 
([PCr]) recovery time (CF: 27.2 ± 11.7 s vs. control: 19.3 ± 7.7 s) in people with CF versus 
controls, whereas there were no significant differences in these variables between healthy 
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controls and people with primary ciliary dyskinesia (561). Furthermore, preliminary findings 
have suggested that skeletal muscle oxidative abnormalities in 7 children with CF (13.5 ± 
2.8 y) and normal lung function (FEV1, 102 ± 6% predicted) are dependent upon exercise 
intensity; whereby, a slowed V̇O2 MRT is present only at exercise intensities above the GET 
(CF: 74.6 ± 19.4 s vs. control: 51.6 ± 8.3 s) (457). Exacerbated ROS generation has also been 
documented during submaximal cycling in CF (524); however, there was no evidence of 
elevated protein carbonylation or lipid peroxidation post-exercise cessation (524). 
Defective CFTR is associated with a reduced activity of the mitochondrial complex I in CF 
cells (471, 472, 534), potentially due to mitochondrial GSH depletion (265), and complex V 
in CF mice (p.Phe508del) (292). Mitochondrial oxidative stress, quantified by aconitase, was 
not different in skeletal muscle subsarcolemmal or interfibrillar mitochondria between CF 
and control mice (292). Therefore, identifying non-mitochondrial sources of ROS, such as: 
NOX, XO and phospholipase A2, is an important area for future research. 
From a respiratory muscle perspective, inspiratory muscle strength has been suggested to 
be well preserved in adults with CF compared to healthy controls (142, 153), potentially 
due to an increased work of breathing (142). Whereas, chronic low-grade inflammation 
from CF lung disease has been shown to contribute to muscle wasting in CF mice (131). 
Furthermore, a reduced fat-free mass may modulate a loss of inspiratory muscle strength 
as CF lung disease is worsened (153). Notably, reductions in fat-free mass may also 
modulate reductions in skeletal muscle dysfunction (202, 488). For instance, significant 
reductions in Wpeak in adults with CF (n = 15; 28.1 ± 6.2 y; mean FEV1, 72% predicted) 
compared to 15 age-, sex- and physical activity-matched healthy controls disappeared once 
data were expressed relative to muscle cross-sectional area of the calf (122). To confirm 
these findings, further research investigating whether correcting the underlying 
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inflammation and nutritional insufficiency associated with CF also improves skeletal muscle 
mass and function is needed.  
1.3.1.5. Dysglycaemia 
As described in section 1.1.3., the development of CFRD is associated with a greater decline 
in lung function (298), worsened nutritional status (280) and poorer prognosis (349). 
Although CFRD is currently the most commonly reported non-respiratory consequence of 
CF (349, 530), to date only 2 studies have investigated the implications of CFRD upon 
outcomes from CPET in people with CF, both of which were limited to paediatric groups 
(172, 256). 
Preliminary reports suggested that Wpeak was significantly reduced in adolescents with 
CFRD compared to age-, sex- and genotype-matched participants with NGT (256). More 
recently, Foster et al. (172) demonstrated that V̇O2peak (NGT: 41.3 ± 9.4 mL·kg-1·min-1 vs. 
IGT: 38.7 ± 10.8 mL·kg-1·min-1 vs. CFRD: 33.0 ± 7.7 mL·kg-1·min-1) was reduced as 
dysglycaemia worsened and, interestingly, plasma [glucose] and [insulin] 120 mins into an 
OGTT significantly predicted V̇O2peak irrespective of age, FEV1 and glycaemic status. In both 
of these trials, moderate positive correlations were observed between FEV1 and  V̇O2peak in 
those with CFRD (172, 256) suggesting that decrements in exercise capacity may, at least 
in part, be due to CFRD-induced lung damage. 
Only a single study by Ziegler et al. (590) has investigated the association between 
functional capacity and dysglycaemia in 88 adults with CF (20 ± 7 y). There was no 
significant difference in 6 min walk test performance amongst the groups with CF and NGT, 
IGT or CFRD  (590). Notably, the validity of the 6 min walk test to predict V̇O2peak is 
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questionable as participants frequently provide a submaximal effort (11). However, the 6 
min walk test may be useful in identifying people with mild to moderate CF lung disease 
who experience clinically meaningful ∆SpO2 during daily activities (88). An important 
finding by Ziegler et al. (590) was that adults with CF and IGT had a significantly greater 
∆SpO2 during exercise compared to their age-matched counterparts with CF and NGT. 
Greater reductions in SpO2 within the CF-related dysglycaemia groups during exercise are 
indicative of ventilatory inefficiency and/or limitation (217).  
Females with CF-related dysglycaemia have significantly worse 6 min walk test than their 
male counterparts with CF and a similar glycaemic status (590) and greater yearly 
decrements in ventilatory efficiency (526) versus their male counterparts. Thus, CF-related 
dysglycaemia induced lung damage may cause ventilatory dysfunction in people with CF 
and contribute to age-related reductions in exercise capacity, especially in females. 
However, further research is required to determine the implications of dysglycaemia upon 
aerobic exercise and ventilatory function in adults with CF using CPET. 
1.4. Thesis Objectives 
Various gaps in the literature have been highlighted within this introduction. The data 
reported within this thesis herein will provide novel results and discussion points to further 
understand the role of dysglycaemia and endothelial perturbation in the development of 
both aerobic exercise and ventilatory dysfunction in CF. The specific objectives of the 
experimental chapters are reported below. 
Prior to determining whether dysglycaemia can alter aerobic exercise and ventilatory 
function in CF, a valid, feasible and safe CPET protocol was required for adults with CF and 
more severe lung disease, compared to the groups that were previously studied (e.g. (453, 
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564)). Therefore, in line with the recommendations from the ECFS Exercise Working Group 
(218), Study 1 (Chapter 3) aimed to determine the validity of CPET with supramaximal 
verification (Smax) in children, adolescents and adults with mild to severe CF lung disease. 
Specifically, the experiments sought to determine: 1) whether a plateau in V̇O2 upon 
exhaustion would occur during ramp incremental exercise testing in people with mild to 
severe CF lung disease, 2) whether traditional secondary verification criteria would be 
achieved at a V̇O2 which is less than V̇O2max, 3) whether Smax-V̇O2peak would exceed ramp-
V̇O2peak by ≥ 9% on an individual basis, and 4) whether the inclusion of Smax would increase 
the number of significant adverse events versus ramp incremental exercise testing alone. 
No study to date had determined whether the development of CF-related dysglycaemia 
alters aerobic exercise and ventilatory function parameters from CPET in adults with CF. 
Therefore, Study 2 (Chapter 4) was designed to investigate whether dysglycaemia affects 
aerobic exercise and ventilatory function in adults with mild to severe CF lung disease. 
Specifically, the experiments sought to determine: 1) whether adults with IGT and CFRD 
have a reduced V̇O2max and earlier occurrence of the GET compared to age- and sex-
matched adults with CF and NGT, 2) whether a greater frequency of ventilatory limitation 
during CPET results in a greater reduction in SpO2 in adults with CFRD compared to age- 
and sex-matched adults with CF and NGT, and 3) whether the inclusion of glycaemic control 
variables within a multiple linear regression model would significantly improve the 
explained variance of V̇O2max in adults with CF. 
It was also unknown whether the expression of CFTR in HLMVEC may contribute to the 
prognostically relevant ventilatory dysfunction observed during CPET in CF. Therefore, 
Study 3 (Chapter 5) was designed to investigate the extent of CFTR expression and activity 
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in HLMVEC, and the role of endothelial CFTR in regulating inflammation, oxidative stress 
and cellular signalling. Specifically, the experiments sought to determine: 1) whether CFTR 
is expressed and constitutively active in HLMVEC, 2) whether CFTR inhibition in HLMVEC 
increases in inflammation (IL-8) and oxidative stress (H2O2 generation), and whether it can 
be reversed with the GSH pre-cursor, N-acetylcysteine (NAC), and 3) whether inhibition of 
CFTR in HLMVEC interferes with cellular signalling by increasing NF-κB and reducing Nrf2 
expression. 
Previous cell culture studies have primarily investigated the role of endothelial CFTR in 
static conditions; however, research investigating the role of CFTR in modulating the 
adaptations experienced during shear stress is required. Therefore, Study 4 (Chapter 6) 
aimed to investigate the effect of pharmacological inhibition of CFTR in HLMVEC on 
alignment with flow and alterations of the action cytoskeleton, ET-1 production or NO 
availability. Specifically, the experiments sought to determine: 1) whether CFTR inhibition 
prevents HLMVEC aligning in the direction of flow after 24 h and 48 h of shear stress, 2) 
whether CFTR inhibition causes actin polymerisation in HLMVEC and, specifically, whether 
the actin cortical rim is redistributed to form cytosolic stress fibres, and 3) whether CFTR 
inhibition causes reduced nitrite content and increases ET-1 content of cell culture 
supernatant in response to shear stress. 
A variety of the pathophysiological mechanisms reported throughout this General 
Introduction have been a consequence of CF-related redox disturbances. However, 
whether systematic oxidative stress is observed in vivo has been debated in people with 
CF. Therefore, Study 5 (Chapter 7) aimed to determine whether redox abnormalities are 
present in the blood of people with clinically-stable CF compared to non-CF control 
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participants. Specifically, the experiments sought to determine: 1) whether blood markers 
of antioxidant status are lowered in people with clinically-stable CF compared to non-CF 
controls, 2) whether blood markers of oxidative stress are elevated in people with clinically-
stable CF compared to non-CF controls, and 3) whether blood markers of antioxidant status 
or oxidative stress are correlated to clinically-relevant outcomes in people with CF. 
1.5. Hypotheses 
The hypotheses of the present thesis were that aerobic exercise and ventilatory function 
in CF would be modulated by the presence of dysglycaemia and microvascular endothelial 
perturbation in the lung. Furthermore, it is hypothesised that ventilatory inefficiency in CF 
will be a result of functional CFTR regulating inflammation, oxidative stress and cell 
signalling in HLMVEC, and regulating action cytoskeleton remodelling in response to shear 
stress. Given that oxidative stress is a common pathophysiological explanation for these 
hypotheses, it was also hypothesised that biomarkers of oxidative stress will be increased 
and antioxidants decreased in the blood of people with clinically-stable CF. 
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Chapter 2 
 
General Methods 
2.1. Scientific Review and Ethical Approval 
The data presented in Chapters 3 and 4 were exempted from review by a National Health 
Service Research Ethics Committee, as it presents retrospective analyses of de-identifiable 
data collected during a routine clinical assessment at the CF Unit (University Hospital 
Southampton NHS Foundation Trust, UK). 
2.2. Funding 
All studies were supported by funding obtained from the School of Sport, Health & Exercise 
Science, Faculty of Science & Health (University of Portsmouth, UK), the Department of 
Diabetes and Endocrinology at the Queen Alexandra Hospital (Portsmouth Hospitals NHS 
Trust, UK) and/or the National Institute for Health Research Southampton Clinical Research 
Facility (University Hospital Southampton Foundation NHS Trust, UK). 
2.3. Study Participants 
Participants with CF who were of a sufficient stature to cycle on the ergometer (i.e. ≥ 130 
cm) were recruited from the paediatric or adult CF Unit at the University Hospital 
Southampton. Participants had a diagnosis of CF that was based on a clinical picture in 
keeping with CF, elevated sweat [Cl-] (> 60 mmolL−1), and a compatible genotype (366). All 
medications and therapies were continued throughout the study periods and documented 
in a clinical information sheet. There was no limit with regards to the severity of lung 
disease or non-pulmonary co-morbidities of the participants with CF who underwent CPET; 
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however, individuals were excluded from CPET if they were colonised with non-
tuberculosis mycobacterium due to concerns regarding infection control. 
CFRD was diagnosed in accordance with the most recent American Diabetes Association 
positional statement (348). On the morning of OGTT, participants were asked to refrain 
from using any of their glucose lowering therapies. Participants who were fasted overnight 
(≥ 10 h) undertook a 2 h OGTT of 1.75 gkg-1 (to a maximum of 75 g) of Rapilose® OGTT 
Solution (Galen Ltd., Craigavon, UK) during a morning clinic. CFRD was diagnosed if 2 h 
plasma [glucose] was ≥ 11.1 mmolL-1 and confirmed on a separate day by either a repeat 
OGTT, fasting plasma [glucose] ≥ 7 mmolL-1, HbA1c ≥ 48 mmolmol-1 or the presence of 
symptoms linked with diabetes (polyuria and polydipsia). IGT was diagnosed if 2 h plasma 
[glucose] was 7.8-11.0 mmolL-1 or impaired fasting plasma [glucose] was ≥ 6.3 mmolL-1. 
2.4. Infection Control and Safety Procedures 
All infection control procedures were in line with those used as standard clinical practice in 
the Wessex CF Unit (University Hospital Southampton). More specifically, prior to any 
laboratory visit, segregation was ensured in all waiting areas and clinic rooms. All clinical 
appointments lasted approximately 1 h. Between these appointments at the University 
Hospital Southampton, the room was ventilated for ≥ 1 h and all flat surfaces and 
equipment cleaned using antimicrobial wipes (Clinell®, Watford, UK). During appointments 
in the adult CF unit, the room was continuously ventilated at ~120 m3/h using an air purifier 
(IQAir®, Staad, Switzerland). 
Participants were continuously monitored throughout all exercise and recovery periods for 
severe discomfort, dyspnoea or arterial hypoxaemia. SpO2 was assessed on a beat-by-beat 
basis at the fingertip using pulse oximetry (ANAPULSE 100, Surbiton, UK). Exercise tests 
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were terminated if SpO2 dropped below 85%, and supplemental O2 was available if a 
spontaneous recovery in SpO2 was not evident within 30 s of exercise cessation. Medical 
and physiotherapy staff were on hand should they be needed to assist with adverse events.  
2.5. Screening 
The medical history of participants was collected to classify their CF phenotype. A 
physiotherapist or consultant within the multidisciplinary team at the CF unit completed a 
study specific clinical information sheet. This included information regarding CF genotype, 
physical activity, lung function, physical characteristics (e.g. clubbing), pancreatic 
sufficiency status, pathogens in sputum, smoking status, pregnancy status, medical 
imaging, liver disease status, glycaemic control, renal function, medications, dietetic review 
and airway clearance methods. 
2.6. Familiarisation 
Prior to undertaking CPET, participants were familiarised with the experimental techniques 
to ensure they understood what the testing involved. In particular, the participants were 
familiarised with performing spirometry to ensure the appropriate guidelines (see section 
2.8) could be achieved within the time constraints of the testing session. Furthermore, the 
practitioner thoroughly explained the scales to determine subjective ratings of perceived 
exertion (RPE) and dyspnoea (RPD). Furthermore, appropriate adjustments were made to 
the cycle ergometer seat, handlebars, and pedal cranks and recorded for subsequent visits 
(Figure 2.1). Participants were then familiarised with exercising on a cycle ergometer with 
a facemask to avoid hyperventilation at the beginning of the CPET, as well as keeping a 
consistent cadence of 60-80 rpm during incremental exercise. Participants were free to 
withdraw at any time. 
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2.7. Age and Anthropometry 
Decimal age was calculated to the nearest 0.1 y as the difference between the participant’s 
date of birth and the date of CPET (416). Measurements of anthropometry were taken by 
the same researcher throughout, with the participant wearing shorts/leggings and a t-
shirt/vest. Footwear was removed and participants were instructed to empty their pockets 
prior to measurements. 
Body mass was measured to the nearest 0.1 kg using electronic weighing scales (Salter® 
9073, Kent, UK). Stature was measured to the nearest 1.0 cm using a stadiometer (Seca®, 
Hamburg, Germany). Participants were instructed to stand upright with their heels against 
the stadiometer, feet together and looking forward. BMI was calculated using the following 
equation: 
 BMI = body mass (kg) / stature (m)2                          Equation 2.1. 
2.8. Pulmonary Function Assessment 
Pulmonary function was assessed using a flow-volume spirometer (MicroLab MK8, 
CareFusion, CA, USA), according to the British Thoracic Society guidelines (63). To perform 
spirometry, participants were sitting down and then instructed to place their lips tightly 
around an antibacterial mouthpiece and were provided with a single-use nose clip. 
Participants were instructed to perform 3 ‘normal’ breaths into the mouthpiece, and then 
to subsequently take a deep breath in, immediately followed by a maximal ‘blow out’ until 
no further air could be exhaled and the practitioner told them to breathe back in (³ 5 s). 
FEV1 and FVC were determined as the highest of three consistent (≤ 5% variability) 
manoeuvres and presented as a percentage of the Global Lung Function Initiative reference 
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values (416). These values provide age-, height-, sex- and ethnicity-specific reference values 
derived from a database of 97,759 healthy non-smokers (55.3% females) aged 2-95 y of age 
(416). Lung disease classifications were in accordance with Global Initiative for Chronic 
Obstructive Lung Disease guidelines (6), whereby mild (FEV1: ≥ 80% predicted), moderate 
(FEV1: 50-79% predicted), severe (FEV1:  30-49% predicted) and very severe (FEV1: < 30% 
predicted) airflow limitations were defined. 
2.9. Exercise Testing Procedures 
Participants were instructed to arrive at exercise testing sessions in a rested and hydrated 
state, ≥ 2 h postprandial and having avoided consuming caffeine. They were also asked not 
to participate in exhaustive exercise within the 24 h prior to exercise testing. 
2.9.1. Equipment 
All exercise was performed on a cycle ergometer (Lode Corival, Groningen, The 
Netherlands). This cycle ergometer has a digital screen which displayed cadence (in rpm) 
throughout all exercising procedures. Participants were instructed to keep this number 
between 60-80 rpm during all familiarisation and experimental procedures.   
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Figure 2.1. A figure of: A) the Lode Corival cycle ergometer and B) the set-up for CPET. 
2.9.2. Measurements of pulmonary gas exchange and ventilation 
A portable metabolic gas exchange and ventilation analyser (K5, COSMED, Rome, Italy) was 
used to measure breath-by-breath V̇O2, V̇CO2 and V̇E. Prior to each test, the gas analyser 
was calibrated using gases of a known concentration (approximately 15% O2 and 5% CO2) 
and a 3 L calibration syringe (COSMED, Rome, Italy). The same gas analyser was used for all 
studies within this thesis to ensure that no between equipment variances could influence 
the results from CPET. When calibrated according to the manufacturer’s 
recommendations, the accuracy of measuring volume and gas fractions are 1.6% for V̇O2 
and 2.2% for V̇CO2 when compared to a VacuMed simulator (CA, USA)  at various metabolic 
rates (24). Within this study (24), the reliability of the K5 system was determined at each 
metabolic rate by repeating the simulation 6 times, whereby the inter-class correlation 
coefficients all ranged between 0.98 – 1.00.  
The data collected using this analyser was subsequently used to calculate ventilatory 
equivalents (V̇E/V̇O2 and V̇E/V̇CO2) and the RER: 
Laptop with  
Omnia Software 
Lode Corival 
Cosmed K5 
Facemask 
A B 
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 V̇E/V̇O2 = V̇E (in Lmin-1) / V̇O2 (in Lmin-1)                          Equation 2.2. 
 V̇E/V̇CO2 = V̇E (in Lmin-1) / V̇O2 (in Lmin-1)              Equation 2.3. 
 RER = V̇CO2 (in Lmin-1) / V̇O2 (in Lmin-1)             Equation 2.4. 
2.9.3. Measurements of HR and SpO2 
HR was measured continuously during exercise on a beat-to-beat basis by telemetry 
(Premium H Monitor, Garmin, KS, USA). Fingertip SpO2 was measured on a beat-by-beat 
basis by pulse oximetry (ANAPULSE 100, Surbiton, UK).  
2.9.4.  Measurements of RPE and RPD 
RPE were measured at baseline, exhaustion and 1 min intervals during exercise using the 
Borg 6-20 (50) for adults and the Pictorial Children’s Effort Rating Table (578) for those < 
16 y of age. RPD was measured at baseline, exhaustion and 1 min intervals during exercise 
using the 0-10 category-ratio scale (50). Furthermore, the Dalhousie dyspnoea scale (405) 
was measured at baseline and exhaustion in all participants regardless of age. Since gas 
exchange and ventilation parameters were being concurrently measured, participants 
were asked not to speak, but instead point at the number denoting their RPE and RPD. 
2.9.5. CPET 
All studies in this thesis utilised a combined ramp incremental and Smax CPET protocol 
previously used in children and adolescents with mild to moderate CF (453, 454). Following 
a 3 min warm-up (20 W), resistance was increased incrementally using a continuous ramp 
protocol by a pre-determined rate of 10-25 Wmin-1 (based on sex, age, height/body mass 
and spirometry), aiming to achieve a recommended test duration of 8-12 mins (69). 
Participants were required to maintain a self-selected cadence between 60-80 rpm and 
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were instructed to keep this consistent throughout the tests until volitional exhaustion. 
Volitional exhaustion was defined as a drop in cadence of ≥ 10 rpm for 5 s despite verbal 
encouragement. A 5 min cool-down (20 W) and 10 mins of seated rest then preceded Smax. 
Smax consisted of a 3 min warm-up (20 W), followed by a ‘step’ transition to a constant 
work-rate bout at an intensity equivalent to 110% of the Wpeak achieved during the ramp 
incremental phase. Participants were required to maintain the cadence requirements 
outlined above until exhaustion, at which point a 5 min active recovery (20 W) period 
concluded CPET. 
A maximal effort during CPET was accepted if the participant achieved a plateau in V̇O2 
despite an increasing work-rate or their achieved V̇O2peak during Smax did not exceed the 
V̇O2peak achieved during the ramp test by ≥ 9%, which represents the short-term reliability 
of this protocol in children and adolescents with mild to moderate CF (454). Given that no 
CPET and Smax reproducibility data is available in adults with CF, this threshold was used in 
all subsequent analyses. In Chapter 3, secondary criteria were used to verify a maximal 
effort had been provided in the absence of a V̇O2 plateau. In-line with recent guidelines 
from the ECFS Exercise Working Group (217), a maximal effort was satisfied if the 
participant achieved one of the following: predicted V̇O2peak (385); predicted Wpeak (189, 
255); predicted HRmax  (155, 439); V̇E ≥ 80% of predicted MVV (489, 555); RER ≥ 1.03 for 
children and adolescents or 1.05 for adults, or RPE of ≥ 9 for participants < 16 y of age or ≥ 
17 for participants ≥ 16 y of age. 
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2.10. Determination of Exercise Parameters 
2.10.1. %̇O2max 
Figure 2.2. The process of determining whether a plateau in V̇O2 has been achieved. A) A scatterplot is 
created, plotting work rate (W) x V̇O2 (Lmin-1), B) a linear regression line is plotted through the linear portion 
of the work rate x V̇O2 response, C) the linear regression line is extrapolated to the end of the test (165 W in 
this case), and D) residuals are assessed to determine whether or not a V̇O2 plateau was achieved. In the 
present example, a V̇O2 plateau was evident as the result was -5.30 residuals.  
The primary criteria for the determination of V̇O2max is a plateau in V̇O2 despite an 
increasing work rate, which is determined using methodology previously described 
elsewhere (31, 434, 453). Specifically, V̇O2 and power output data were interpolated to 15 
s averages and exported to GraphPad Prism (California, USA) for analysis. Data was 
subsequently plotted on a scattergraph, with each point representing a 15 second average 
for power output x V̇O2 (Figure 2.2A). A linear regression line was subsequently positioned 
from 120 s following the start of the ramp test to 180 s prior to volitional exhaustion and, 
A B 
C 
D 
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in some cases, altered to ensure the regression line encaptured the linear portion of the 
power output x V̇O2 response (Figure 2.2B). This linear regression line was subsequently 
extrapolated to exhaustion (Figure 2.2C), and, the residuals from the extrapolated 
regression line during the final 60 s of the test were interpreted. A V̇O2 plateau was 
accepted if the average of the residuals during the final 60 s w as ≤ -5 residuals (Figure 
2.2D).  
Upon exhaustion during a maximal ramp incremental test, 3 responses can be noted: an 
acceleration, deceleration or linear V̇O2 response from the extrapolated line (409). A V̇O2 
deceleration was accepted as a plateau if the average of the residuals during the final 60 s 
was ≤ -5 residuals. Whereras, a significant acceleration in the V̇O2 response during the final 
stages of exercise was noted if the average residuals were ≥ 5 residuals.  
 
Figure 2.3. Example profiles of a A) deceleration, B) linear, and C) acceleration of V̇O2 response upon 
exhaustion during a ramp incremental cycling test.  
A B 
C 
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Given that a V̇O2 plateau is not commonly observed in paediatric or clinical populations the 
Smax phase is required to determine V̇O2max when a plateau is not present (409). Indeed, the 
additional phase tests the theory that V̇O2max occurs when a failure of the respiratory, 
cardiovascular and/or muscular systems mean that V̇O2 does not increase despite an 
increased work rate (409). A measurement of V̇O2max was accepted if Smax-V̇O2peak did not 
exceed ramp-V̇O2peak by > 9%. This threshold represents the within-subject variability of 
V̇O2max in children and adolescents with CF using this combined CPET protocol (454); 
however, since no published data exists for adults this was the most relevant threshold to 
apply to the data presented hereon. 
2.10.2. GET 
The GET was determined using the V-slope method (35) and confirmed using ventilatory 
equivalents. Specifically, V̇O2 (in Lmin-1) was plotted against V̇CO2 (in Lmin-1). The V̇O2 
value which indicated the GET was the first value whereby there was a break in linearity in 
the V̇O2 x V̇CO2 response to incremental exercise.  
 
Figure 2.4. The determination of the GET using the V-slope method (35). The GET is determined at the first 
point in which V̇O2 increases at a disproportionate rate compared to V̇CO2; therefore, breaking linearity of 
the V̇CO2/V̇O2 relationship. 
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This data point was then verified as the GET by plotted the ventilatory equivalents (V̇E/V̇O2 
and V̇E/V̇CO2 (in Lmin-1) x time). The first point whereby V̇E/V̇O2 increased with no increase 
in V̇E/V̇CO2 was indicative of the GET, and subsequently compared to the GET value 
obtained using the V-slope method (35). 
The HR and power output values at the time point the GET was achieved were subsequently 
noted. The determination of the GET was completed independently by two experienced 
exercise physiologists trained in such determination. If there was a disagreement in the 
determination of the GET, a third exercise physiologist adjudicated.  
2.10.3. %̇O2-gain  
The functional V̇O2-gain (ΔV̇O2/ΔWR) was determined by plotting a linear regression line 
through the linear portion of the work rate x V̇O2 response. The linear portion of the work 
rate x V̇O2 response was determined as described previously (see section 2.10.1).  
The decision was verified by independent visual observation of the data by two trained 
exercise physiologists. A normative V̇O2 gain was taken as ≥ 9.9 mLmin-1W-1 for males and 
≥ 9.3 mLmin-1W-1 for females < 18 y (213), or ≥ 9.8 mLmin-1W-1 for males and ≥ 8.5 
mLmin-1W-1 for females ≥ 18 y (4), as recommended by the ECFS Exercise Working Group 
(217).  
2.10.4. Ventilatory drive 
The ventilatory drive, or ∆V̇E/∆V̇CO2, was determined by plotting a linear regression line 
through the power output x V̇E/V̇CO2 response up to the respiratory compensation point 
(RCP; denoted as the second inflection of the V̇O2 x V̇CO2 response) (499). A V̇/Q̇-mismatch 
was considered evident if ∆V̇E/∆V̇CO2 was ≥ 34 (499).  
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2.10.5. O2 pulse  
The O2 pulse, or V̇O2/HR, was determined by a standard equation (217): 
V̇O2/HR (mLbeat-1) = V̇O2 (in mLmin-1) / HR (beatsmin-1)            Equation 2.5. 
This equation has recently been validated for use at baseline and peak exercise in adults 
with mild-to-moderate CF when compared to the acetylene rebreathing technique (542). 
2.11. Human Cell Culturing 
Primary HLMVEC (Lonza, Basel, Switzerland; catalogue number CC-2527) were used during 
early passages (3-9), as later passaged (28-32) endothelial cells are shown to have a 
differential responsiveness to shear stress (110). Cells were grown in EGM-2 MV full growth 
medium (FGM) (CC-3202), which consisted of basal medium (CC-3156) and supplemental 
EGM-2 MV (CC-4147). The supplemental media consisted of a final concentration of the 
following: 5% (v/v) fetal bovine serum (FBS), 0.4% (v/v) hydrocortisone, 4% (v/v) human 
fibroblast growth factor (hFGF-B), 1% (v/v) VEGF, 1% (v/v) R3-IGF-1, 1% (v/v) ascorbic acid, 
1& (v/v) human epidermal growth factor (hEGF) and 1% (v/v) gentamycin and amphotericin 
B (GA-1000). 
In addition to HLMVEC, a human bronchial epithelial cell line (the highly CFTR expressing 
16HBE cell line (103)) and a human embryonic kidney cell line (HEK293 that does not 
express CFTR (135)) were used as a positive and negative control, respectively. HEK293 and 
16HBE cells were cultured in Minimum Essential Medium Eagle (MEM) or Dulbecco's 
Modified Eagle Medium (DMEM), respectively; supplemented with 10% (v/v) FBS, 1% (v/v) 
penicillin-streptomycin and 1% (v/v) L-glutamine. Cell lines were maintained until passage 
30.  
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2.11.1. Seeding cells 
Cells were stored in liquid nitrogen. Prior to thawing the cells, 10 mL of FGM was added to 
the 75 cm2 flasks (Fisherbrand™, Loughborough, UK) and incubated at 37oC and 5% CO2 for 
10 mins. Cells were thawed in a 37oC water bath for 1-2 mins then seeded in the 75 cm2 
flask(s) at a density of 5 x 103 viable cells per cm2; whereby, cell viability was assumed to 
be 60%. Cells were incubated at a temperature of 37oC and 5% CO2, and FGM was changed 
24 h after the initial seeding, and every 48 h thereafter, until the cells achieved 90% 
confluence (Figure 2.5). 
Figure 2.5. HLMVEC at varying degrees of confluence. A) < 10% confluence after 24 h of incubation, B) 50% 
confluence after 3 d of incubation, C) 70% confluence after 5 d of incubation, and D) 90% confluence after 6 
d of incubation. Images were captured at 10x magnification. 
D 
A B 
C 
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2.11.2. Passaging and subculturing cells 
Once the cells reached 90% confluence, they were either passaged into experimental plates 
or split between multiple 75 cm2 flasks. To do this, media was removed and adhered cells 
were washed twice with 5 mL of 1x phosphate-buffered saline (PBS; -Ca/Mg; 2.7 mM KCl, 
1.5 mM KH2PO4, 136.9 mM NaCl, 8.9 mM Na2HPO47H2O; pH 7.1-7.5) (10x DPBS Gibco), to 
ensure the removal of FGM and FBS that contains protease inhibitors. Following this, 5 mL 
of 1x trypsin-EDTA (Sigma, Tokyo, Japan) prepared in PBS (-Ca/Mg) were added to the flasks 
for 2-3 mins, with gentle tapping of the flasks against the bench top to encourage 
detachment of cells. Cells were checked every 30 s under the inverted microscope and, 
once 90% of cells were detached, 2 mL of FBS (Sigma, Tokyo, Japan) was added to inhibit 
trypsin activity. The cell suspensions were transferred to 15 mL Falcon tubes and 
centrifuged at 200 g for 5 mins. The clear supernatant was subsequently removed, and the 
cell pellet was re-suspended gently in 1 mL of FGM, which had been warmed to 37oC. 
To ensure the correct density of cells were seeded to the experimental plates and/or flasks, 
10 μL of the cell suspension was added to 90 μL of 0.4% Trypan Blue (Sigma, Tokyo, Japan) 
and re-suspended. 10 μL of this cell suspension was then loaded into a haemocytometer 
chamber, and cells were counted according to the following equation: 
Cells per mL = mean n of 2 counts of cells in a 25 squared grid x 10 (dilution factor) 
x 104 (factor)                                    Equation 2.6. 
Cells were then either split into further 75 cm2 flasks at the density described in Table 2.1, 
or were divided into either 6-well or 96-well plates (Table 2.1). 
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Table 2.1. Number of cells seeded and volume of FGM required for flasks and plates. 
Type of seeding Seeding density of cells Volume of FGM required 
75 cm2 flask 37.5 x 104 cells/flask 10-15 mL 
6-well plate 25 x 104 cells/well 2 mL 
6-well plate w/ silicon disk 25 x 104 cells/well 1 mL 
96-well plate 8 x 103 cells/well 0.1 mL 
 
2.11.3. Cryopreservation of cells 
Cells were lifted from 75 cm2 flasks as described during the passaging protocol (see section 
2.11.2). After counting the cells, they were subsequently re-centrifuged and then 
suspended in freezing medium, which consisted of: 80% (v/v) FGM, 10% (v/v) FBS and 10% 
(v/v) dimethyl sulfoxide (DMSO; Sigma, Tokyo, Japan). Cells were then transferred to 2 mL 
cryovials at a density of 1 x 106 cells per 1 mL of freezing medium, which were stored 
overnight at -80oC in a Mr. Frosty (ThermoFisher, MA, USA), and then transferred to liquid 
nitrogen the following day.  
2.11.4. Collagen IV coating of plates 
Endothelial cells in vivo adhere to an extracellular matrix that is rich in various proteins, 
named the basement membrane (305). One of the most abundant basement membrane 
proteins is collagen type IV (516). Therefore, all experimental plates were coated with a 
thin layer of human placental collagen IV (Sigma, Tokyo, Japan) prior to the seeding of cells. 
The collagen was prepared by dissolving 5 mg of collagen IV into 1 mL of 3% acetic acid for 
1 h at room temperature. This mixture was then further diluted into 50 mL of 3% acetic 
acid to give a final concentration of collagen IV of 0.1 mg/mL. Collagen IV was used on 3 
separate occasions and stored in a 4oC fridge between uses. 
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Collagen IV was dispensed into the wells at the volumes outlined for FGM in Table 2.1, left 
for 2 h at room temperature and then removed. The wells were left to dry for 1 h, also at 
room temperature, then washed 3 times with basal media that contains phenol red to 
ensure all of the acid was removed from the wells. Following this, wells were also washed 
with 70% ethanol and then left to dry completely at room temperature, often overnight. 
Plates coated in collagen IV were stored in 4oC until use.  
2.11.5. Shear stress manipulations 
A Digital Orbital Shaker (Crystalgen Inc., NY, USA) was placed inside the CO2 incubator and 
cells were exposed to 8 h, 24 h or 48 h of orbital shaking, or a static control condition. For 
these manipulations, cells were seeded in collagen coated 6-well plates (as per Table 2.1), 
that had an adhesive silicone disk attached to the centre of the well to avoid cell adherence. 
Cells were left to attach for 24 h, after which the silicon disk was removed and cells were 
treated with 2 mL of either GlyH-101 (20 μM), TNF-α (10 ng/mL, PeproTech, London, UK) 
or a vehicle control (0.1% DMSO). Cells were subsequently exposed to 8 h, 24 h or 48 h of 
static incubation or orbital shaking at a speed of 220 rpm. This speed was selected in line 
with previous research (110), that demonstrated orbital shaking at a speed of 220 rpm 
resulted in a flow rate of 11.1 dynecm2 in the peripheries of the well. Notably, 220 rpm 
results in only 4.8 dynecm2 of flow in the centre of the well (110); therefore, a silicon disk 
was used to avoid cellular adhesion to the centre of the well and all images for 
immunocytochemistry were taken from the periphery of the well. 
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2.12. Biochemistry 
2.12.1. CFTR activity assay 
CFTR activity was measured using the FLIPR Blue (Molecular Probes, OR, USA) membrane 
potential assay, according to the manufacturer’s instructions (316) in HLMVEC, 16HBE and 
HEK293. Cells were seeded into 96-well collagen IV coated optical-bottom black 96-well 
plates, and cultured for 48 h, with FGM being changed after 24 h. A schematic of the 
experimental protocol is presented in Figure 2.5. 
Figure 2.6. A schematic overview of the protocol for the FLIPR blue assay timeline. Fk, Forskolin, IBMX, 3-
isobutyl-1-methylxanthine. 
The FLIPR probe contains bis-barbituric acid oxonols and a blue lipophilic quencher dye, 
which enters the cell under circumstances of depolarisation and binds to intracellular 
proteins or membranes, thus contributing to greater fluorescence (316). Indeed, increased 
fluorescence in indicative of enhanced depolarisation (i.e. activation of CFTR) and reduced 
fluorescence is indicative of hyperpolarisation (i.e. inhibition of CFTR) (Figure 2.6). To 
prepare the FLIPR Blue probe, 5 mL of FGM was added to the vial containing FLIPR Blue and 
mixed well. Subsequently, a further 5 mL of FGM was added and kept at room temperature 
until use. To initiate the assay, 100 μL of FLIPR blue was added directly to the well that 
already contained 100 μL of FGM. The 96-well plates were read in a Spextramax i3 
(Molecular Devices, CA, USA) fluorometric plate reader at baseline and 2 mins following 
Time = 0 min
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FLIPR blue
Time = 25 min
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fluoresence 
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Time = 30 min
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the addition of the CFTR activators and inhibitors, with fluorescence measurements taken 
at an excitation wavelength of 530 nm and an emission wavelength of 565 nm.  
Figure 2.7. A schematic diagram of CFTR activation using a Fk/IBMX-cocktail. Fk enters the cell via the B2R 
receptors and directly activates adenyl cyclase, which increases cAMP content (241). However, under 
conditions of increased cAMP content, cAMP is inactivated enzymatically to AMP by hydroxylation with PDE 
complexes; notably, this process is limited in the presence of IBMX which is a nonspecific PDE inhibitor. 
Therefore, in the presence of both Fk and IBMX the cell is significantly depolarised in a cAMP-dependant 
pathway, i.e. increasing Cl- efflux by CFTR, and increasing the uptake of the FLIPR Blue probe resulting in a 
greater degree of fluorescence.  
Thirty mins following the addition of the FLIPR Blue probe and 5 mins following a baseline 
read, cells were treated with the reversible, voltage-dependent CFTR chloride channel 
blocker (547), GlyH-101 (20 μM, 0.1% DMSO) or 0.1% (v/v) DMSO in FGM as a control 
solution (Figure 2.6). Additionally, cAMP-regulated ion channels were strongly activated 
using a cocktail of Fk and IBMX (Figure 2.7) (179). Final concentrations of 100 μM Fk (0.2% 
DMSO) and 1,000 μM IBMX (0.2% DMSO) were used, and a 0.2% (v/v) DMSO in FGM 
solution was used as a control. 
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2.12.3. Supernatant processing 
Cell supernatant (2 mL) was extracted, harvested and cleared by centrifugation at 1500 x g 
for 10 mins at 4oC. Acellular supernatant was then frozen and stored at -80oC for future 
analysis.  
2.12.4. Supernatant ET-1 content 
Supernatant [ET-1] was measured by a commercially available Endothelin Pan Specific 
ELISA Kit (DY1160; Abcam, Cambridge, UK) with ET-1 standards. Samples were diluted 1:2 
before loading to the plates and data was transformed to concentration according to the 
standard ranging from 3.91-250 pg/mL. The ELISA was performed as per the 
manufacturer’s instructions. 
2.13. Immunocytochemistry 
2.13.1. Crystal violet staining 
To detect cellular morphology following orbital shaking, cells were stained with crystal 
violet (Sigma-Aldrich, MO, USA), which is a triarylmethane dye that binds to DNA in the 
nuclei. HLMVEC were washed with 2 mL/well of PBS (-Ca/-Mg), and subsequently fixed with 
2 mL/well of fresh 4% paraformaldehyde (in PBS [-Ca/-Mg]) for 2 mins. The 4% 
paraformaldehyde was then removed and cells were washed twice with 2 mL/well of PBS 
(-Ca/-Mg). Cells were then stained with 1 mL/well of 0.125% (w/v)  crystal violet (in UHQ) 
for 10 mins. The 0.125% crystal violet was then removed and cells were washed thrice with 
2 mL/well of PBS (-Ca/-Mg).  
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Figure 2.8. ImageJ was used for the 4-step process of converting the crystal violet images from A) an RGB 
image, to B) an 8-bit grey-scale image. The 8-bit grey-scale image was then converted to C) a binary image 
and D) cell outlines were highlighted and included if they were ≥ 200 pixels in size. Cells on the boundary of 
the image were excluded. Images were captured at 10x magnification. 
Data was collected from 3 independent experiments for each time point. HLMVEC were 
imaged in the periphery of the well where flow was horizontal or vertical, in duplicate, at a 
magnification of 10x. ImageJ software (National Institute for Health) was used to quantify 
changes in cellular morphology (Figure 2.8). Specifically, RGB images were converted to 
grey scale (8-bit) and made binary. The direction of alignment was quantified by identifying 
the angle formed by the longest axis of the nucleus (Feret’s Diameter) with the abscissa 
axis (Feret’s Angle) (165, 515). The Feret’s Angle ranges from 0-180o and a reduced variance 
A B 
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of the Feret’s angle within an image of > 500 cells was indicative of a greater alignment 
with flow. 
2.13.2. F-actin staining 
HLMVEC were washed with 2 mL/well of PBS (-Ca/-Mg), and subsequently fixed with 2 
mL/well of fresh 4% paraformaldehyde (in PBS [-Ca/-Mg]) for 10 mins. The 4% (w/v) 
paraformaldehyde was then removed and cells were washed twice with 2 mL/well of PBS 
(-Ca/-Mg). Cells were then permeabilised with 2 mL/well of 0.1% Trition X-100 (in PBS [-
Ca/-Mg]) for 5 mins. The 0.1% Trition X-100 was then removed and cells were washed twice 
with 2 mL/well of PBS (-Ca/-Mg). Cells were then incubated at room temperature in 660 
μL/well of 100 nM of Rhodamine Phalloidin (ThermoFisher; in 1% BSA prepared in PBS [-
Ca/-Mg]) for 20 mins, followed by an additional washing step with PBS (-Ca/-Mg) and, 
subsequently, cells were co-stained with 1 mL/well of 5 μg/mL Hoechst 33342 (Molecular 
Probes, OR, USA) for 10 mins.  
Data was collected from 3 independent experiments at each time point. HLMVEC at the 
periphery of the well were imaged in triplicate at a magnification of 20x. ImageJ was also 
used to quantify Rhodamine Phalloidin and Hoechst 33342. Specifically, RGB colour images 
were converted to a RGB stack; red fluorescence was measured between 20-255 
thresholds, whereas blue fluorescence was measured between 40-255 thresholds (Figure 
2.9). RawIntDen of red was expressed relative to RawIntDen of blue to quantify total F-
actin relative to the quantity of the cells within the image. 
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Figure 2.9. ImageJ was used for the process of measuring raw integrated density (RawIntDen) for Rhodamine 
Phalloidin and Hoechst 33342. RGB stack images of A) Rhodamine Phalloidin and B) Hoechst 33342, were 
analysed for RawIntDen of C) F-actin (red fluorescence) between a 20-255 threshold and D) cell nuclei (blue 
fluorescence) between a 40-255 threshold. Images were captured at 20x magnification. 
2.14. Statistical Analyses 
Statistical analyses were performed using either SPSS® v.24 (IBM, IL, USA), Graphpad Prism 
v.8 (GraphPad Software, Inc., CA, USA) or Revman v.5.3 (Cochrane, London, UK). Data was 
tested for normality and expressed as mean ± standard deviation (SD; in vivo human data), 
mean ± standard error of the mean (SEM; in vitro cell culture data), or standardised mean 
differences (95% CI; meta-analysis data) (225) accordingly. The statistical tests used were 
dependent upon the data collected; however, statistical significance was accepted as α = 
0.05.  
A B 
C D 
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3.1. Abstract 
Introduction: The validity and safety of using Smax to confirm a maximal effort during CPET 
in people with CF and/or those with severe disease has been questioned. Therefore, this 
study aimed to investigate these concerns in children, adolescents and adults with mild-to-
severe CF lung disease. Methods: Retrospective analysis of 17 pediatric and 28 adult 
participants with CF (age range: 9.2-62.9 y; forced expiratory volume in 1 s: 66.7% [range: 
29.9-102.3%]; 30 males) who completed a routine ramp incremental cycling test to 
determine V̇O2peak. V̇O2max was subsequently confirmed by Smax at 110% of Wpeak. Results: 
All participants satisfied the criteria to verify a maximal effort during CPET. However, Smax-
V̇O2peak exceeded ramp-V̇O2peak in 3/14 (21.4%) of pediatric and 6/28 (21.4%) adult exercise 
tests. A valid measurement of V̇O2max was attained in 85.7% of pediatric and 96.4% of adult 
exercise tests, as Smax-V̇O2peak did not exceed ramp-V̇O2peak by > 9%. Nine adults 
experienced a ≥ 5% reduction in arterial O2 saturation during CPET; 4 during both the ramp 
and Smax, 3 during only the ramp and 2 during Smax only. Smax did not significantly worsen 
perceived breathing effort, chest tightness, throat narrowing or exertion compared with 
ramp incremental testing. Conclusions: Given the clinical importance of aerobic fitness in 
people with CF, incorporating Smax is recommended to provide a safe and valid measure 
of	V̇O2max in children, adolescents and adults who span the spectrum of CF disease severity.  
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3.2. Introduction 
CPET is an important health-related assessment for chronic respiratory diseases (389), such 
as CF (217). In people with CF, a higher aerobic fitness status V̇O2peak is associated with an 
improved quality of life (221), a reduced risk of being hospitalized with pulmonary 
exacerbation (397) and a better prognosis (402). Maximal and submaximal indices of 
aerobic fitness are also used to evaluate the effectiveness of therapeutic interventions 
(415), such as lung transplantation (377, 509) or pharmaceutical treatments (147, 455). 
Given the growing clinical importance of CPET, debate continues regarding the most 
appropriate protocol to determine aerobic fitness in different populations with 
cardiorespiratory disease. 
A recent Cores of Reproducibility in Physiology expert statement refuted the utility of 
V̇O2peak (i.e. the highest V̇O2 value obtained during a single exercise test, which is verified 
as ‘maximal’ using secondary criteria) as a measure of aerobic fitness (409). The 
measurement of V̇O2peak during a single incremental test is said to result in an inaccurate 
surrogate of aerobic fitness (409). It is well documented that the criteria to verify a maximal 
effort during incremental exercise testing can be achieved at submaximal V̇O2 values, 
subsequently resulting in the practitioner wrongly accepting a submaximal V̇O2peak as 
maximal, with evidence demonstrating this in children and adolescents with mild-to-
moderate CF (453, 564), as well as healthy children, adolescents and adults (31, 410, 434). 
Instead, the Cores of Reproducibility in Physiology statement recommends that aerobic 
fitness should be characterized by determining V̇O2max (i.e. the upper limit of the body’s 
ability to uptake, transport or utilize O2) (409), which can be achieved using a post-
incremental Smax phase (performed at an intensity > 100% Wpeak) (31, 410, 434, 453, 454, 
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564). Whilst the benefits of incorporating Smax into CPET protocols are well documented 
(199, 409), some questions regarding its utility in a clinical setting (199), including those 
with CF (218),  have been raised.  
The recent statement on exercise testing from the ECFS Exercise Working Group 
recommends a single-stage incremental cycling protocol to determine V̇O2peak. However, 
this statement occluded data demonstrating that a valid and reproducible measurement of 
V̇O2max was achievable in pediatric groups with mild-to-moderate CF (453, 454, 564). It is 
important to note that the ECFS Exercise Working Group have more recently acknowledged 
the current body of evidence supporting the use of Smax as a means to confirm V̇O2max in 
people with CF (453, 454, 564) and have subsequently called for research to investigate the 
safety and feasibility of Smax in adults with CF and/or those with severe lung disease (218).  
This study was therefore designed to retrospectively investigate the safety and validity of 
a combined ramp incremental and Smax CPET protocol across the spectrum of CF severity. 
It was hypothesized that in both pediatric and adult groups with mild-to-severe CF: (1) a 
plateau in V̇O2 upon exhaustion would rarely occur during ramp incremental exercise 
testing, (2) traditional secondary verification criteria would be achieved at a to V̇O2 which 
is less than V̇O2max, and (3) Smax-V̇O2peak would exceed ramp-V̇O2peak by ≥ 9% in individual 
cases. The present study also aimed to determine whether the inclusion of Smax would 
increase the number of significant adverse events versus ramp incremental exercise testing 
alone. 
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3.3. Materials and Methods 
3.3.1. Study Participants and Design 
Individuals attending the pediatric and adult CF services at University Hospital 
Southampton for annual CPET, between July 2017 – January 2018, were included. All 
participants had a diagnosis of CF based on a clinical picture in keeping with CF, elevated 
sweat chloride levels and a compatible genotype (366). CPET with Smax is standard practice 
within our center and this study presents a retrospective analysis of de-identifiable data, 
therefore, it was exempted from National Health Service Research Ethics Committee and 
Confidentiality Advisory Group approvals. 
3.3.2. Procedures 
All testing procedures were conducted in an outpatient clinic room, with medical and 
physiotherapy staff on hand. All appointments lasted approximately 1 h. In-between 
appointments, the room was ventilated for ≥ 1 h and all flat surfaces and equipment 
cleaned using antimicrobial wipes. During appointments in the adult unit, the room (35-40 
m3) was continuously ventilated at 120 m3h-1 using an air purifier (IQAir®, Staad, 
Switzerland). 
Pulmonary function was assessed pre- and post-CPET using flow-volume spirometry (3500 
MicroLab Spirometer MK8, CareFusion, CA, USA), in accordance with the British Thoracic 
Society guidelines (63). FEV1 and FVC were determined as the highest of three consistent 
(≤ 5% variability) maneuvres and presented as a percentage of the Global Lung Function 
Initiative 2012 reference values (416). Clinical information was obtained from the 
participant’s most recent clinical assessment (Table 3.1).  
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Our center employs a combined ramp incremental and Smax CPET protocol, previously 
shown to produce a valid and reproducible measurement of V̇O2max in children and 
adolescents with mild-to-moderate CF (453, 454). All exercise was performed on a cycle 
ergometer (Lode Corival, Groningen, The Netherlands). Following a 3 min warm-up (20 W), 
resistance was increased incrementally using a continuous ramp protocol by a pre-
determined rate (10-25 Wmin-1 [based on sex, age, height/body mass and spirometry]), 
aiming to achieve a recommended test duration of 8-12 min (69). Participants were 
required to maintain a self-selected cadence between 60-80 rpm and were instructed to 
keep this consistent throughout the tests until volitional exhaustion. Volitional exhaustion 
was defined as a drop in cadence of ≥ 10 rpm for 5 consecutive seconds despite verbal 
encouragement. A 5 min cool-down (20 W) and 10 mins of seated rest then preceded Smax. 
Smax consisted of a 3 min warm-up (20 W), followed by a ‘step’ transition to a constant 
work-rate bout at an intensity equivalent to 110% of the Wpeak achieved during the ramp 
incremental phase. Participants were required to maintain the cadence requirements 
outlined above until exhaustion, at which point a 5 min active recovery (20 W) period 
concluded CPET. 
Breath-by-breath pulmonary gas exchange and ventilation were measured via a face mask 
and turbine system (K5, COSMED, Rome, Italy). Prior to each test, gas analyzers were 
calibrated using gases of known concentrations and the turbine volume transducer using a 
3 L calibration syringe (COSMED, Rome, Italy). HR was measured on a beat-to-beat basis by 
telemetry (Premium HR Monitor, Garmin, KS, USA). Fingertip SpO2 was measured using 
pulse oximetry. Exercise was terminated if SpO2 dropped ≤ 85%. RPE was measured using 
the Borg 6-20 (50) for adults and the Pictorial Children’s Effort Rating Table (578) for those 
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< 16 y of age. Dyspnea was measured using the 0-10 category-ratio scale (50) throughout 
exercise, as well as the Dalhousie dyspnea scale (405) at baseline and exhaustion. 
3.3.3. Data Analysis 
HR, V̇O2, V̇CO2, V̇E and RER data were interpolated to 15 s averages, and peak values were 
taken as the highest 15 s average achieved during the ramp incremental or Smax phase of 
testing. The presence of a V̇O2 plateau was determined using methodology 
comprehensively described elsewhere (31, 434, 453). In line with recent recommendations 
for people with CF (217), a maximal effort was accepted if one of the following secondary 
criteria were achieved during incremental testing: predicted V̇O2peak (385), predicted Wpeak 
(189, 255), predicted HRpeak  (155, 439), V̇E ≥ 80% of predicted MVV (489, 555), RER ≥ 1.03 
for children and adolescents or 1.05 for adults, or RPE of ≥ 9 for participants < 16 y of age 
or ≥ 17 for participants ≥ 16 y of age. 
A measurement of V̇O2max was accepted if Smax-V̇O2peak did not exceed ramp-V̇O2peak by > 
9%. This threshold represents the within-subject variability of V̇O2max in children and 
adolescents with CF using this combined CPET protocol (454), however, no data exists for 
adults. If available, a V̇O2max value was taken as the highest 15 s average from either the 
ramp incremental or Smax tests. Wpeak was determined as the highest power output 
achieved during the ramp incremental test. The GET was determined using the V-slope 
method (35) and confirmed using ventilatory equivalents for O2 and CO2. Breathing reserve 
was calculated by expressing V̇Epeak as a percentage of predicted MVV (adult MVV (555) = 
FEV1 (in L) x 40; pediatric MVV (489) = (27.7 x FEV1 [in L]) + (8.8 x predicted FEV1 [in L])).  
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3.3.4. Statistical Analysis 
Data were expressed as means ± SD unless otherwise stated. Statistical significance was set 
at α = 0.05. A two-way mixed model ANOVA was used to determine the group x test 
interaction for V̇O2peak, Dalhousie dyspnea ratings and lowest SpO2. Measures of effect sizes 
during ANOVA were reported as partial eta-squared (ƞ2). Bonferroni corrected post-hoc 
paired samples t-tests determined significant differences between measures obtained 
from the ramp incremental and Smax phases of testing. 
Linear regression and Bland and Altman analyses (mean bias and 95% CI) examined the 
agreement between ramp- and Smax-V̇O2peak, as well as ramp-V̇O2peak vs. V̇O2 at secondary 
criteria. Analyses were performed using SPSS v.24.0 (IBM, IL, USA) and GraphPad Prism 
(GraphPad Software, Inc., CA, USA). 
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3.4. Results 
3.4.1. Participant characteristics 
Table 3.1. Group characteristics. 
    Pediatric Adult Range 
Sample size, n 17 28 - 
Age, y 12.9 ± 2.6 31.3 ± 12.1 9.2 – 62.9 
Males, n (%) 12 (70.6) 18 (64.3) - 
Body mass, kg 45.6 ± 14.2 62.4 ± 11.3 26.3 – 91.8 
Height, m 1.53 ± 0.13 1.67 ± 0.90 1.30 – 1.86 
BMI, kg/m2 19.2 ± 3.2 22.3 ± 3.6 15.0 – 33.7 
FEV1, L 2.15 ± 0.85 2.22 ± 0.67 1.18 – 4.07 
FEV1, % predicteda 77.4 ± 15.4 60.2 ± 19.2 29.9 – 102.3 
FVC, L 2.48 ± 0.93 3.38 ± 0.87 1.52 – 5.71 
FVC, % predicteda 82.3 ± 16.0 77.2 ± 14.9 44.5 – 114.7 
Resting SpO2, % 97 ± 2 97 ± 1 92 – 99 
CFTR genotype class, n (%)    
 Class I-III 17 (100) 27 (96.4) - 
 Class IV-V 0 (0) 0 (0) - 
 Unknown  0 (0) 1 (3.6) - 
Chronic P. aeruginosa infection, n (%) 2 (11.8) 21 (75.0) - 
Pancreatic insufficient, n (%) 14 (82.4) 21 (75.0) - 
CF-related diabetes, n (%) 1 (5.9) 11 (39.3) - 
Data are expressed as means ± SD unless otherwise stated. a According to Global Lung Function Initiative 2012 
reference values (416). 
Seventeen pediatric and 28 adult participants (including 15 adult inpatients who were 
admitted for intravenous antibiotics following the development of an acute respiratory 
exacerbation) with CF completed a routine exercise test within the specified time period. 
The present study included participants with severe (n =12), moderate (n = 20) and mild (n 
= 13) lung disease. Additional characteristics of the participants are presented in Table 3.1. 
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Table 3.2. Group characteristics from cardiopulmonary exercise testing. 
 Pediatric Adult Range 
VpO2max, mLkg-1min-1 40.1 ± 6.3 32.0 ± 9.5 18.7 – 59.4 
VpO2max, % predicteda 90.2 ± 19.7 78.1 ± 17.5 54.1 – 138.1 
Ramp-VpO2peak, Lmin-1 1.86 ± 0.70 2.08 ± 0.69 1.00 – 3.91 
Smax-VpO2peak, Lmin-1 1.84 ± 0.72 1.98 ± 0.64 0.99 – 3.73 
VpEpeak, Lmin-1 77.0 ± 24.6 82.2 ± 27.1 41.6 – 152.0 
Breathing reserve, %b 5.4 ± 20.2 4.9 ± 22.8 -38.0 – 44.5 
GET, Lmin-1 1.08 ± 0.41 1.12 ± 0.30 0.56 – 2.08 
GET, % of VpO2max 57.5 ± 5.6 55.0 ± 9.6 29.3 – 74.6 
HRpeak, beatsmin-1 185 ± 14 168 ± 15 138 – 205 
HRpeak, % predictedc 94.7 ± 7.0 92.3 ± 7.5 74.4 – 105.1 
Wpeak, W 135 ± 50 147 ± 56 70 – 300 
Wpeak, % predictedd 94.1 ± 20.5 80.9 ± 21.3 46.9 – 133.2 
Data are expressed as means ± SD unless otherwise stated. VpO2max is reported as the highest value obtained 
during either the ramp incremental or Smax phase of testing. All other parameters were obtained from the 
ramp incremental test only. a According to Orenstein et al. (385) in Lmin-1; b MVV according to Wasserman 
et al. (555) (adult) and Stein et al. (489) (pediatric); c According to Fairbarn et al. (155) (adult) and Rowland et 
al. (439) (pediatric); d According to Jones et al. (255) (adult) and Godfrey et al. (189) (pediatric). 
3.4.2. Safety and feasibility of CPET 
All pediatric and adult participants completed the ramp incremental test, with acceptable 
test durations of 9 mins 46 s ± 2 mins 18 s and 8 mins 54 s ± 2 mins 23 s, respectively. Fifteen 
pediatric (88.2%) and all adult participants completed Smax, with test durations of 76 s ± 22 
s and 105 s ± 36 s, respectively. Two pediatric participants did not complete Smax due to 1) 
parental time restriction and 2) an unwillingness to exercise further following the ramp 
incremental test. Poor signal by telemetry meant that HR data was missing for 4 adults and 
central-line catheters obstructed the detection of HR in 2 adults. HR and pulmonary gas 
exchange and ventilation data were lost for 1 pediatric Smax test due to technical issues. 
RPE was not recorded in 2 individuals (1 adult CPET; 1 pediatric Smax test) due to 
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uncomfortable hyperventilation upon exhaustion which required attention from the 
practitioner running the test. 
Table 3.3. Measures of hypoxemia and perceived discomfort for the ramp incremental and Smax phases of 
CPET.  
 Pediatric Care Adult Care 
 Ramp Smax Ramp Smax 
Lowest SpO2, %                   95 ± 2 96 ± 2 94 ± 4 94 ± 4 
Breathing effort, 1-7 6 ± 1 5 ± 2 5 ± 1 6 ± 1 
Chest tightness, 1-7 4 ± 2 3 ± 2 4 ± 2 4 ± 2 
Throat narrowing, 1-7 4 ± 2 3 ± 2 3 ± 2 3 ± 2 
Perceived exertion, 1-7 6 ± 2 6 ± 2 6 ± 1 6 ± 1 
Data are expressed as means ± SD. Measured of perceived discomfort were measured using the Dalhousie 
dyspnoea scale (405). 
SpO2 values could not be obtained during 1 ramp incremental and 2 Smax tests in the 
pediatric group due to poor signal during exercise. Nine adults (2 inpatients) desaturated 
(≥ 5% drop in SpO2) during CPET; 4 during both the ramp incremental and Smax phases, 3 
during only the ramp incremental test and 2 during Smax only. Supplemental O2 was not 
required as SpO2 spontaneously recovered within 30 s of exercise cessation. Mixed-model 
ANOVA revealed a significant interaction between test (baseline vs. ramp vs. Smax) x group 
(pediatric vs. adult) for SpO2 (p < 0.03, ƞ2 = 0.10). Post-hoc analyses revealed no significant 
differences in the change of SpO2 from baseline to the lowest recorded (ΔSpO2) during the 
ramp incremental versus Smax test in either pediatric (ramp-Smax ΔSpO2: -0.8 ± 3.0%, p = 
0.39) or adult participants (ramp-Smax ΔSpO2: 0.7 ± 2.7%, p = 0.21; Table 3.3).  
Dalhousie dyspnea ratings were only obtained in 7 pediatric and 16 adult exercise tests due 
to a protocol amendment within our center. There were no significant test (ramp vs. Smax) 
x group (pediatric vs. adult) interactions for Dalhousie ratings of breathing effort (p = 0.06, 
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ƞ2 = 0.13), chest tightness (p = 0.13, ƞ2 = 0.08), throat closure (p = 0.39, ƞ2 = 0.03) or exertion 
(p = 0.74, ƞ2 = 0.00; Table 3.3). 
3.4.3. The assessment of '̇O2max and '̇O2peak 
Table 3.4. Primary and secondary criteria for the verification of a maximal effort during ramp incremental 
CPET. 
  Pediatric Adult 
Plateau in VpO2 4 (23.5) 3 (10.7) 
≥ Predicted VpO2peaka 4 (23.5) 4 (14.3) 
≥ Predicted PPOb 7 (41.2) 4 (14.3) 
≥ Predicted HRpeakc 5 (29.4) 4 (18.2) 
VpEpeak ≥ 80% MVVd 13 (76.5) 20 (71.4) 
RER ≥ 1.03e or 1.05f 16 (94.1) 20 (71.4) 
RPE ≥ 9g or 17h 13 (81.3) 24 (88.9) 
Verified maximal effort 17 (100) 28 (100) 
The numbers (percentages) of participants who satisfy each criterion. a According to Rowland et al. (385) in 
Lmin-1; b According to Jones et al. (255) (adult) and Godfrey et al. (189) (pediatric); c According to Fairbarn et 
al. (155) (adult) and Rowland et al. (439) (pediatric); d according to Wasserman et al. (555) (adult) and Stein 
et al. (489) (pediatric); e RER cut-off for children and adolescents; f RER cut-off for adults; g RPE cut-off for 
participants < 16 y of age; h RPE cut-off for participants ≥ 16 y of age.  
CPET parameters are presented in Table 3.2. The mean goodness of fit (R2) for the linear 
portion of the V̇O2 x work-rate response was 0.90 ± 0.06 for pediatric and 0.89 ± 0.10 for 
adult tests.  Smax-V̇O2peak exceeded ramp-V̇O2peak in 3/14 (21.4%) pediatric and 6/28 (21.4%) 
adult tests by 8.8 ± 6.8% (range: 2.2-24.4%; Figure 3.2). Interestingly, the V̇O2peak derived 
from 35.7% of female ramp incremental tests was deemed submaximal when compared to 
Smax-V̇O2peak, whereas only 14.3% of male ramp incremental tests elicited a submaximal 
V̇O2peak. Furthermore, this increase exceeded the 9% threshold previously outlined (454) in 
1 adult and 2 pediatric CPETs, meaning Smax enabled confirmation of a valid measure of 
V̇O2max in 12/14 (85.7%) pediatric and 27/28 (96.4%) of adult exercise tests. Mixed-model 
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ANOVA revealed no significant interaction between test (ramp vs. Smax) x group (pediatric 
vs. adult) for V̇O2peak (p = 0.58, ƞ2 = 0.01). There was a significant positive linear relationship 
between ramp incremental and Smax V̇O2peak values (adjusted R2 = 0.94, p < 0.01). 
3.5. Discussion 
This is the first study to investigate the safety and feasibility of incorporating Smax into 
clinical CPET, and whether incorporating Smax improves the validity of measuring aerobic 
fitness in children, adolescents and adults with mild-to-severe CF. The present 
retrospective data revealed 4 main findings: (1) a V̇O2 plateau upon exhaustion only 
occurred in 23.5% of pediatric and 10.7% of adult ramp incremental cycling tests, (2) a 
submaximal V̇O2peak was reported in 21.4% of both the pediatric and adult ramp 
incremental tests using the currently recommended verification criteria, (3) a valid 
measurement of V̇O2max was attained in 85.7% of pediatric and 96.4% of adult exercise tests 
when Smax was used, and (4) incorporating Smax within CPET did not increase the risk of 
hypoxemia or perceived discomfort compared to standard incremental exercise testing in 
either the pediatric or adult groups, including those with severe CF lung disease. These 
findings support the rationale for determining V̇O2max using Smax, rather than V̇O2peak using 
a single stage protocol and current verification criteria, in children, adolescents and adults 
with CF, both in clinical practice and interventional trials. 
Despite the recent Cores of Reproducibility in Physiology expert statement advocating the 
measurement of V̇O2max rather than V̇O2peak in healthy, athletic and, where possible, clinical 
populations (409), the use of Smax in clinical groups (540), including CF (218), was challenged 
due to concerns regarding its feasibility and added validity within a clinical setting, as well 
as safety in those with more severe disease (218). CPET is achieved in both our pediatric 
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and adult regional CF centers through a weekly clinic with 1 h appointments, testing up to 
4 participants per clinic. In this study, Smax was not feasible in only 2 pediatric participants 
due to parental time restrictions and the unwillingness of 1 adolescent to exercise further 
following their ramp incremental test. To address previous concerns (218), all adult 
participants who underwent CPET were willing and able to successfully complete Smax 
testing.  
From a safety perspective, there were no significant adverse events, however 9 adult 
participants (20.0%) did experience a ≥ 5% drop in SpO2 during combined ramp incremental 
and Smax CPET, with no children or adolescents reaching this threshold. Of these, 4 
participants desaturated during both the ramp incremental and Smax phase, 3 during only 
the ramp incremental and 2 during only Smax phases. The frequency of a drop in SpO2 of ≥ 
5% during CPET with Smax in the present study was, however, no greater than CPET without 
Smax (22.7%) (441). Importantly, the present findings suggest that including Smax does not 
increase the risk of hypoxemia during CPET in people with CF, even those with more severe 
lung disease (FEV1: 29.9-102.3%). Previous reports have shown that cardiac arrhythmias 
can occur in up to 7% of exercise tests in CF (441), however since electrocardiography was 
not included in this study, future studies including this measure during combined ramp 
incremental and Smax protocols would be useful. Incorporating Smax also did not increase 
the participants’ perceived discomfort during CPET (Table 3.4). These findings suggest that 
incorporating Smax into CPET is feasible and readily achievable within a pediatric and adult 
clinical setting. 
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Figure 3.1. Bland-Altman analysis of the agreement between the V̇O2 at the recommended secondary criteria 
to confirm a maximal effort versus VpO2max. a According to Rowland et al. (385) in Lmin-1; b According to Jones 
et al. (255) (adult) and Godfrey et al. (189) (pediatric); c According to Fairbarn et al. (155) (adult) and Rowland 
et al. (439) (pediatric); d According to Wasserman et al. (555) (adult) and Stein et al. (489) (pediatric); e RER 
cut-off of 1.03 for pediatric and 1.05 for adult tests.  
Historically, the primary criterion to confirm V̇O2max was a plateau in V̇O2 despite an 
increasing work-rate (511). However, this is uncommon (434), especially in pediatric and 
clinical populations (453), meaning V̇O2peak is often reported. The observation of a V̇O2 
plateau in only 23.5% of pediatric ramp incremental tests was unsurprising and is in keeping 
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with previous literature, which have reported frequencies of 7.1% (453) and 31.3% (564). 
However, this is the first study to report the frequency of a V̇O2 plateau in adults with CF 
during ramp incremental testing (10.7%), which was substantially lower than the pediatric 
group. Given that a true maximal effort can present as an accelerated, linear or decelerated 
V̇O2 profile upon exhaustion, there is rationale to development methodologies which 
distinguish V̇O2max from V̇O2peak. 
When the currently recommended objective and subjective secondary verification criteria 
were examined (217), 100% of both pediatric and adult ramp incremental tests were 
classified as maximal (Table 3.4). This suggests a valid measure of V̇O2peak had been 
achieved in all participants. Specifically, all participants achieved their respective RPE, RER 
or V̇E/MVV cut-offs indicative of a maximal effort during testing (Table 3.4). However, such 
criteria have previously been shown to falsely classify a submaximal V̇O2peak as maximal in 
children and adolescents with mild-to-moderate CF, by as much as 38.3% (453). In line with 
this, data from the present study (Figure 3.1D) demonstrates that these criteria have a 
mean bias of up to -0.25 Lmin-1 (95% CI: -0.70-0.20 Lmin-1), compared to the groups’ 
highest V̇O2 achieved during either the ramp incremental or Smax tests (i.e. V̇O2max). These 
data suggest that verifying a maximal effort using only a single secondary criteria, as 
recommended by the ECFS Exercise Working Group (217), has the potential to meaningfully 
under-report aerobic fitness in children, adolescents and adults with CF.  
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Figure 3.2. Bland-Altman analysis of the agreement between supramaximal verification recorded V̇O2peak 
versus ramp incremental recorded V̇O2peak, with V̇O2peak expressed (A) as a percentage difference and, (B) in 
absolute terms. 
Our findings demonstrate that Smax identified 21.4% of both paediatric and adult ‘maximal’ 
ramp incremental exercise tests as submaximal, which supports previous evidence in 
children and adolescents with mild-to-moderate CF from the UK and The Netherlands 
(16.6-28.4%) (453, 564). Moreover, we are the first to demonstrate similar findings in adults 
with CF. Interestingly, this frequency is much lower than that observed in healthy 
individuals, whereby 0/38 (0%) of adults aged 19-61 y and 1/13 (8%) of children aged 9-10 
y experienced an increase in V̇O2peak during Smax (31, 115). Interestingly, the frequency of a 
submaximal ramp-V̇O2peak was considerably higher in females compared to males (35.7% 
vs. 14.3%, respectively). Furthermore, the greatest increase in V̇O2peak (+ 24.4%) with Smax 
was reported in a female (26.1 y; 1.57 m; 48.2 kg; FEV1 80.7% predicted). Her ramp 
incremental test was deemed maximal based upon achieving a RER of 1.10 and a RPE of 19 
at exhaustion. Using existing prognostic thresholds (402), her ramp-V̇O2peak (29.1 mLkg-
1min-1), verified with current criteria, would falsely stratify her into the highest risk 
mortality group. However, her Smax-V̇O2peak (36.3 mLkg-1min-1) would place her in the 
median tertile of aerobic fitness, indicating a reduced mortality risk (402). Given that 
Determination of $̇O2max is safely achieved in people with CF 
Page 87 of 300 
 
exercise testing has been advocated to provide prognostic information (389) and to assess 
the effectiveness of therapeutic interventions (415) in CF, even in those with unstable 
disease (377, 420, 463, 509) or receiving intravenous antibiotics (102), obtaining a valid 
measurement of aerobic fitness is essential.  
Although this study included a small heterogeneous cohort from a large regional CF 
network in the South of England, further investigation of the safety and validity of 
combined CPET testing in other international cohorts is warranted to account for different 
lifestyle and environmental factors which may alter the CF phenotype. Furthermore, 
investigations comparing the reliability of V̇O2max versus V̇O2peak measurements in a larger, 
more heterogeneous cohort than previously studied (454) would be useful. Since this was 
a retrospective study, a limitation is that the sample size was not based on an a priori power 
calculation. However, future interventional studies using CPET as an outcome measure 
would need a power calculation to detect a significant change in V̇O2max. Previous studies 
estimate a coefficient of variation of 9% amongst people with CF (454), whilst our cohort 
has a standard deviation of 6.3 and 9.5 mLkg-1min-1 in our pediatric and adult groups, 
respectively (Table 3.2). On this basis, with an α-level set at 0.05 and 80% power, 50 (within-
subject design) or 91 (between-subject design) pediatric and 173 (within-subject design) or 
344 (between-subject design) adult participants would be required to detect a statistically 
significant difference of ≥ 9% in V̇O2max.  
In conclusion, incorporating Smax within CPET protocols for children, adolescents and adults 
with CF, including those with severe lung disease, is achievable within both pediatric and 
adult CF clinics and does not appear to increase the prevalence of exercise-induced 
hypoxemia or perceived discomfort. Smax should, however, increase the practitioner’s 
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confidence that a true maximal effort has been given by the participant, compared with 
current secondary criteria which often leads to aerobic fitness being under-reported. 
Incorporating Smax into CPET protocols to determine V̇O2max is therefore recommended for 
children, adolescents and adults with mild-to-severe CF. 
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We thank Prof. Cooper for his comments (19) on our recent article (Chapter 3), in which he 
questions the rationale for conducting Smax and, indeed, CPET in people with CF. Whilst he 
should be commended on his vision to further develop the exercise testing toolkit for use 
in a clinical setting, this is disparate to the aims of our investigation. Specifically, our study 
focused on the added value of using Smax to improve confidence in the measurement of 
maximal parameters during incremental CPET, a procedure recognized and advocated by 
the European Respiratory and CF Societies (217), due to its functional and prognostic 
evaluative ability.  
Several of Prof. Cooper’s viewpoints are worthy of challenge. Firstly, Prof. Cooper 
misinterpreted our article, to surmise that inaccuracies during incremental testing “can be 
‘corrected’ by an additional test in which the participant exercises to exhaustion at a 
supramaximal constant work-rate” (19). To reiterate the premise of Smax, this recognized 
concept (409) enables us to 1) confirm a maximal effort has been provided or, importantly, 
2) demonstrate that an incremental exercise test effort was submaximal. Given the 
reported validity concerns surrounding secondary verification criteria (4), this is a simple 
extension that may “improve the practitioner’s confidence that a true maximal effort has 
been given by the participant” (Chapter 3). Indeed, we reported a case whereby Smax 
elevated V̇O2peak 24.4% higher than the preceding ‘exhaustive’ incremental cycling test. We 
acknowledge that the cut-off criteria used was based on the typical error for V̇O2max in 
children and adolescents with CF, this threshold (9%) is comparable to the 10% used in Prof. 
Cooper’s calculations, and the data suggested by his simulation model would still not 
account for such a large increase in exercise capacity. 
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Prof. Cooper also raises concerns about the safety of Smax. We acknowledge within our 
paper that cases of hypoxemia did occur during Smax, however, the pertinent finding was 
that its addition did not significantly increase the frequency or magnitude of desaturation 
compared with incremental cycling alone. Given the pulmonary consequences of CF, cases 
of exercise-induced hypoxemia will of course occur. However, CPET allows us to identify 
the exercise intensity at which this occurs, which can be “useful in managing their daily life 
activities and benefiting their health”, a recommendation advocated by Prof. Cooper.  
Lastly, we acknowledge Prof. Cooper’s viewpoint that “adding uncomfortable procedures 
to an already challenging and time consuming test is not likely to advance CPET in clinical 
research or practice”. However, as the evidence supporting the value of Smax continues to 
grow (409), we feel this additional time (of ~ 20 mins) is time well spent. Furthermore, 
considering patients’ feedback, data from our research group demonstrated that the 
majority of young people with CF (75%) enjoyed CPET with Smax, and completing the test 
empowered 50% of them to seek advice regarding physical activity (263). Therefore, we 
would conclude that CPET with Smax, when interpreted correctly, may actually fit the criteria 
Prof. Cooper recommends for modern exercise testing (19). 
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We thank Askew and Green for their comments (19) on our recent article (Chapter 3) and 
kind words regarding the novel insight it provides into the safety and feasibility of CPET 
with Smax for people with CF. Askew and Green (19) did, however, question the validity of 
Smax citing concerns about “confirmation bias”.  
We incorporate Smax testing in our laboratory and clinical CPET protocols because of the 
evidence that it increases the practitioner’s confidence that a true maximal effort has been 
achieved by the participant, compared with current secondary criteria which can result in 
aerobic fitness being under-reported (Chapter 3). Given that maximal parameters during 
CPET facilitate functional understanding (e.g. breathing reserve, O2 pulse) and are of 
prognostic value (220), we believe it is important to identify lower than ‘normal’ values as 
a result of either physiological dysfunction, deconditioning or simply a submaximal effort. 
The consequences of misinterpreting data in this way were clearly demonstrated in our 
article using a case-based approach (Chapter 3).   
We believe that Askew and Green (19) are incorrect in suggesting the presence of 
confirmation bias. There is of course a positive and negative distribution around the mean 
for the V̇O2peak difference scores for ramp versus Smax phases (Figure 3.2). However, we are 
primarily interested in identifying submaximal efforts during ‘exhaustive’ incremental 
testing. Negative mean differences are to be expected when residual fatigue prohibits 
participants from exercising for a sufficient duration to achieve a V̇O2peak within the limits 
of agreement during Smax. This might be exacerbated in individuals such as children with CF 
and/or more severe lung disease who can have significantly prolonged V̇O2 recovery 
dynamics during the 10 mins following CPET (491). 
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Askew and Green (19) propose that achievement of V̇O2max should be rejected if 
participants fail to achieve a V̇O2peak during Smax above the negative limit of agreement 
determined during incremental exercise testing. The greatest negative difference between 
ramp-Smax V̇O2peak values in our study (-20.9%) was evident in a boy with mild CF (9.3 y old, 
FEV1: 102.3% predicted). During incremental testing, he achieved a V̇O2peak of 45.1 mLkg-
1min-1 (138.1% predicted normal), with a significant ventilatory limitation evident at peak 
exercise (measured V̇E was 132.1% of predicted MVV). Using Askew and Green’s (19) 
suggestions, an accurate reflection of V̇O2max would have been rejected. In the clinical 
application of CPET, we question the value of rejecting measurements of V̇O2max from 
incremental exercise testing based solely on a failure to achieve a Smax-V̇O2peak above the 
negative limit of agreement. Smax usefully identifies individuals who have achieved 
submaximal effort during CPET, and quantifies if they are capable of achieving higher levels 
of performance during ‘maximal’ testing. 
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4.1. Abstract 
Background: The development of CFRD in paediatric groups is associated with a reduced 
aerobic fitness. However, this has yet to be investigated in adults with more severe lung 
disease. Methods: Cardiopulmonary exercise and glycaemic control tests were 
retrospectively analysed in 46 adults with CF (age: 26.9 y [range: 16.3–66.5 y]; FEV1: 65.3% 
[range: 26.8–105.7%]; 26 males), diagnosed with CFRD (n = 19), IGT (n = 8) or NGT (n = 19). 
Results: V̇O2max was reduced in adults with IGT and CFRD compared to their age- and 
gender-matched counterparts with NGT (p < 0.05); however, there was no difference when 
lung function was included as a covariate (all p > 0.05). V̇O2max was greater in adults who 
experienced post-reactive hypoglycaemia (PRH) vs. NGT without hypoglycaemia (p < 0.05). 
The frequency of ventilatory limitation (84%, 63% and 37%, respectively; p < 0.05) but not 
V̇/Q̇-mismatch (42%, 38% and 16%, respectively; p > 0.05), was greater with CFRD and IGT 
vs. NGT. There was also no difference in SpO2 changes between groups (p > 0.05). Gender 
and body mass index were significant predictors of V̇O2max (adjusted R2 = 0.37, p < 0.01), 
but glycaemic control did not explain additional variance (p > 0.05). Conclusions: Adults 
with CF-related dysglycaemia had a reduced V̇O2max compared to age- and gender-matched 
counterparts, due to a greater degree of CF lung disease in these populations.  
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4.2. Background 
The primary cause of mortality in CF is respiratory failure, however, the increasing survival 
age means that non-respiratory consequences have a greater bearing upon quality and 
longevity of life (530). For example, approximately 35% of adults with CF develop CFRD 
(530). CFRD is associated with a greater decline in lung function (298), worsened nutritional 
status (280) and poorer prognosis (349). CPET is advocated by both the ECFS and ERS (217, 
389) as a routine clinical assessment. This is because higher levels of aerobic fitness 
(V̇O2peak) are associated with an improved quality of life (221), reduced risk of being 
hospitalised with a pulmonary exacerbation (397) and better prognosis (220). To date, 
ventilatory (526), cardiac (433), vascular (411, 430) and skeletal muscle (131) abnormalities 
have been reported to modulate aerobic fitness in CF. However, only a small number of 
studies have investigated the impact of CF-related dysglycaemia on outcomes from CPET 
(172, 256).  
Lower V̇O2peak (172) and Wpeak (256) have been reported in children and adolescents with 
CFRD compared to those with CF and NGT or IGT. However, no difference in 6 min walk test 
performance was reported between adults with NGT, IGT and CFRD, although a greater 
exercise-induced reduction in SpO2 was observed in those with IGT (590). This latter finding 
may suggest an abnormal ventilatory response to exercise in people with CF-related 
dysglycaemia (217). Importantly, ventilatory parameters have been shown to be associated 
with prognosis in CF (220) and are more sensitive to changes in CF lung disease than V̇O2peak 
(526). However, previous studies investigating the relationships between dysglycaemia and 
aerobic fitness were limited by sample size (256), focusing largely on children and 
adolescents with mild lung disease (172) and/or inaccuracies in the exercise testing 
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protocols used (590). There is a need, therefore, to investigate the relationships between 
dysglycaemia, aerobic exercise and ventilatory function across the spectrum of CF severity. 
This study was designed to investigate whether there are differences in aerobic exercise 
and ventilatory function between adults with CF and NGT, IGT or CFRD. It was hypothesised 
that (1) adults with IGT and CFRD would have a reduced V̇O2max and earlier occurrence of 
the GET compared to age- and gender-matched adults with CF and NGT; (2) greater 
frequency of ventilatory limitation during CPET would cause a greater reduction in SpO2 in 
adults with CFRD compared to age- and gender-matched adults with CF and NGT; and (3) 
the inclusion of glycaemic control variables within a multiple linear regression model would 
significantly improve the explained variance of V̇O2max in adults with CF. 
4.3. Materials and Methods 
4.3.1. Study design 
This study was a retrospective analysis of data collected during out-patient clinic visits at 
the Adult Wessex CF Unit. Participants were included if they completed CPET and OGTT (or 
they had an existing diagnosis of CFRD) between July 2017 - August 2018. Participants with 
CFRD were age- and gender-matched to an individual with CF and NGT (± 2 years). All 
participants had a diagnosis of CF based on a clinical picture in keeping with CF, elevated 
sweat [Cl-] (> 60 mmolL−1) and a compatible genotype (366). As the findings presented are 
a retrospective analysis of de-identifiable data, this study was exempted from National 
Health Service Research Ethics Committee approval. 
4.3.2. Glycaemic control 
All participants were screened for CFRD in line with the American Diabetes Association 
guidelines (348). Glucose lowering therapies were omitted on the morning of OGTT. 
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Participants who were fasted overnight (≥ 10 h) undertook a 2 h OGTT of 1.75 gkg-1 
(maximum of 75 g) of anhydrous glucose during a morning clinic. CFRD was diagnosed if 2 
h plasma [glucose] was ≥ 11.1 mmolL-1 and confirmed on a separate day by either a repeat 
OGTT, fasting plasma [glucose] ≥ 7 mmolL-1, HbA1c ≥ 48 mmolmol-1 or the presence of 
symptoms linked with diabetes (polyuria and polydipsia). IGT was diagnosed if 2 h plasma 
[glucose] was 7.8-11.0 mmolL-1 or impaired fasting plasma [glucose] was ≥ 6.3 mmolL-1. 
PRH was defined by 2 h plasma [glucose] ≤ 3.9 mmolL-1.  
4.3.3. CPET procedures 
Lung function was assessed using flow-volume spirometry (3500 MicroLab Spirometer 
MK8, CareFusion, CA, USA), in accordance with the British Thoracic Society guidelines (63). 
FEV1 and FVC were determined as the highest of three consistent (≤ 5% variability) 
manoeuvres and presented as a percentage of the Global Lung Function Initiative (2012) 
reference values (416).  
Our centre employs a combined ramp incremental and Smax CPET protocol on a cycle 
ergometer (Lode Corival, Groningen, The Netherlands; this protocol is comprehensively 
described in Chapter 3). Breath-by-breath pulmonary gas exchange and ventilation (K5, 
COSMED, Rome, Italy), beat-by-beat HR (Premium HR Monitor, Garmin, KS, USA) and 
fingertip SpO2 were measured throughout exercise. Exercise was terminated if SpO2 
dropped ≤ 85%. Subjective RPE were measured using the Borg 6-20 scale (50). RPD was 
measured using the 0-10 category-ratio scale (50) every 1 min throughout exercise. 
4.3.4. CPET Analysis 
A ‘maximal’ effort during the ramp test was accepted when Smax-V̇O2peak did not exceed 
ramp-V̇O2peak by ≥ 9% or a V̇O2 plateau was present upon exhaustion (Chapter 3), with a 
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plateau determined using methodology comprehensively described elsewhere (31). HR, 
V̇O2, V̇CO2, V̇E and V̇E/V̇O2 and V̇E/V̇CO2 data were interpolated to 15 s averages and peak 
values taken as the highest 15 s average achieved during the ramp incremental test. 
V̇O2max was taken as the highest 15 s average from either the ramp incremental or Smax 
tests. GET was determined using the V-slope method (35) and confirmed through visual 
inspection of the ventilatory equivalents. O2 pulse, an index of SV, was calculated by 
expressing V̇O2 as a function of HR (mLbeat-1). ∆V̇E/∆V̇CO2 was determined by plotting a 
linear regression line through the power output x V̇E/V̇CO2 response up to the respiratory 
compensation point (499). A V̇/Q̇-mismatch was considered evident if ∆V̇E/∆V̇CO2 was ≥ 34 
(499). V̇E/MVV was calculated by expressing V̇Epeak as a percentage of predicted MVV (MVV 
(555) = FEV1 (in L) x 40).  
4.3.5. Statistical Analysis 
Data were expressed as means ± SD unless otherwise stated. Statistical significance was set 
at α = 0.05. ANOVA tests were conducted to determine differences between the groups’ 
anthropometric and clinical data (Table 4.1). A series of analysis of covariance (ANCOVA) 
tests were subsequently used to determine between group differences in aerobic exercise, 
ventilatory and cardiovascular function during CPET. Principle component analysis was 
used to compute a 2-component score of lung function, where 93.1% and 6.9% of the 
variance was explained by FEV1 and FVC, respectively. The 2-component score was included 
as a single covariate in ANCOVA. Tukey’s HSD or Games-Howell post-hoc t-tests were 
conducted on homogeneous and heterogeneous data, respectively. Chi-squared tests were 
used to determine significant difference in nominal variables. Measures of effect sizes were 
reported as ƞ2. 
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Pearson’s correlation coefficients were used to determine linear associations between 
variables. Hierarchical multiple linear regression models were used to determine predictors 
of V̇O2max. A significant multiple regression model of gender, age, BMI, FEV1, FVC, 
pancreatic sufficiency and intravenous antibiotic days over 12 months (IVAB) was 
computed. The variables of dysglycaemia (i.e. IGT and CFRD, yes vs. no) and HbA1c were 
then entered to determine whether glycaemic control explains significantly more variance 
of V̇O2max. Statistical analyses were performed using SPSS v.24.0 (IBM, IL, USA). 
4.4. Results 
4.4.1. Participant and CPET information 
Forty-six adults were eligible for inclusion in this analysis as they achieved V̇O2max and 
undertook an OGTT (or had previously been diagnosed with CFRD) in the given period, with 
the average time between CPET and OGTT being 4 ± 2 months. Characteristics of the 
included participants are presented in Table 4.1. Nineteen of the 46 participants were 
diagnosed with CFRD (median time since diagnosis: 5.6 y [range: 0.02 – 18.38 y]), of which 
1 was prescribed with metformin alone (for the treatment of polycystic ovary syndrome), 
and 10 received a combination of short and long acting insulin injections. The participants 
who did not receive glucose lowering therapies were either diet controlled (n = 5) or 
monitoring blood glucose levels (n = 3). 
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Table 4.1. Participant characteristics. 
    NGT IGT CFRD p-value n2 
Sample size, n 19 8 19 - - 
Males, n (%) 11 (57.9) 4 (50.0) 11 (57.9) - - 
Age, y 27.5 ± 7.6 23.4 ± 7.6 27.8 ± 6.9 0.34 0.05 
Height, cm 168.7 ± 10.8 171.1 ± 14.6 169.4 ± 8.0 0.85 0.01 
Body mass, kg 65.4 ± 11.5 61.6 ± 7.6 63.4 ± 12.9 0.72 0.02 
BMI, kgm2 23.0 ± 3.5 21.2 ± 2.6 22.0 ± 3.2 0.38 0.05 
FEV1, % predicteda 77.3 ± 19.4 52.1 ± 15.2* 58.9 ± 17.5* <0.01 0.26 
 (29.9 – 105.7) (36.4 – 75.4) (26.8 – 95.9) - - 
FVC, % predicteda 89.4 ± 12.0 72.8 ± 7.1* 75.0 ± 15.4* <0.01 0.26 
 (61.4 – 106.1) (65.8 – 82.7) (44.5 – 106.5) - - 
Resting SpO2, % 97 ± 2 96 ± 2 96 ± 2 0.60 0.03 
CFTR genotype class, n (%) - - - - - 
 Class I-III 17 (89.4) 8 (100.0) 19 (100.0) - - 
 Class IV-V 1 (5.3) - - - - 
 Unknown  1 (5.3) - - - - 
P. aeruginosa infection, n (%) 11 (57.9) 4 (50.0) 15 (78.9) - - 
Pancreatic insufficient, n (%) 11 (57.9) 8 (100.0) 19 (100.0) - - 
Fasting plasma [glucose], mmolL-1 4.7 ± 0.4 5.3 ± 0.9 4.0 ± 0.3b 0.39 0.07 
2 h plasma [glucose], mmolL-1 4.3 ± 1.3 8.0 ± 2.7 15.0 ± 3.8b <0.01 0.42 
 (2.7 – 7.4) (4.2 – 10.4) (11.3 – 18.8) - - 
HbA1c, mmolmol-1 34.3 ± 3.8 39.7 ± 3.6* 48.6 ± 15.6* <0.01 0.26 
 (27 – 43) (32 – 48) (33 – 100) - - 
Time on IVAB, days 10 ± 10 39 ± 20* 27 ± 22* <0.01 0.27 
 (0 – 28) (10 – 69) (0 – 70) - - 
Data are expressed as means ± SD unless otherwise stated. * denotes a significant difference with the adult 
NGT group (p < 0.05). Range is provided in brackets for the variables obtaining statistical significance duing 
ANOVA. a According to Global Lung Function Initiative 2012 reference values (416); b glycaemic control 
assessments are not routinely conducted in people with established diabetes (‘CFRD’ n = 4).  
4.4.2. Aerobic fitness 
V̇O2max (% predicted only) was significantly reduced in adults with CFRD and IGT compared 
to age- and gender-matched controls with CF and NGT (p < 0.05). Notably, however, 
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ANCOVA including FEV1 and FVC as covariates revealed no significant differences in 
maximal (V̇O2max) or submaximal (GET) parameters of aerobic fitness between age- and 
gender-matched groups with NGT, IGT or CFRD (Figure 4.1). Subgroup analysis also 
revealed those who experienced PRH during OGTT (n = 8) had a significantly greater V̇O2max 
vs. those with NGT without PRH (n = 11; Figure 4.2).  
There were no significant differences in Wpeak, expressed in absolute terms (181 ± 60 vs. 
139 ± 47 vs. 156 ± 47 W, p = 0.87, n2 = 0.01) or relative to body mass (2.8 ± 0.9 vs. 2.2 ± 0.6 
vs. 2.5 ± 0.6 Wkg-1, p = 0.82, n2 = 0.01) between the NGT, IGT or CFRD groups, respectively. 
4.4.3. Ventilatory and cardiovascular parameters 
There was no significant difference in ∆SpO2 between adults with NGT, IGT or CFRD (NGT: 
-3 ± 3 vs. IGT: -4 ± 2 vs. CFRD: -3 ± 3%; p = 0.62, n2 = 0.03), but there was a significant 
difference in dyspnoea at exhaustion between adults with NGT vs. CFRD (NGT: 7 ± 2 vs. IGT: 
7 ± 2 vs. CFRD: 6 ± 2, p = 0.03, n2 = 0.17). Notably, absolute SpO2 values of < 90% were 
experienced in 10.5% and 11.1% of adults with CFRD and IGT, respectively, but no adults 
with NGT. 
There were no significant differences in the ∆V̇E/∆V̇CO2 (Figure 4.1), V̇E/MVV (Figure 4.1), 
V̇Epeak (96.0 ± 31.1 vs. 80.0 ± 22.7 vs. 86.6 ± 23.5 Lmin-1, p = 0.89, n2 = 0.01), V̇E/V̇CO2 at GET 
(Figure 4.1), V̇E/V̇CO2peak (38.1 ± 5.3 vs. 43.7 ± 5.8 vs. 39.9 ± 6.5 Lmin-1, p = 0.18, n2 = 0.08) 
or V̇E/V̇O2peak (41.3 ± 6.1 vs. 41.7 ± 5.8 vs. 42.8 ± 7.7 Lmin-1, p = 0.42, n2 = 0.04) between 
the NGT, IGT or CFRD groups, respectively. Notably, a significantly higher proportion of 
participants with CFRD and IGT presented with ventilatory limitation (NGT: 37% vs. IGT: 
63% vs. CFRD: 84%; p < 0.01), but not V̇/Q̇-mismatch (NGT: 16% vs. IGT: 38% vs. CFRD: 42%; 
p = 0.19) vs. the NGT group.  
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There were no significant differences in HRpeak (178 ± 13 vs. 171 ± 9 vs. 174 ± 10 beatsmin-
1, p = 0.94, n2 < 0.01) or peak O2 pulse (14.3 ± 3.4 vs. 13.6 ± 4.7 vs. 12.9 ± 3.5 mLbeat-1, p = 
0.84, n2 = 0.01) between the NGT, IGT or CFRD groups, respectively. 
4.4.4. Predictors of aerobic fitness in those with- and without-CFRD 
Table 4.2. Multiple linear regression model investigating the explained variance of V̇O2max by anthropometric, 
lung function and glycaemic control variables in adults with CF. 
 %̇O2max (mLkg-1min-1) 
 B SE p-value 
Gender, male vs. female -9.33 2.26 <0.01 
Age, y -0.04 0.17 0.82 
BMI, kgm2 -1.28 0.41 <0.01 
FEV1, % predicteda 0.05 0.11 0.64 
FVC, % predicteda 0.15 0.15 0.33 
Pancreatic insufficient, no vs. yes -1.53 3.70 0.68 
IVAB, days 0.06 0.08 0.46 
Dysglycaemia, no vs. yesb -2.42 1.60 0.14 
HbA1c, mmolmol-1 0.08 0.10 0.46 
Data are expressed as the linear regression slope (B), standard error (SE) and p-value. a According to Global 
Lung Function Initiative 2012 reference values (416); b Dysglycaemia accounts for adults with IGT or CFRD.  
Overviews of the regression and correlation analyses are presented in Tables 4.2 and 4.3, 
respectively. The inclusion of age, gender, BMI, FEV1, FVC, pancreatic sufficiency status and 
d on IVAB resulted in a significant regression model of V̇O2max relative to body weight with 
an adjusted R2 of 0.37 (F(7,36) = 4.67, p < 0.01). The inclusion of HbA1c and glycaemic control 
status did not significantly increase the explained variance (R2 change = 0.03, p = 0.33). 
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Table 4.3. Pearson’s correlation coefficients between V̇O2max and clinical variables in people with CF, with and 
without CFRD. 
  
  
Participants w/o CFRD (n = 27) Participants w/ CFRD (n = 19) 
V̇O2max  
(mLkg-1min-1) 
V̇O2max  
(% predicted) 
V̇O2max  
(mLkg-1min-1) 
V̇O2max  
(% predicted) 
Age, y 0.14 0.28 -0.55* -0.12 
FEV1, % predicteda 0.14 0.43* 0.48* 0.54* 
FVC, % predicteda 0.17 0.44* 0.47* 0.49* 
Resting SpO2, % 0.01 -0.04 0.01 0.29 
FPG, mmolL-1 0.18 -0.03 -0.31a -0.44a 
2 h plasma [glucose], mmolL-1 -0.13 -0.42* 0.50a 0.63a 
HbA1c, mmolmol-1 0.17 -0.08 -0.34 -0.01 
Time on IVAB, days -0.47 -0.41* 0.39 0.45* 
Data is presented as Pearson’s correlation coefficient. * denotes a statistically significant correlation 
coefficient (p < 0.05). a OGTT was only conducted in 4 participants with CFRD during the study period. N.B. 
the ‘Participants w/o CFRD’ group contains adults with NGT and IGT. 
4.5. Discussion 
This is the first study to investigate the impact of dysglycaemia upon the aerobic exercise 
and ventilatory function of adults with mild to severe CF lung disease. Three key findings 
were observed: (1) V̇O2max as a percentage predicted was reduced in adults with CFRD and 
IGT compared to their counterparts with NGT, which was dependant on the groups with 
CFRD and IGT having a greater severity of lung disease (2) ∆SpO2 did not significantly differ 
between age- and gender-matched groups despite ventilatory limitation during maximal 
exercise being more prevalent in adults with CFRD compared to NGT; and (3) variance in 
V̇O2max was primarily explained by gender and BMI in adults without CFRD, with glycaemic 
control explaining no additional variance. 
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Figure 4.1. Parameters of aerobic fitness and ventilatory function during cardiopulmonary exercise testing in 
adults with CF and NGT, IGT and CFRD. Panels represent the following: (A) V̇O2max expressed relative to body 
mass (mLkg-1min-1), (B) V̇O2max as a percentage of normative values, (C) V̇O2 at GET expressed relative to 
body mass (mLkg-1min-1), (D) GET as a percentage of V̇O2max, (E) ∆V̇E/∆V̇CO2 and (F) V̇E expressed relative to 
predicted MVV. The statistics reported in this figure are those derived from ANCOVA, where FEV1 and FVC 
were included as covariates. N.B. the dotted line at 34 (Panel E) and 85% (Panel F) denotes the threshold for 
a V̇/Q̇-mismatch and ventilatory limitation during CPET, respectively. 
The key finding of the present study was that V̇O2max, as a percentage predicted, was 
reduced in people with CFRD and IGT compared to their counterparts with NGT. 
Furthermore, 57% of adults with CFRD were at a heightened mortality risk (i.e. V̇O2max ≤ 
81% (220)), compared to only 21% of the NGT group. Interestingly, when FEV1 and FVC 
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were included as covariates the statistical significance in V̇O2max between groups was not 
evident (Figure 4.1), suggesting that advanced lung disease in adults with CF-related 
dysglycaemia was the primary modulator of aerobic fitness in comparison to their 
counterparts with NGT. The latter finding is in contrast to previous reports, where V̇O2peak 
was reduced in paediatric participants with CFRD compared to their NGT counterparts even 
after FEV1 was included as a covariate (172). Notably, this could be a due to the adult NGT 
group in the present study having a worse V̇O2max compared to the V̇O2peak values reported 
for the children and adolescents with mild-to-moderate CF lung disease (38.9 ± 9.7 vs. 41.3 
± 9.4 mLkg-1min-1, respectively) (172). Furthermore, adults with CF-related dysglycaemia 
underwent significantly more IVAB days than their counterparts with NGT, which could 
indicate a greater interaction with physiotherapy staff who are likely to promote physical 
activity. Therefore, it would be of interest for future prospective trials to measure physical 
activity alongside CPET to account for such covariance.  
The secondary finding of the present study was that ∆SpO2 during CPET was not 
significantly different between groups, which is contrast to previous reports in adults who 
reported that ∆SpO2 was significantly greater in those with CF-related dysglycaemia vs. NGT 
(590). This was somewhat surprising given that 84% of participants with CFRD were 
ventilatory limited during CPET compared to 37% of those with NGT (Figure 4.1). Despite a 
greater frequency of ventilatory limitation in those with CFRD, it is important to note that 
there were no significant differences between groups in V̇E/MVV, or other prognostically 
relevant outcomes such as V̇E/V̇O2peak and V̇E/V̇CO2peak (Figure 4.1). Interestingly, in the 
present study, the values reported for V̇E/MVV, V̇E/V̇O2peak and V̇E/V̇CO2peak in adults with 
CF, irrespective of glycaemic status, were comparable to the clusters at greatest risk of 
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mortality (220). This evidence supports contemporary suggestions in predominantly 
paediatric groups that the development of CFRD does not significantly reduce survival 
probability (220). Conversely, a medium effect size (n2 = 0.11) suggested that ∆V̇E/∆V̇CO2 
may be elevated in those with CF-related dysglycaemia, even after accounting for the 
influence of FEV1 and FVC. These findings suggest that additional variables, that are not 
included in our study, may modulate aerobic exercise and ventilatory function in CF. For 
example, CFTR expression in the endothelium could cause microvascular dysfunction in the 
lung (518), a parameter which is exacerbated by the inflammation and oxidative stress 
which result from dysglycaemia (460). 
In accordance with previous data in children and adolescents (172, 256), the present study 
did not find a significant correlation between V̇O2max and HbA1c in adults with CFRD (Table 
4.3). Notably, the use of HbA1c has been debated in CF because it does not distinguish 
between variable bouts of hypo- and hyperglycaemia as opposed to time spent within an 
optimal range of blood glucose levels (458). Additionally, glycaemic control variables did 
not explain a significant proportion of the variance in V̇O2max between participants. Instead, 
variance in V̇O2max was primarily explained by gender and BMI (Table 4.2). The only 
parameter of cardiac function in the present study, O2 pulse, was not significantly different 
between groups. However, cardiovascular parameters in other studies have been 
highlighted as modulators of aerobic fitness (411, 430, 433), and the inclusion of more 
investigative parameters may have improved the present study’s multiple regression 
model.  
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Figure 4.2. V̇O2max in adults with CF and NGT, with or without PRH, during OGTT. (A) Represents V̇O2max 
expressed relative to body mass, and (B) V̇O2max as a percentage of normative values. * denotes a significant 
difference between groups (p < 0.05). 
Interestingly, the only group with a V̇O2max of ≥ 100% predicted was those who experienced 
PRH during OGTT (Figure 4.2). PRH is a phenomenon of NGT in people with CF, reportedly 
present in 7-69% of people with CF without diabetes (18% in the present study; (17)). 
Traditionally, PRH was considered a precursor to the development of CFRD, where delayed, 
increased and extended insulin responses have been proposed as potential mechanisms 
(17, 208). More recently, however, large trials with 3.5 y (418) and 10 y (319) follow-up 
durations have shown no association between PRH and the development of CFRD and, 
instead, have demonstrated improved clinical outcomes (18, 319). Interestingly, reports 
have also observed a reduced insulin response at 2 h of an OGTT in those who experience 
PRH (18), therefore, implicating improved insulin sensitivity in the aetiology of PRH. 
Notably, similar mechanisms have been postulated to cause PRH in multi-ethnic 
populations without CF (392). Given that structured exercise training can improve insulin 
sensitivity in adults with CF (34), in addition to quantifiable physical activity levels not being 
routinely monitored in our clinic, it is not possible to determine whether the improved 
V̇O2max in the PRH group was a pathophysiological consequence, or a product of a more 
physically active lifestyle. Further research to investigate the association between insulin 
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sensitivity, physical activity and aerobic fitness in people with CF would be useful in 
furthering our understanding of this phenomenon. 
A strength of the present study was the use of a CPET protocol which has shown to produce 
a valid measurement of V̇O2max in children, adolescents, and adults with mild to severe CF 
lung disease (Chapter 3). A notable limitations are is that the retrospective nature of the 
data analysis meant the sample size of a heterogeneous cohort was relatively modest, the 
IGT group size was considerably smaller and more descriptive physiologically relevant 
measurements were not conducted (i.e. CGM as opposed to HbA1c), and the IGT group size 
was considerably smaller. Indeed, investigating glycaemic control using HbA1c in people 
with CF is debated, as HbA1c analysis does not distinguish between variable bouts of hypo- 
and hyperglycaemia as opposed to time spent within an optimal range of blood glucose 
levels (556). However, as yet, no alterative measure has been widely accepted in routine 
clinical practice. Furthermore, as the present study was cross-sectional this data only 
demonstrates an association and not a causal effect between dysglycaemia and aerobic 
fitness. Therefore, future prospective studies are needed to further investigate the clinical 
implications of these associations and whether they are a suitable outcome for 
interventional trials (e.g. impact of IVAB on glycaemic control and exercise capacity during 
a pulmonary exacerbation).  
To conclude, in this study, CF-related dysglycaemia was associated with a significantly 
reduced aerobic fitness in adults with CF due to advanced CF lung disease in this 
population. Additionally, CFRD and IGT were associated with ventilatory dysfunction during 
exercise independent of lung function. The modulators of V̇O2max in this cohort, including 
adults with mild to severe CF lung disease appear to be gender and BMI. 
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5.1. Abstract 
Background: Perturbation of endothelial function in people with CF has been reported, 
which may be associated with endothelial cell expression of the CFTR. Previous reports 
indicate that CFTR activity upregulates endothelial barrier function, eNOS expression and 
NO release, while limiting IL-8 release, in HUVECs in cell culture. In view of reported 
microvascular dysfunction in people with CF we have investigated the role of CFTR 
expression and activity in the regulation of oxidative stress, cell signalling and inflammation 
in HLMVECs in cell culture. Methods: HLMVECs were cultured in the absence and presence 
of the CFTR inhibitor GlyH-101 and CFTR siRNA. CFTR expression was analysed using 
quantitative real-time polymerase chain reaction (qRT-PCR), immunocytochemistry and 
western blot, and function by membrane potential assay. IL-8 expression was analysed 
using qRT-PCR and ELISA. Nrf2 expression, and NF-κB and AP-1 activation were determined 
using immunocytochemistry and western blot. The role of epidermal growth factor (EGF) 
receptor (EGFR) in CFTR signalling was investigated using the EGFR tyrosine kinase inhibitor 
AG1478. Oxidative stress was measured as intracellular ROS and H2O2 concentration. VEGF 
was measured in cell culture supernatants by ELISA. Results: HLMVECs express low levels 
of CFTR that increase following inhibition of CFTR activity. Inhibition of CFTR, significantly 
increased intracellular ROS and H2O2 levels over 30 mins and significantly decreased Nrf2 
expression by 70% while increasing SOD2 expression over 24h. CFTR siRNA significantly 
increased constitutive expression and release of IL-8 by HLMVECs. CFTR inhibition activated 
the AP-1 pathway and increased IL-8 expression, without effect on NF-κB activity. 
Conversely, TNF-α activated the NF-κB pathway and increased IL-8 expression. The effects 
of TNF-α and GlyH-101 on IL-8 expression were additive and inhibited by AG1478. Inhibition 
of both CFTR and EGFR in HLMVECs significantly increased VEGF expression. The 
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antioxidant NAC significantly reduced ROS production and the increase in IL-8 and VEGF 
expression following CFTR inhibition. Conclusions: Functional endothelial CFTR limits 
oxidative stress and contributes to the normal anti-inflammatory state of HLMVECs. 
Therapeutic strategies to restore endothelial CFTR function in CF are warranted. 
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5.2. Introduction 
CF lung disease is associated with neutrophilic airway inflammation, bronchiectasis, 
respiratory failure and early mortality (367). Defective or deficient expression of the CFTR 
protein in airway epithelial cells leads to dehydration of airway secretions with failure of 
mucociliary clearance and mucus plugging. In the early stages of CF lung disease this may 
lead to sterile inflammation (586), but inevitably the airways become chronically infected 
leading to further inflammation (367). In more severe disease, increased peribronchial 
vascularity contributes to the immune and inflammatory responses in the CF airway, as well 
as the risk of haemoptysis (322).  
A number of studies have indicated macro- and microvascular endothelial perturbation in 
people with CF (411, 430, 432, 483) that may be associated with defective endothelial CFTR 
function (65, 372, 399, 518). Increased circulating levels of von Willebrand factor and t-PA, 
indicative of endothelial damage and altered haemostasis (432), and reduced FMD of the 
brachial artery, which was associated with more severe airway disease and symptomatic of 
reduced NO availability (411), were reported in CF. H2O2-induced oxidative stress and 
apoptosis required functional CFTR in HLMVEC, effects that were reversed by the CFTR 
inhibitor CFTRinh-172 (372). Reduced endothelial apoptosis in the vasculature of the CF 
lung has previously been reported which may be associated with reduced endothelial 
ceramide concentration (372). Endothelial CFTR plays an important role in maintaining 
hydration of the endothelial glycocalyx (399), the endothelial barrier function (65, 518) and 
the availability of NO, while limiting IL-8 release (518).  
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Thus, together with reports of endothelial expression of CFTR in HUVEC (518, 519), HLMVEC 
(519) and HPAEC (408, 518), there is a growing body of evidence for expression and 
function of CFTR in the endothelium.  
The present study focusses on the pulmonary microvasculature and investigates the 
expression and function of CFTR as a regulator of oxidative stress, expression of the key 
transcriptional regulator of antioxidant defences Nrf2, the angiogenic VEGF, the neutrophil 
chemoattractant IL-8 and inflammatory cell signalling in HLMVECs grown on the basement 
membrane component, collagen IV.  
Some of the findings in the current study are similar to those previously demonstrated for 
CFTR inhibition in airway epithelial cells, notably the increased release of IL-8 (396) and 
VEGF (322) and decreased Nrf2 expression (86) following CFTR inhibition. However, 
endothelial and epithelial responses differ in the signalling pathway leading to increased 
IL-8 expression, involving NF-κB activation in airway epithelial cells (396), but activation of 
AP-1 signalling with increased phospho-c-Jun in HLMVECs. Further, inhibition of EGFR 
tyrosine kinase limited epithelial expression of VEGF (322), but enhanced endothelial 
expression of VEGF. 
5.3. Methods 
Materials. All reagents were from Merck unless indicated otherwise. 
5.3.1. Cell culture 
HLMVEC from non-smoking donors (Lonza Biologics) were maintained in complete EGM-
2MV medium (EBM-2MV basal medium supplemented with 5% (v/v) FBS, 0.04% (v/v) 
hydrocortisone, 0.4% (v/v) hFGF, 0.1% (v/v) VEGF, 0.1% (v/v) IGF-1, 0.1% (v/v) ascorbic acid, 
0.1% (v/v) hEGF and 0.1% (v/v) GA-100 (Lonza Biologics) and used at passage 5-8. The 
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growth medium was changed 1 d after seeding and then every other day to 90 % 
confluence. Cells were passaged using trypsin-EDTA to detach them, neutralized with 
warmed FBS and pelleted by centrifugation. The cell pellet was re-suspended in FGM and 
seeded in multi-well plates (25 x 104 /6-well plate, 5 x 104 /24-well plate) coated with 
human collagen IV (0.1 mg/mL) and allowed to adhere overnight before treatment at the 
indicated times with the CFTR inhibitor GlyH-101 (5, 10, 20 µM), DMSO (0.1 %; v/v) as 
vehicle control or TNF-α (10 ng/mL, Peprotech) for up to 24 h. The specificity of GlyH-101 
was confirmed using the potent (IC50 4.8 µM) and specific VRAC inhibitor DCPIB (4-(2-butyl-
6,7-dichlor-2-cyclopentyl-indan-1-on-5-yl) oxybutyric acid) (Tocris) at 20 µM and the potent 
(IC50 77 nM) TMEM16A-specific inhibitor Ani9 (2-(4-chloro-2-methylphenoxy)-N-[(2-
methoxyphenyl)methylideneamino]-acetamide), that lacks inhibitory activity against CFTR 
and VRAC (468), at 10 µM in HLMVEC cultures. HLMVECs were cultured in 5 % CO2 at 37 °C 
and used until passage 8. 
In separate experiments, HLMVECs were treated with NAC (5 or 10 mM, as indicated) and 
the EGFR inhibitor AG-1478 (10 µM) for 3 h, followed by incubation with GlyH-101 (20 µM) 
alone, and with TNF-α (10 ng/mL) for 16 and 24 h in full growth medium. 
HEK293 which do not express CFTR (175) and 16HBE which do express CFTR (103) were 
used as negative and positive controls respectively. HEK293 and 16HBE cells were cultured 
as described above in DMEM or MEM media, respectively, supplemented with 10% (v/v) 
FBS, 1% (v/v) penicillin-streptomycin, 1% (v/v) L-glutamine. Cells were maintained until 
passage 30. 
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5.3.2. CFTR activity 
CFTR activity was measured in HLMVECs, 16HBE and HEK293 cells using the FLIPR Blue 
membrane potential assay (Molecular Devices), according to the manufacturer’s 
instructions, and as described by Maitra et al. (316). Cells were seeded at 8 x 103 cells per 
well and cultured overnight in collagen IV-coated optical-bottom black 96-well plates in 100 
µl FGM. FLIPR Blue (100 µl) was directly added to the wells for 45 mins at 37 °C in FGM. 
Agonists, Fk (100 µM)/ IBMX (1000 µM), concentrations that significantly increase 
endothelial intracellular cAMP, were applied for 2 mins and fluorescence measured with 
excitation 530 nm and emission 565 nm, using the Molecular Devices Spectramax® i3x 
fluorescent plate reader. GlyH-101 (20 µM) or DMSO (0.1 %; v/v) control were applied 15 
mins before the agonists. Experimental conditions were tested in quadruplicate in each of 
three independent experiments. 
5.3.3. Preparation of cell lysates for CFTR and Nrf2 western blot. 
Cells were lysed directly with 35 µl/well for 24-well (Nrf2) and 75 µl/well for 6-well (CFTR) 
plates of 1X sample buffer (7.5% (v/v) glycerol, 50 mM Tris-Base, 2% (w/v) sodium dodecyl 
sulphate, 100 mM DL-dithiothreitol, 0.01% (w/v) bromophenol blue, 2 mM MgCl₂, 0.05% 
(v/v) benzonase nuclease, 2x protease inhibitor cocktail I), on ice for 10 mins. Finally 1 µl of 
0.25 M EDTA was added to each lysate and samples heated in a water bath at 50 °C for 20 
mins.  
5.3.4. Preparation of cell lysates for phospho-c-Jun western blot. 
HLMVECs in 6-well plates were treated with DMSO (0.1 %; v/v), GlyH-101 (20 µM) or TNF-
α (10 ng/ml) for 30 mins and the cells lysed in 100 µl/well lysis buffer (125 mM NaCl, 1 mM 
MgCl₂, 20 mM Tris-HCl, 1% (v/v) Triton X-100, Complete protease inhibitor cocktail (Roche) 
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and phosphatase inhibitor (PhosSTOP, Roche)) at 4˚C for 30 mins. The cell lysates were 
centrifuged at 24000 RCF, at 4˚C for 30 mins and stored at -80˚C. Cell lysates (30 µl) were 
mixed with 10 µl 4X sample loading buffer (30% v/v glycerol, 200 mM Tris-HCl pH 6.8, 8% 
(w/v) sodium dodecyl sulphate, 400 mM DL-dithiothreitol, 0.04% (w/v) bromophenol blue), 
and placed in a water bath (95˚C) for 4 mins. 
5.3.5. Gel electrophoresis and western blotting. 
Samples (35 µl) were loaded onto 7.5 % (CFTR) or 10 % (Nrf2, p-c-Jun) sodium dodecyl 
sulphate-PAGE gels, and resolved proteins transferred to 0.45 µm nitrocellulose membrane 
(Bio-Rad, UK). Membranes were blocked with 3 % (w/v) skimmed milk powder in PBS 
(without Ca/Mg) with 0.1 % Tween-20 (PBS-T), overnight at 4°C. For CFTR, blots were 
incubated with 2 µg/mL ‘Mr Pink’ rabbit polyclonal antibody (kindly provided by Prof Ineke 
Braakman, Utrecht University through the CFTR Folding Consortium, USA) diluted 1:500 in 
PBS-T. Blots were incubated with antibody for 1 h at room temperature, washed and 
incubated with 0.05 µg/ml goat anti-rabbit-HRP (Dako) for 1 h at room temperature. For 
Nrf2, membranes were stained with 1 µg/mL rabbit polyclonal anti-Nrf2 (Santa Cruz) in 
blocking buffer for 1 h at room temperature, washed in PBS-T, and incubated with 0.125 
µg/ml goat anti-rabbit-HRP (Dako) for 1 h at room temperature. For p-c-Jun, membranes 
were stained with 0.2 µg/mL rabbit polyclonal anti-p-c-Jun ((Ser 63/73) Santa Cruz) 
overnight at 4˚C in blocking buffer, and then 0.125 µg/mL goat anti-rabbit-HRP (Dako) for 
2 h at room temperature. After washing in PBS, blots were incubated for 5 mins in the dark 
with chemiluminescence substrate (Promega), followed by detection of the bands with 
ChemiDoc™ MP System (Bio-Rad). The bands were normalised to β-actin in the samples, 
which was detected after stripping and re-probing membranes with rabbit polyclonal anti-
β-actin for 1 h at room temperature followed by 1 h incubation at room temperature with 
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0.05 µg/mL goat anti-rabbit HRP (DAKO). Bands were quantified using scanning 
densitometry and Quantiscan software. 
5.3.6. Preparation of supernatants and cell lysates for quantification of IL-8, VEGF, SOD2 
and catalase (CAT) by ELISA. 
Supernatants from HLMVECs grown in 24-well plates were cleared by centrifugation (1500 
RCF for 10 mins at 4 °C). Cells were lysed for 10 mins on ice in hypotonic buffer (20 mM 
NaCl, 1 % Triton X-100, and 20 mM Tris-base, pH 7.4), containing Complete protease 
inhibitors (Roche), and protease inhibitor cocktail I (Calbiochem). Lysates were centrifuged 
at 5000 RCF for 10 mins at 4 °C and samples stored at -80 °C prior to analysis. IL-8 and VEGF 
were measured using Duo-Set ELISA kits (R&D Systems) according to the manufacturer’s 
instruction. Mitochondrial Mn-dependent SOD2 and CAT were measured in neat cell 
lysates using ELISA kits (AbCam) according to manufacturer’s instructions, with standard 
curves prepared in the range 7.8-500 ng/mL.  
5.3.7. Measurement of intracellular ROS and H2O2. 
HLMVECs were seeded in 35 mm dishesfor live cell imaging (25 x 104 cells/dish), and 
HLMVECs and 16HBEs were seeded (8 x 103/well/100 µL) for quantification of ROS in 96-
well plates coated with collagen IV and incubated overnight. In some experiments, NAC (10 
mM) was added for three h in FGM before adding the ROS detector, carboxy-H₂DFFDA (5-
(and-6)-carboxy-2ʹ,7ʹ-difluorodihydrofluorescein diacetate, (Invitrogen) in serum-free 
Hanks’ Balanced Salt Solution (+Ca/Mg) at 10 µM for 30 mins. Cells were washed and 
incubated for 30 mins in FGM, before challenge with GlyH-101 and TNF-α for 5, 10 and 30 
mins in FGM. Changes in fluorescent intensity were compared with cells treated with 0.1% 
(v/v) DMSO or media alone, as controls for GlyH-101 and TNF-α respectively, and 
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designated 100% at each time point. In some experiments, the mitochondrial targeting 
antioxidant MitoQ was added at 1 µM for 30 mins in FGM prior to challenge of the cells 
with GlyH-101 for 5 mins. Plates were read at 37 °C in 5 % CO₂, Polar Star Optima plate 
reader, with excitation wavelength at 485 nm and emission wavelength at 520 nm. For live 
cell imaging, dishes were examined on a ZEISS LSM 710 confocal microscope with 
immersion objectives and stage with temperature control, but without atmospheric 
control. 
H2O2 was measured in HLMVECs seeded at 5 x 104 cells/well/300 µl FGM in wells of 24-well 
plates, incubated in the absence and presence of 10 µM diphenyleneiodonium chloride 
(DPI) in FGM for one hour, before challenge with CFTR inhibitor GlyH-101 (20 µM) and 
control DMSO (0.1 %; v/v) for 5, 10, 30 mins. Cells were lysed in 125 µl of hypotonic lysis 
buffer (20 mM NaCl, 1 % Triton X-100, 20 mM Tris-base, and pH to 7.4, with protease 
inhibitors (Calbiochem), and sodium azide (0.1 % w/v), to inhibit CAT and peroxidase 
activity) and H2O2 quantified against an H2O2 standard in the range 3.125-200 µM using the 
Amplex Red assay (86). 
5.3.8. MTT assay 
MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (0.5 mg/ml) added to 
cells for 4 h was reduced by cellular metabolic activity to formazan, which was solubilised 
with 10 % sodium dodecyl sulphate in 0.01 M HCl, and the absorbance read at 570 nm. 
5.3.9. Immunocytochemistry for CFTR, Nrf2, NF-κB and phospho-c-Jun 
Cells in collagen-coated eight-well chamber slides were fixed in paraformaldehyde (4 %) 
and permeabilised with Triton X-100 (0.1 %). No primary antibody controls were included 
for each analysis. 
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For CFTR staining, non-specific antibody-binding sites were blocked with BSA (2 %, for 16 h 
at 4 °C) and cells incubated with rabbit anti-CFTR antibody “Mr. Pink” (1/500), followed by 
goat anti-rabbit antibody conjugated to Alexa Fluor-555 (2 µg/mL; Molecular Probes).  
For NF-κB localisation, non-specific antibody-binding sites were blocked with rabbit serum 
(5 %, for 1 h) and cells incubated with mouse anti-p65 (4 µg/ml; Santa Cruz), for 16 h at 4°C, 
followed by rabbit anti-mouse antibody conjugated to Alexa Fluor-488 (2 µg/mL; Molecular 
Probes) for 1 h at room temperature.  
For Nrf2 staining, cells were blocked with 5% goat serum overnight at 4°C, then rabbit 
polyclonal anti-Nrf2 (Santa Cruz) at 4 µg/mL was added for 1 h at 4°C, followed by Alexa 
Fluor-555 goat anti-rabbit IgG (2 µg/mL; Molecular Probes) for 1 h at room temperature.  
For phospho-c-Jun staining cells were blocked with 5% goat serum overnight at 4˚C, then 
rabbit anti-p-c-Jun (Ser 63/73), Santa Cruz) at 0.8 µg/mL was added for 1 h at 4˚C, followed 
by goat anti-rabbit Alexa Fluor-555 (Molecular Probes) at 2 µg/mL for 1 h at room 
temperature.  
Nuclei were stained with 5 µg/mL Hoechst 33342 (Molecular Probes) for 10 mins, and slides 
mounted in Fluor-Preserve Reagent for imaging with a Zeiss LSM 710 confocal microscope. 
5.3.10. RNA extraction and reverse transcription 
Total RNA was extracted using ReliaPrep RNA Cell Miniprep System (Promega) according to 
manufacturers’ instructions. The concentration and purity (absorbance ratios at 260/230 
and 260/280 of ≥ 2.0) of RNA in samples was determined using a Nanodrop 
spectrophotometer. RNA was then reverse transcribed into cDNA using the first step of the 
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GoTaq 2-Step RT-qPCR System (Promega) and either stored at -20 °C or immediately used 
in quantitative PCR. 
5.3.11. Quantitative real-time polymerase chain reaction (qRT-PCR) 
CFTR, IL-8 and β-actin transcripts were amplified from cDNA (1 µg), using the following 
primers: CFTR (105 bp) sense 5ʹ- ATG CCC TTC GGC GAT GTT TT -3ʹand antisense 5ʹ- TGA 
TTC TTC CCA GTA AGA GAG GC -3ʹ;  
IL-8 (194 bp) sense 5ʹ- TTT TGC CAA GGA GTG CTA AAG A -3ʹ and antisense 5ʹ- AAC CCT CTG 
CAC CCA GTT TTC -3ʹ:  
β-actin (93 bp) sense 5ʹ- CGC GAG AAG ATG ACC CAG AT -3ʹ and antisense 5ʹ- GCC AGA GGC 
GTA CAG GGA TA -3. The cycles for the qRT-PCR were: 2 min at 95 °C, then 35 cycles for 
quantitation of IL-8 expression and 40 cycles for detection of CFTR mRNA of 10 s at 95 °C, 
20 s at 62 °C, and 60 s at 72 °C. Data were collected using a Roche Diagnostics International 
Ltd LightCycler 96.  
For nested or two-step, quantitative PCR, a 526 bp region of CFTR was first amplified using 
primers: sense 5ʹ- ACA GCG CCT GGA ATT GTC AGA C -3ʹand antisense 5ʹ- AGC GAT CCA CAC 
GAA ATG TGC C -3ʹ, followed by a second round of amplification using the CFTR-specific 
primers and conditions used in the single-step quantitative PCR. 
 To exclude the possibility of amplification from contaminating genomic DNA during the 
qRT-PCR reaction, we utilised a DNAse step in the ReliaPrep protocol during mRNA 
extraction, and primers were designed to span at least one or more large (>20,000 bp) 
introns, precluding amplification from genomic DNA directly. Negative control reactions, 
not including template cDNA (no template control) or reverse transcriptase (“-RT”, or no 
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amplification control), were also performed and accepted when the threshold value (Ct) 
was at least five cycles greater than the experimental amplifications. Measurements were 
performed in duplicate and accepted if the difference between the Ct values of the 
duplicates was less than 1. The generation of a single product of appropriate size was 
routinely checked by the presence of a single melt peak and by agarose gel electrophoresis. 
Data were analyzed using Roche LightCycler software. A relative expression method was 
implemented, normalizing the data by the internal control β-actin and expressing the final 
result relative to the control group. 
5.3.12. Electroporation and CFTR silencing 
Electroporation were used to introduce small interfering RNA to target the CFTR gene in 
HLMVECs. HLMVECs (0.75 X 10⁶) were suspended in 100 µl of OptiMEM medium and 
transferred to a sterile cuvette for the NEPA21 electroporator and 2 µl of siRNA for CFTR 
or validated non-targeting siRNA pool (50 µM) was added to a final concentration of 1 µM. 
For CFTR siRNA (ON-TARGET plus Human CFTR (1080) siRNA-SMART pool (Dharmacon) was 
used, which consists of a mixture of 4 siRNA with target sequence as the following: 
1- GAACACAUACCUUCGAUAU 
2- GUACAAACAUGGUAUGACU 
3- GUGAAAGACUUGUGAUUAC 
4- GCAGGUGGGAUUCUUAAUA 
The cells were electroporated according to the pulse settings in Table 5.1. 
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Table 5.1.  Electroporation pulse settings 
Poring Pulse Transfer Pulse 
V Length 
ms 
Interval 
ms 
No. D. 
Rate 
(%) 
Polarity V Length 
ms 
Interval 
ms 
No. D. 
Rate 
(%) 
Polarity 
170 2.5 50 2 10 + 20 50 50 5 40 +/- 
 
After electroporation cells were transferred to the wells of a collagen-coated 6 well plate 
at a final concentration of 1.5 x 10⁶ cell/well/ 2ml of FGM. The medium then was changed 
every 24 hour, for a total of 72 hour, then the supernatants for the last 24 hour were 
harvested and processed and used to analyse IL-8 concentrations by ELISA. 
5.3.13. Statistical analysis 
Statistical analysis was carried out using GraphPad Prism version 8. Data is presented 
graphically as mean ± SEM, and analysed by one-way or two-way ANOVA with post-hoc 
tests for multiple comparisons as appropriate and as indicated in the Figure legends. 
5.4. Results 
5.4.1. CFTR expression. 
CFTR could be detected on western blot as two high molecular weight bands in HLMVEC 
lysates, the partially glycosylated band B (140 kDa) and fully mature band C (170 kDa) 
(Figure 5.1A). However, the level of expression was highly variable between preparations. 
Levels of CFTR detected by IHC appeared to be lower in HLMVECs than in the 16HBE 
bronchial epithelial cell line and, in addition to the plasma membrane, CFTR was detected 
in association with intracellular organelles possibly the endoplasmic reticulum around the 
nucleus (Figure 5.1B). Additionally, much lower levels of CFTR mRNA were detected in 
HLMVECs compared to 16HBE cells (Figure 5.1C). The expression of CFTR mRNA In 
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HLMVECs was confirmed by nested PCR (Figure 5.1D) which increased the intensity of the 
expected 100 bp CFTR product observed in single round PCR while the expected 500 bp 
product was faintly detected. 
Figure 5.1. CFTR expression in HLMVECs. A) Immunoblot of CFTR in whole cell extracts of HLMVEC, 16HBE 
and HEK293 cells. All data are representative of that obtained in at least three independent experiments. B) 
Immunolocalisation of CFTR in HLMVEC, 16HBE and HEK293 cells (the control refers to the no-primary 
antibody negative control). All images were acquired and displayed under identical conditions. C) RT-PCR 
amplification of CFTR (light grey), β-actin (solid) and reverse-transcription negative control (-RT CFTR, dotted 
line) in HLMVECs, and CFTR in 16HBE cells (positive control, dark grey). D) Gel analysis of CFTR cDNA amplified 
from HLMVEC, 16HBE mRNA and -RT control following single and nested RT-PCR. E&F) CFTR expression in 
HLMVECs cell lysate by western blot after 16 h incubation with GlyH-101 (20 µM) and DMSO (0.1 %; v/v) 
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vehicle control. Data were normalised to β-actin, numbers expressed as average of 3 independent 
experiments. Each experiment was conducted on HLMVECs obtained from three different donors. (p < 0.05 
for the difference between GlyH-101 and control). The scale bar represents 50 µm. 
In view of previous reports of the negative regulation of CFTR expression by CFTR activity 
(550), we investigated the effect of CFTR inhibition on CFTR expression. The abundance of 
CFTR in cells treated for 16 h with GlyH-101 (20 µM) was significantly higher (p < 0.05, one-
tailed t-test) than control cells treated with DMSO (0.1 %; v/v) (Figure 5.1E and F).  
5.4.2. GlyH-101 and HLMVEC viability 
Incubation of cells with GlyH-101 at concentrations of 5-20 µM for up to 24 h had no 
significant effect on HLMVEC metabolic activity (MTT reduction) compared to control 
(Figure 5.2). After 48 h incubation with 20 µM GlyH-101, the significant (p < 0.01) 40 ± 1.6% 
decrease in MTT reduction compared with the DMSO control was associated with a 
reduction in the number of cells adherent to the plate. Experiments using GlyH-101 to 
inhibit CFTR were therefore conducted over periods of up to 24 h. 
Figure 5.2. Effect of GlyH-101 on HLMVEC metabolic activity. HLMVECs were treated for 16, 24 and 48 h with 
CFTR inhibitor GlyH-101 at 5, 10 and 20 µM. Results were compared with DMSO vehicle (0.1%; v/v). Data 
were expressed as mean ± SEM (**p ˂ 0.01 comparing GlyH-101 (20 µM) to DMSO (0.1 %; v/v) at 48 hour, n 
= 3 independent experiments). Data were analysed with two-way ANOVA and Tukey’s multiple comparison 
test.   
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5.4.3. CFTR activity 
CFTR activity was detected as membrane depolarisation leading to increased uptake and 
fluorescence of intracellular FLIPR Blue. The significant (p < 0.001) inhibitory effect of GlyH-
101 on control cells indicates constitutive activity of CFTR in HLMVECs (Figure 5.3A). This 
was not seen in HEK293 cells used as a negative control or 16HBE cells used as a positive 
control. The cAMP-elevating agent Fk (an AC activator) together with IBMX (a PDE inhibitor) 
strongly stimulated CFTR activity and HLMVEC membrane depolarisation, measured as an 
increase in fluorescence that was significantly (p < 0.05) inhibited 34 % by GlyH-101 (20 
µM) (Figure 5.3B). The depolarisation response of 16HBE cells was significantly (p < 0.05) 
greater than that of HLMVECs and was significantly inhibited 26.4% by GlyH-101. This 
decrease in fluorescence was attributed to inhibition of CFTR activity. HEK293 cells that do 
not express CFTR (175) showed a significantly (p < 0.05) greater depolarisation in response 
to Fk/IBMX than HLMVECs, but there was no significant inhibitory effect of GlyH-101 
(Figure 5.3B) and no effect on unstimulated control cells (Figure 5.3A). 
Figure 5.3. CFTR activity in HLMVECs at baseline and following cAMP-dependent activation. CFTR activity was 
measured at baseline (A) and following cAMP-dependent activation (B) of HLMVECs, non-CFTR expressing 
HEK293 cells and CFTR expressing 16HBE cells for comparison.  CFTR activity at baseline was measured as a 
decrease in fluorescence (ΔRFU) following treatment of cells with the CFTR inhibitor GlyH-101 (20 µM, grey 
bars), reflecting membrane hyperpolarisation and decreased uptake of FLIPR compared to cells treated with 
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0.1% DMSO vehicle control (black bars). Activation of CFTR (B) was measured as an increase in fluorescence 
(ΔRFU) following membrane depolarisation of HLMVECs, HEK293 and 16HBE cells activated with Fk (100 µM) 
plus IBMX (1000 µM) (F/I) for 2 mins in the absence (black bars) and presence (grey bars) of GlyH-101 (n = 3 
independent experiments, each carried out in quadruplicate). Data were analysed by two-way ANOVA and 
Holm-Sidak multiple comparisons test (* p < 0.05, ** p < 0.01, *** p < 0.001 for the comparisons indicated). 
5.4.4. CFTR and oxidative stress. 
Using live-cell imaging, low levels of intracellular ROS were observed at time zero, which 
increased over 30 mins after treating the cells with GlyH-101 (Figure 5.4A). However, using 
a quantitative approach to measuring ROS generation, a faster response was detected in 
stimulated cells compared to unstimulated control cells (Figure 5.4B). The slower response 
during live cell imaging may reflect the absence of atmospheric control during the 
experiment. 
Both TNF-α, included as a positive control, and GlyH-101 induced a significant increase in 
ROS of 165.2 ± 35.1 % and 170 ± 11.5 %, (p < 0.01, p < 0.001) respectively, compared to 
unstimulated control cells at 5 mins. The response to GlyH-101 was sustained over 30 mins 
and was significantly higher than the response to TNF-α at 10 and 30 mins (p < 0.01, p < 
0.05, respectively), while the response to TNF-α was back to control levels at 10 mins 
(Figure 5.4B).  
NAC (10 mM), added 3 h before GlyH-101, had no effect on ROS production at 5 and 10 
mins following stimulation with GlyH-101. After 10 mins, ROS production in response to 
GlyH-101 was 164.5 ± 9.9% of the control value, and in the presence of NAC was still 156.9 
± 50% of the control value (n = 6). However, NAC (10 mM) not only reversed the effect of 
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GlyH-101 on ROS levels at 30 mins, but also significantly (p < 0.01) reduced the level of ROS 
to 42.8 ± 28.1 % fluorescence intensity, below that observed in control cells (Figure 5.4B). 
Figure 5.4. Oxidative stress in HLMVECs following CFTR inhibition with GlyH-101. A) Intracellular ROS in 
HLMVECs using live cell imaging. Intracellular ROS in HLMVECs detected using carboxy H2-DFFDA. GlyH-101 
(20 µM) was added and the fluorescence detected at 0, 10 and 30 mins. Scale bar 50 µm. Images 
representative of duplicate wells in a single experiment. B) Quantification of intracellular ROS in HLMVECs 
using carboxy-H2DFFDA. HLMVECs were incubated for 5-30 mins in the absence and presence of GlyH-101 
(20 µM) and TNF-α (10 ng/ml) and ROS detected by intracellular DFFDA. The experiments were conducted in 
triplicate, n = 6 independent experiments for GlyH-101 in the absence and presence of 10 mM NAC, and n = 
3 for TNF-α. Control values at each time point were designated 100% (filled circles). Data points represent 
the mean ± SEM. Results were analysed with two-way ANOVA and Tukey’s multiple comparisons test. (****p 
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< 0.0001, *** p < 0.001) comparing GlyH-101 to control and (** p < 0.01) comparing TNF-α to control, (††, p 
< 0.01, † p < 0.05 comparing GlyH-101 and TNF-α). C) Quantification of intracellular H2O2 using Amplex Red. 
HLMVECs were treated with GlyH-101 for 5-30 mins, and H2O2 measured in cell lysates using Amplex Red 
reagent. **p ˂ 0.01 in comparison to DMSO after 30 mins, (n = 4). Data were expressed as average ± SEM and 
analysed with two way ANOVA and Tukey’s post hoc test. D) Intracellular SOD2. SOD2 was measured by ELISA 
in HLMVECs cell lysates following CFTR inhibition with GlyH-101 (20 µM). Data were analysed with one way 
ANOVA and Dunnett’s test, n = 3. (* p < 0.05, ** p < 0.01 compared to DMSO control at 24 h). E) Quantification 
of intracellular ROS in HLMVECs using carboxy-H2DFFDA. HLMVECs were incubated for 30 mins with/without 
MitoQ (1 µM) followed by 5 mins incubation with GlyH-101 (20 µM) and ROS detected by intracellular DFFDA. 
The experiments were conducted in quadruplicate, n = 3 independent experiments. F) Quantification of 
intracellular ROS in 16HBEs using carboxy-H2DFFDA. 16HBEs were incubated for 30 mins with/without MitoQ 
(1 µM) followed by 5 mins incubation with GlyH-101 (20 µM) and ROS detected by intracellular DFFDA. The 
experiments were conducted in quadruplicate, n = 4 independent experiments. 
The staining pattern observed during live cell imaging was punctate, which suggested a 
mitochondrial source of ROS. However, the mitochondrial-targeting antioxidant MitoQ had 
no effect in HLMVEC or 16HBE cells on ROS production over 5 mins following challenge with 
GlyH-101 (Figure 5.4E and F)  
H2DFFDA detects intracellular oxidative stress rather than a specific reactive species (154). 
We therefore measured H2O2, one of the major ROS in cells. H2O2 was not detected in 
supernatants, but intracellular H2O2 was significantly (p < 0.01) increased following 30 mins 
treatment with GlyH-101 (36.1 ± 2.7 µM) compared to control (13.2 ± 2.5 µM), with no 
significant changes at earlier time points (Figure 5.4C). Incubation of cells with 10 µM DPI 
for 1 hour prior to and during GlyH-101 challenge had no effect on H2O2 concentrations. 
Intracellular SOD2 protein levels were significantly increased over 16-24 h following CFTR 
inhibition (Figure 5.4D), although no significant changes in CAT protein levels were 
observed over 24 h (data not shown). 
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5.4.5. CFTR and Nrf2 expression 
Chen et al. (86) reported significantly reduced Nrf2 expression in CF epithelia and in normal 
epithelial cells treated with the CFTR inhibitor CFTRinh-172. Therefore, Nrf2 expression in 
HLMVECs was investigated following CFTR inhibition with GlyH-101 (20 µM) for up to 24 h. 
IHC demonstrated that Nrf2 was mostly absent from the cytoplasm after 24 hour 
incubation with GlyH-101, compared to control cells (Figure 5.5A). The overall abundance 
of Nrf2 was significantly (p < 0.05) decreased at 6 h and had decreased further still by 70.8 
± 11.6 % at 24 h, p < 0.001, compared to control cells (Figure 5.5B and C). 
Figure 5.5. The effect of CFTR inhibition on Nrf2 expression. The effect of CFTR inhibition on Nrf2 expression 
over 24 h was investigated by immunocytochemistry (A) and by western blot (B,C). A) CFTR inhibition by GlyH-
101 (20 µM) results in loss of cytosolic Nrf2 (arrows in control) with residual Nrf2 in nuclei. Scale bar 50 µm. 
Images are representative of 2 independent experiments. B,C) Nrf2 was detected on western blot as an 85 
kDa band in control cells (lane C) at 24 h (B), this value was significantly reduced by 70 % with GlyH-101 over 
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24 h (C). Bars indicate mean ± SEM (***p < 0.001) for comparison with 24 h control, n = 3 independent 
experiments. 
5.4.6. CFTR and VEGF expression 
Since ROS induce the expression of endothelial VEGF (274), we investigated the effect of 
GlyH-101 on VEGF levels in HLMVEC culture supernatants. GlyH-101 significantly (p < 0.05) 
increased VEGF concentration in the supernatants (202.1 ± 22.1 pg/ml) compared to 
control (74.24 ± 11.8 pg/ml) over 16 h (Figure 5.6A). TNF-α, alone, did not have a significant 
effect on VEGF levels, but further significantly (p < 0.01) increased the response to GlyH-
101 (394.5 ± 50.4 pg/ml). Treatment of cells with NAC (5 mM) significantly reduced VEGF 
levels in the presence of GlyH-101 plus TNF-α to 105.6 ± 21.8 pg/ml, which was thus found 
not significantly higher than control levels (data not presented graphically).  
Figure 5.6. The effect of CFTR inhibition on VEGF concentrations in HLMVEC culture supernatants. A) VEGF 
concentration after 16 h CFTR inhibition with GlyH-101 (20 µM), in the absence and presence of TNF-α (10 
ng/mL). VEGF was measured by ELISA, and concentrations expressed as average ± SEM (* p < 0.05, **p < 0.01, 
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*** p < 0.001). Data were analysed with one-way ANOVA test and Tukey’s multiple comparison test, n = 6 
independent experiments, each carried out in triplicate. B) The effect of AG1478 on VEGF concentration 
alone, and after 24 h CFTR inhibition with GlyH-101 (20 µM) in the absence and presence of TNF-α. VEGF was 
measured by ELISA, and concentrations expressed as average ± SEM (*** p < 0.001). Data were analysed with 
one-way ANOVA test and Tukey’s multiple comparison test, n = 3 independent experiments, each carried out 
in triplicate. 
In cultured airway epithelial cells, treatment with CFTR inhibitors triggered EGF receptor 
(EGFR) phosphorylation that was required for VEGF synthesis (322). We therefore 
investigated the effect of EGFR inhibition on VEGF synthesis in HLMVECs. Pre-treatment 
with the EGFR inhibitor AG1478 (10 µM) caused a non-significant increase in VEGF levels at 
16 h (results not shown). However, a significant increase in VEGF (481.6 ± 59.2 pg/ml) was 
seen following EGFR inhibition with AG1478, alone, compared to control (13.48 ± 2.9 
pg/ml) over 24 h (Figure 5.6B). The effect of AG1478 was observed in the presence of GlyH-
101, and in the presence of both the CFTR inhibitor and EGFR inhibitor VEGF levels were 
598.8 ± 63.7 pg/ml. Addition of TNF-α at this time point had no further significant effect on 
VEGF levels. 
5.4.7. CFTR and IL-8 expression 
Control, unstimulated, HLMVECs expressed IL-8 that was predominantly in soluble form 
and released into supernatants (Figure 5.7). The CFTR inhibitor GlyH-101 (20 µM) 
significantly (p < 0.05) increased IL-8 protein levels in both supernatants and HLMVEC cell 
lysates (Figure 5.7A). IL-8 concentrations were significantly higher in supernatants than 
lysates under all conditions. TNF-α (10 ng/ml), in the absence and presence of GlyH-101, 
further significantly increased IL-8 levels in both fractions over 16 h. The response to TNF-
α plateaued at 16 h (Figure 5.7B), but the combination of GlyH-101 (20 µM) and TNF-α (10 
ng/ml) significantly (p < 0.001) increased IL-8 levels even at 24 h compared to the effect of 
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TNF-α alone. AG1478 (10 µM) and NAC (5 mM) significantly (p < 0.01 and p < 0.05 
respectively) inhibited the response to the combination of TNF-α plus GlyH-101 at 24 h. 
The increase in protein concentration mirrored the increase in IL-8 mRNA expression 
following 16 hour incubation with GlyH-101 (20 µM) and TNF-α (10 ng/ml), alone and in 
combination (Figure 5.7C).  
Figure 5.7. IL-8 in HLMVEC cells and supernatants. A) Concentration response curve for CFTR inhibitor GlyH-
101 in the absence and presence of TNF-α (10 ng/ml) for 16 h. GlyH-101 at 20 µM significantly increased IL-8 
in supernatant, cell lysate, with and without TNF-α (* p ˂ 0.05, ** p ˂ 0.01, *** p ˂ 0.001) comparing GlyH-
101 with control for each condition. TNF-α significantly increased IL-8 in lysate (p = 0.01) and in supernatant 
(p = 0.001). IL-8 concentration in supernatant was significantly higher than in lysate (p ˂ 0.001) in the absence 
and presence of TNF-α. B) Time course for the effect of TNF-α (10 ng/ml) alone and in the presence of GlyH-
101 (20 µM) on IL-8 levels in HLMVEC supernatants.  (**** p < 0.0001 compared to 24h control, FGM), († p < 
0.01, †† p < 0.001 compared to TNF-α alone), (n = 3). AG1478 (10 µM, filled triangle) and NAC (5 mM, open 
circle) significantly (p < 0.01 and p < 0.05 respectively) inhibited the response to the combination of TNF-α 
plus GlyH-101 at 24 h. Data were expressed as mean ± SEM. The data were analysed with two-way ANOVA 
and Tukey’s multiple comparison test, or one-way ANOVA for the effects of AG1478 and NAC on the response 
to the combination of TNF-α plus GlyH-101. C) Quantitative changes in IL-8 mRNA levels, normalised to β-
actin, following 16 h incubation with GlyH-101 (20 µM) and TNF-α (10 ng/ml), alone and together, compared 
to DMSO (0.1 %; v/v) control. * p < 0.05 comparing GlyH-101 with DMSO control, and TNF-α+GlyH-101 with 
TNF-α alone (n = 3). 
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5.4.8. Specificity of GlyH-101 
Melis et al. (332) reported non-specific inhibitory effects of GlyH-101 on volume-sensitive 
ORCC, also termed VRAC, and CaCC in murine cell lines expressing CFTR. More recently, 
Friard et al. (175) also reported inhibitory effects of GlyH-101 on VRAC conductance in the 
immortalised human embryonic kidney cell line, HEK293 cells, with an IC50 of 9.5 µM and 
80 % inhibition at 20 µM.  
HEK293 cells, unlike endothelial cells, do not express CFTR or the calcium-activated chloride 
ion channels anoctamin-1 and anoctamin-2 (ANO1/2, also termed TMEM16A and 
TMEM16B, respectively) (175). Therefore to investigate whether the pro-inflammatory 
effects of GlyH-101 effects on HLMVEC were due to inhibitory effects on VRAC activity, 
HEK293 cells were incubated with 20 µM GlyH-101 for 24 h and IL-8 levels measured in cell 
culture supernatants. Because HEK293 cells express moderate levels of endogenous TNF-α 
receptors (197), TNF-α (10 ng/ml) was used as a positive control. TNF-α (10 ng/ml), but not 
GlyH-101, significantly increased IL-8 concentrations in HEK293 cell culture supernatant 
compared to control levels (Figure 5.8A), indicating the effect of GlyH-101 was not 
mediated by VRAC. 
This was confirmed using the potent (IC50 4.8 µM) and specific VRAC inhibitor DCPIB (4-(2-
butyl-6,7-dichlor-2-cyclopentyl-indan-1-on-5-yl) oxybutyric acid (175), in cultures of 
HLMVECs with GlyH-101 (20 µM) and TNF-α (10 ng/mL) as positive controls. Both TNF-α 
and GlyH-101 significantly increased IL-8 in culture supernatants, but DCPIB at 20 µM had 
no effect (Figure 5.8B). 
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Figure 5.8. CFTR-specific inhibition mediates pro-inflammatory effects in HLMVECs. A) non-CFTR expressing 
HEK293 cells were incubated with GlyH-101 (20 µM) and TNF-α (10 ng/ml) as a positive control, and IL-8 was 
measured in culture supernatants by ELISA (n = 3). B) HLMVECs were cultured for 24 h in the absence and 
presence of the CFTR inhibitor GlyH-101 (20 µM), the TMEM16A-specific inhibitor Ani-9 (10 µM), the VRAC-
specific inhibitor DCPIB (20 µM) and TNF-α (10 ng/mL) as a positive control, and IL-8 was measured in culture 
supernatants by ELISA (n = 3). Data were analysed by one-way ANOVA with Dunnett’s multiple comparisons 
post-hoc test. 
Additionally, the potent (IC50 77 nM) TMEM16A-specific inhibitor Ani9 (2-(4-chloro-2-
methylphenoxy)-N-[(2-methoxyphenyl)methylideneamino]-acetamide), that lacks 
inhibitory activity against CFTR and VRAC (468) did not induce significant IL-8 expression by 
HLMVECs at the relatively high concentration of 10 µM (Figure 5.8B).  
5.4.9. Effect of CFTR gene silencing 
The anti-inflammatory function of endothelial CFTR was confirmed using a siRNA approach 
to CFTR gene silencing. A significantly (p < 0.05) higher concentration of IL-8 was measured 
in the supernatants of HLMVECs transfected with CFTR siRNA compared with cells 
transfected with non-targeting siRNA. The non-targeted cells yielded 160.01 ± 17.2 pg/ml 
IL-8 in HLMVEC supernatants, while silencing of CFTR (siCFTR) in HLMVECs gave 265.4 ± 
36.7 pg/ml IL-8 in the supernatant (Figure 5.9) confirming constitutive CFTR activity in 
HLMVECs.  
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Figure 5.9. CFTR gene silencing using siRNA in HLMVECs induced a significant increase in IL-8 in supernatants. 
After targeting CFTR mRNA for 72 hour, the results were compared with non-targeting siRNA as negative 
control. (* p < 0.05, n = 4 independent experiments, with each experiment carried out in duplicate). Data 
were expressed as mean ± SEM and analysed by t-test. 
5.4.10. CFTR and cell signalling 
We investigated the effect of CFTR inhibition on activation of NF-kB and AP-1, two key 
signalling pathways leading to IL-8 expression (230), with TNF-α (10 ng/ml) as a positive 
control stimulus. While TNF-α clearly stimulated nuclear translocation of the NF-kB p65 
subunit (Figure 5.10A, panel 2), CFTR inhibition with GlyH-101 (20 µM) had no effect (Figure 
5.10A, panel 3). However, both GlyH-101 and TNF-α significantly (p < 0.05) increased 
phosphorylation of the AP-1 c-Jun subunit (Figure 10, C1 and C2) and increased its nuclear 
translocation (Figure 5.10B and D). 
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Figure 5.10. The effect of GlyH-101 on cell signalling. A) NF-κB immunocytochemistry of HLMVECS after 1 
hour of 1; DMSO (0.1 %; v/v), 2; TNF-α (10 ng/ml), 3; GlyH-101 (20 µM). B) p-c-jun immunocytochemistry of 
HLMVECs after 30 min of 1; DMSO (0.1 %; v/v),2; TNF-α (10 ng/ml), 3; GlyH-101 (20 µM). C) p-c-jun western 
blotting. C1) image of whole cell lysate after treating HLMVECs with DMSO (0.1 %; v/v), TNF-α (10 ng/ml), 
GlyH-101 (20 µM) for 30 min. C2) quantification p-c-jun on western blots from 3 independent experiments. 
Data were analysed with one-way ANOVA and Fisher post-hoc t-test. (* p ˂ 0.05, n = 3). D) 
Immunocytochemistry quantification of relative nuclear to cytoplasmic p-c-jun intensity, data represent 3 
independent experiments, in which 20 cells were quantified from each condition. Data were analysed with 
one-way ANOVA, and Fisher test (* p ˂ 0.05, ** p ˂ 0.01, n = 3). Scale bars equate 50 µM. 
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5.5. Discussion 
Endothelial CFTR expression was confirmed in the present study, but appeared to be lower 
in our model than previously reported in HLMVECs (519), possibly reflecting growth on 
collagen IV, which is an exclusive component of basement membranes that regulates 
endothelial cell function (551). Levels of expression varied greatly between HLMVEC 
preparations, as reported for other tissues (428), and appeared to be largely associated 
with intracellular organelles with punctate staining indicating localisation in the 
endoplasmic reticulum surrounding the nucleus, as previously reported in endothelial cells 
(519). However, the low levels of mature CFTR in the plasma membrane were activated by 
cAMP-elevating agents, Fk plus IBMX, to cause cell depolarisation. This response was 
inhibited by GlyH-101, a water-soluble glycine hydrazide reported to bind to CFTR 
externally in the channel pore where, at 10 µM, it rapidly and completely inhibited CFTR 
chloride channel activity in human airway epithelial cells (354). The cAMP-elevating agents 
strongly stimulated depolarisation in both HLMVECs and 16HBEs and the non-CFTR 
expressing HEK293 cells. Significant inhibition of the response by GlyH-101 in HLMVECs and 
16HBEs indicated that depolarisation was partly due to CFTR. However, other cAMP-
activated channels, such as cAMP-gated non-selective cation channels (370), which are not 
inhibited by GlyH-101, may also contribute to depolarisation in these cells. 
Oxidative stress is a key contributor to vascular endothelial dysfunction in people with CF 
(525). In the present study, increased intracellular oxidative stress in HLMVECs and 16HBEs 
was demonstrated in response to CFTR inhibition. Chen et al. (86) previously reported an 
increase in intracellular H2O2 following 72 h of CFTR inhibition in human bronchial epithelial 
cells. The difference lies in the rapid response in HLMVECs, in which intracellular ROS were 
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significantly induced over 5 to 30 mins following CFTR inhibition with GlyH-101 and was 
reflected in a significant increase in intracellular H2O2 concentrations at 30 mins. NAC has 
only weak direct antioxidant properties towards O₂̇‾ and H2O2 (5). However, as a precursor 
of cysteine (Cys), and thus of GSH synthesis, NAC is effectively an indirect antioxidant, GSH 
being a direct antioxidant and a substrate of several antioxidant enzymes (5). A rapid, 
within 10 mins, significant 50% decrease in GSH in airway epithelial cells following CFTR 
inhibition with the CFTR inhibitor CFTRinh-172 was recently reported (116). Thus, if CFTR 
inhibition similarly lowers intracellular GSH concentrations in HLMVECs, this may 
contribute to the observed rapid increase in ROS following treatment with GlyH-101. On 
the other hand, the significant decrease in ROS observed in the presence of 10 mM NAC 
may reflect an increase in intracellular GSH, as previously reported for human pulmonary 
vascular endothelial cells treated with 10 mM NAC (216). Major sources of ROS production 
in vascular endothelial cells include the mitochondria, endoplasmic reticulum, plasma 
membrane and cytosolic enzymes (62). However, the mitochondrially targeting antioxidant 
MitoQ did not attenuate ROS production in HLMVEC or 16HBEs, and since the NOX/Duox 
inhibitor, DPI at 10 µM, failed to inhibit H2O2 formation, another source of ROS is indicated, 
which warrants further investigation.  
Mitochondrial defects and increased production of ROS, although controversial (461), have 
been reported in CF lung (21, 535) and gut (276) epithelial cells. Previous work has 
demonstrated, in intestinal epithelial cells, that CFTR knockout significantly increased 
mitochondrial levels of H2O2 and decreased mitochondrial levels of Nrf2 (276). As in 
bronchial epithelial cells (86), CFTR inhibition in HLMVECs led to a 70% decrease in 
endothelial Nrf2 expression in the present study. Although further work is needed to 
demonstrate the subcellular organelle distribution of Nrf2 in HLMVECs, its disappearance 
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from the extranuclear compartments over 24 h is indicative of degradation of cytosolic Nrf2 
released from Kelch-like ECH associated protein (Keap-1) under conditions of oxidative 
stress. In addition to regulation by proteosomal degradation, cytosolic Nrf2 levels are 
regulated at the stage of Nrf2 gene transcription. Amongst factors that increase Nrf2 
transcripts is Nrf2 itself (504), possibly contributing to the overall significant decrease in 
Nrf2 levels following CFTR inhibition. Of interest, is the recent observation that clinically 
approved CFTR modulators rescue Nrf2 dysfunction in CF airway epithelial cells (49). The 
effect of CFTR modulators on endothelial Nrf2 expression and activity remains to be 
investigated. 
Since GlyH-101 did not activate endothelial NF-κB herein (Figure 5.5), the increased 
expression of CFTR following CFTR inhibition, is unlikely to be via activation of the TNF-R 
adaptor molecule (TRADD) and NF-κB activation, as has been previously described in 
bronchial epithelial cells (550). However, Nrf2 has an inhibitory effect on CFTR expression 
(426) and repression of CFTR expression occurs under conditions of prolonged oxidative 
stress in bronchial epithelial cells (585). Thus, significantly reduced levels of endothelial 
Nrf2 may contribute to the observed increase in endothelial CFTR expression. 
Nrf2 expression is central to limiting oxidative stress and inflammation, and reduced levels 
of Nrf2 are likely to activate endothelial redox sensitive pathways. CFTR dysfunction in 
airway epithelial cells was previously reported to significantly increase SOD2, while 
reducing CAT expression (86). Similarly, inhibition of endothelial CFTR induced a significant 
increase in SOD2, albeit in the absence of a significant decrease in CAT expression. 
Increased VEGF expression and peribronchial angiogenesis is a feature of the CF airway. 
VEGF promotes angiogenesis and increased vascular permeability, enhancing inflammatory 
CFTR as a regulator of endothelial inflammation, oxidative stress & cell signalling 
Page 143 of 300 
 
cell recruitment and plasma exudation in the airway. Inhibition of airway epithelial CFTR 
increased VEGF expression, an effect that was dependent on EGFR activity and inhibited by 
the receptor tyrosine kinase inhibitor AG1478 (322). Further, CF airway epithelial cells have 
increased EGFR activity and phosphorylation compared to normal cells (493). Thus it was 
suggested that EGFR tyrosine kinase inhibitors, such as AG1478, might be useful in the 
treatment of CF. However, the findings in the present study clearly indicate that such an 
approach further enhances the increased VEGF expression observed following CFTR 
inhibition in HLMVECs , and in this respect these endothelial cells differ from epithelial cells. 
Conversely, EGFR inhibition reduced IL-8 expression in CFTR-inhibited epithelial cells (273) 
and, as demonstrated in the present study, also in HLMVECs. Since anti-inflammatory 
therapies targeting inhibition of EGFR are likely to increase VEGF expression in endothelial 
cells, other approaches such as those that target oxidative stress (274) are needed.  
This notion is supported by our evidence that the antioxidant NAC significantly reduced 
ROS, and both IL-8 and VEGF expression in HLMVECs. In addition, others have recently 
demonstrated that ingestion of an antioxidant cocktail can improve vascular endothelial 
cell function and oxidative stress in patients with CF (525). 
Diminished Nrf2 levels are proposed to exacerbate activation of redox sensitive pathways 
including activation of AP-1 and NF-κB signalling leading to increased IL-8 expression (230) 
and activation of EGFR signalling pathways (71). GlyH-101 induced a rapid (within 30 mins) 
significant increase in the cellular abundance of phospho-c-Jun, including an increase in the 
concentration of nuclear phospho-c-Jun. These changes are indicative of increased c-Jun 
expression and activation of AP-1 signalling, which contribute to a self-amplifying cycle of 
increased c-Jun abundance (320). However, no nuclear translocation of p65, an indicator 
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of NF-κB activation, was seen following treatment of HLMVECs with GlyH-101 for up to one 
hour, ruling out a role for NF-κB activation via the canonical pathway in the IL-8 response 
to inhibition of CFTR activity.  
Unlike GlyH-101, TNF-α induced activation of both NF-κB and AP-1 signalling, leading to 
significantly increased IL-8 expression in HLMVECs, beyond the response to GlyH-101 alone. 
Of particular interest is the recent report that JNK is activated in CF epithelial cells and 
further activated in response to TNF-α (443). 
The complete inhibitory effect of AG1478 on the GlyH101-induced increase in IL-8 synthesis 
indicates that this response occurred via EGFR signalling, as previously described for human 
airway epithelial cells exposed to the CFTRinh-172 (273). EGFR activation leads to 
immediate response gene expression, including JUN and FOS, occurring over the first 45 
mins (22). The data therefore indicate the early, 30 mins, increase in phospho-c-Jun 
observed in response to GlyH-101 is mediated via hydrogen peroxide-activated EGFR 
signalling (553) and involved in AP-1-mediated IL-8 expression.  
The inhibitory effect of NAC on IL-8 production in response to GlyH-101 in the presence of 
TNF-α further indicates that ROS are involved in signalling pathways leading to IL-8 
synthesis. GlyH-101 appears to act solely through the EGFR cascade and AP-1 activation, 
while TNF-α activates both NF-κB and AP-1 signalling pathways. ROS contribute to EGFR 
activation, and activation of NF-κB and AP-1 signalling pathways, as described above. 
Whether endothelial oxidative stress further contributes to increased IL-8 gene expression 
through remodelling of chromatin structure and increased histone H4 acetylation at the IL-
8 promoter, as seen in CF airway epithelial cell models (33), is not known. 
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Some degree of non-specificity for GlyH-101 has been reported in murine epithelial cell 
lines (332), although these effects appear to be species specific (486). In murine cells, GlyH-
101 inhibited the VSORC and the CaCC, which in endothelial cells is predominantly 
TMEM16A. However, although TMEM16A activity was reported to negatively regulate pro-
inflammatory cytokine, including IL-8, synthesis in human CF bronchial epithelia (545), 
TMEM16A is a positive regulator of endothelial ROS (313), and its inhibition would lead to 
decreased ROS in endothelial cells, and not the increase reported in the current study, 
supporting the involvement of CFTR in the observed responses to GlyH-101. In our control 
experiments, inhibition of other chloride ion channels, VRAC and TMEM16A had no effect 
on IL-8 expression, and GlyH-101 had no effect on IL-8 expression in HEK293 cells that do 
not express CFTR. Together these experiments indicate that the observed effects of GlyH-
101 in HLMVECs reflect inhibition of CFTR activity.  
Others reported non-specific effects of GlyH-101 on mitochondrial respiration and a rapid 
increase in ROS levels that were independent of CFTR channel inhibition, although these 
were largely abrogated in the presence of 10% serum, and under these conditions GlyH-
101 had no effect on basal oxygen consumption (267). Serum (5%) was present in our 
HLMVEC cultures to provide a reducing extracellular environment (82) and as a source of 
albumin to increase intracellular GSH that protects pulmonary cells from oxidant-mediated 
cytotoxicity (77). Under these conditions, but not in the absence of serum, NAC acts as an 
anti-oxidant (82), as we observed. Further, we saw no effect of MitoQ on the GlyH-101 
stimulated ROS production in HLMVECs or 16HBEs, ruling out a direct effect of GlyH-101 on 
mitochondrial ROS. 
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Some of the findings in the current study are similar to those previously demonstrated for 
CFTR inhibition in airway epithelial cells, notably the increased release of IL-8 (396) and 
VEGF (322) and decreased Nrf2 expression (86) following CFTR inhibition. However, 
endothelial and epithelial responses differ in the signalling pathway leading to increased 
IL-8 expression, involving NF-κB activation in airway epithelial cells (396), but activation of 
AP-1 signalling with increased phospho-c-Jun in HLMVECs. Further, inhibition of EGFR 
tyrosine kinase limited epithelial expression of VEGF (322), but enhanced endothelial 
expression of VEGF. 
Systemic inflammation, oxidative stress and endothelial dysfunction were proposed to be 
major risk factors for cardiovascular disease in the aging CF population (427). Further, 
recent evidence suggests specific cardiac impairment in CF (42, 290) that may be associated 
with genotype severity (390).   
However, to date, there are limited options for anti-inflammatory therapy for CF (76). 
Targeting endothelial CFTR for correction and/or potentiation would seem to be a logical 
therapeutic approach, as small molecule correctors and potentiators are already in 
development to restore epithelial CFTR function. It was surprising that 6 months treatment 
with ivacaftor in CF patients with the G551D mutation improved lung function, and reduced 
sweat chloride, indicating an effect on CFTR function, without an effect on pulmonary 
inflammation (438). Systemic inflammation was not measured in the study, so it is not 
possible to appreciate the effect of the oral drug, Ivacaftor, on endothelial function. The 
combination of Lumacaftor with Ivacaftor (Orkambi™) for P.Phe508del patients was 
approved in 2015, but to our knowledge no studies have reported effects on systemic 
inflammation. 
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Correction of CFTR expression in the bronchial epithelium by gene transfer in 10-25% of 
cells in a population was sufficient to restore normal chloride conductance and epithelial 
function (251, 584). However, it is currently unclear whether low-level expression in many 
cells (e.g. 10% of residual CFTR expression) or a low number of cells expressing high levels 
of CFTR are required to restore normal function and achieve clinical benefit after gene 
therapy (200). Recent revised estimates of the number of endothelial cells in the human 
body indicate a total of 6 x 1011 cells (467), and low level of expression of CFTR in all of them 
may be sufficient to maintain normal barrier, anti-inflammatory and anti-oxidant 
endothelial function. 
Since, Nrf2 expression is central to limiting oxidative stress and inflammation (86), the 
reduced expression of Nrf2 in CF airway epithelium (86), and now demonstrated in 
pulmonary endothelial cells, strongly indicate Nrf2 may be a target to limit airway 
inflammation, by increasing its expression and activation in CF. Such an approach has been 
demonstrated using the synthetic triterpenoid CDDO (2-cyano-3,12-dioxooleana-1,9(11)-
dien-28-oic acid) in airway epithelial cell and animal models of CF (368). The effects of pre-
treatment with CDDO include the ability to reduce NF-κB activation while increasing the 
activity of Nrf2. As these two signalling pathways appear to be pivotal in regulating the net 
inflammatory response in the CF airway, it was suggested that these compounds may 
represent a promising anti-inflammatory therapy for CF lung disease. Other Nrf2 activators 
include natural products such as curcumin (28) and sulforaphane, an isothiocyanate 
enriched in broccoli sprouts, which has been proposed as a dietary supplement to activate 
Nrf2 (232). 
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In addition to inherited defects in CFTR in people with CF, inhibition of CFTR on endothelial 
cells increased the loss of barrier function induced by exposure of endothelial cells to 
cigarette smoke (65). Raju et al. (422) showed that smoking causes systemic CFTR 
dysfunction and that acrolein present in cigarette smoke mediates CFTR defects in 
extrapulmonary tissues in smokers. Endothelial dysfunction is associated with loss of lung 
function, severity of disease and reduced exercise capacity in COPD (198). Together, these 
findings indicate that acquired loss of endothelial CFTR function in response to cigarette 
smoking may be relevant to the development of vascular disease and other co-morbidities 
in COPD, and a further target for therapy. 
In conclusion, targeting endothelial CFTR for correction and/or potentiation would seem to 
be a logical therapeutic approach, as small molecule correctors and potentiators are 
already in development to restore epithelial CFTR function for a range of genotypes. 
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6.1. Abstract 
Problem statement: Compromised micro- and macrovascular endothelial dysfunction in 
response to shear stress has been observed in CF, as a consequence of inflammation and 
oxidative stress. However, it is currently unknown whether CFTR inhibition disrupts 
endothelial actin cytoskeleton dynamics and cellular morphology in response to flow. 
Methods: HLMVEC were cultured in either GlyH-101 (20 µM), TNF-α (10 ng/mL) or a vehicle 
control (0.1% v/v DMSO) during 24 h and 48 h of exposure to shear stress (11.1 dynes/cm2) 
or static conditions. Changes in F-actin and cellular morphology were detected using 
immunocytochemistry. [Nitrite] and [ET-1] content were determined in cell culture 
supernatant by chemiluminescence and ELISA, respectively. Results: Treatment with TNF-
a significantly increased total F-actin after 24 h (vs. control, p < 0.05), which was 
independent of shear stress. Whereas, GlyH-101 significantly increased F-actin after 24 h 
and 48 h (vs. control, p < 0.05), which was dependent on shear stress. GlyH-101 treatment 
also prevented alignment of HLMVEC in the direction of flow after 24 h and 48 h of shear 
stress, compared to both vehicle control and TNF-α (both p < 0.05). Shear stress decreased 
[ET-1] after 48 h (p < 0.05), but neither [Nitrite] or [ET-1] was affected by GlyH-101 (all p > 
0.05). Conclusions: Functional CFTR appears to limit cytosolic actin polymerisation, while 
maintaining a cortical rim actin distribution that is important for maintaining cellular 
integrity and promoting alignment with flow. 
 
  
CFTR prevents F-actin formation and promotes morphological alignment with flow 
Page 151 of 300 
 
6.2. Introduction 
CF is a multi-organ, life-shortening autosomal recessive disease that affects more than 
70,000 people worldwide. The aetiology of CF is a mutation of the gene encoding the CFTR 
protein, which is commonly expressed within epithelial cells (152). Expression of CFTR has, 
however, also been demonstrated in HLMVEC (519), HUVEC (519) and HPAEC (408, 518). 
Furthermore, micro- and macrovascular endothelial perturbations have recently been 
shown to characterise children and adolescents with relatively mild CF lung disease (411, 
430).  
The endothelium forms a semi-permeable barrier between tissues and the blood stream, 
and is essential for regulating vascular tension, molecular transport and immune cell 
trafficking. In vivo endothelial cells are constantly exposed to shear stress resulting in the 
activation of several mechanoresponsive networks, which increase the expression of genes 
that regulate inflammation (e.g. VCAM-1) (587) and increase NO bioavailability (e.g. eNOS). 
In CF, defective FMD of the brachial artery suggests NO bioavailability is reduced in 
response to shear stress (411). This notion is further supported by the observation that 
acute supplementation with 20 mg/kg of oral BH4 significantly improved FMD, through 
reduced O₂̇‾ production and increased NO, which is indicative of improved eNOS coupling 
(248). 
The endothelial actin cytoskeleton is the first-responder to changes in shear stress, and 
comprises an cortical rim, cytosolic stress fibers and the membrane skeleton (312). Cortical 
rim F-actin is essential for facilitating cell-to-cell interaction and function, by tethering cell-
matrix complexes such as VE-cadherin (149) and eNOS (498). Endothelial inflammation and 
oxidative stress cause the formation of F-actin cytosolic stress fibres (150, 570), thereby, 
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increasing cellular stiffness and limiting NO release (162). Functional CFTR is reported to 
limit inflammation and oxidative stress by upregulating the expression of Nrf2 in the 
epithelium (86) and endothelium (Chapter 5). It is, therefore, possible that a loss of 
endothelial CFTR function may contribute to a pro-inflammatory and pro-oxidant state that 
causes a re-organisation of the F-actin cytoskeleton and, subsequently, reduce NO 
bioavailability. 
The purpose of the present study was therefore to investigate the implications of 
pharmacological CFTR inhibition on actin polymerisation, morphological alignment in 
response to shear stress in vitro, and cell culture supernatant nitrite and ET-1 content in 
the human lung microvascular endothelium.  
6.3. Methods 
6.3.1. Materials 
All reagents were purchased from Merck & Co. (NJ, USA) unless indicated otherwise.  
6.3.2. Culture of HLMVEC 
HLMVEC (Lonza Biologics, Slough, UK) were maintained in 5% CO2 at 37°C and used until 
passage 9. Cells were grown in Lonza EGM-2 MV full growth medium (FGM) (CC-3202), 
which consisted of basal medium (CC-3156) and supplemental EGM -2 MV (CC-4147). The 
supplemental media consisted of (final concentration) 5% (v/v) FBS, 0.4% (v/v) 
hydrocortisone, 4% (v/v) human fibroblast growth factor (hDGD-B), 1% (v/v) VEGF, 1% (v/v) 
R3-IGF-1, 1% (v/v) ascorbic acid, 1% (v/v) hEGF and 1% (v/v) gentamycin and amphotericin 
B (GA-1000). 
HLMVEC (250 x103 cells/well in 1 mL of FGM) were seeded in 6-well plates coated with 
human collagen IV (0.1 mg/mL). An adhesive silicon disk was attached to the centre of each 
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well to prevent cell attachment. After 24 h, this disk was removed and cells were then 
treated with 2 mL of FGM containing either GlyH-101 (5 μM, 10 μM and 20 μM), TNF-α (10 
ng/mL, Peprotech) or a vehicle control (0.1% [v/v] DMSO), with exposure to either 8 h, 24 
h or 48 h of static incubation or orbital shaking conditions at a speed of 220 rpm, which 
results in 11.1 dynes/cm2 of flow at the periphery of the well (110).  
6.3.3. Crystal violet staining 
HLMVEC were washed with 2 mL/well of PBS (-Ca/-Mg), and subsequently fixed with 2 
mL/well of fresh 4% paraformaldehyde (in PBS [-Ca/-Mg]) for 2 mins. The 4% 
paraformaldehyde was then removed and cells were washed twice with 2 mL/well of PBS 
(-Ca/-Mg). Cells were then stained with 1 mL/well of 0.125% (w/v) crystal violet (in UHQ) 
for 10 mins. The 0.125% (w/v) crystal violet was then removed and cells were washed three 
times with 2 mL/well of PBS (-Ca/-Mg). Data was collected from singular wells of 3 
independent experiments for the 24 and 48 h time points. 
HLMVEC were imaged in duplicate (at a magnification of 10x) in the periphery of the well, 
where flow was horizontal or vertical. ImageJ software (National Institute for Health, MD, 
USA) was used to quantify changes in cellular morphology. Specifically, RGB images were 
converted to grey scale (8-bit) and made binary. Following this, cells were identified as 
being ≥ 200 pixels in size. The direction of alignment was quantified by identifying the angle 
formed by the longest axis of the nucleus (Feret’s Diameter) with the abscissa axis (Feret’s 
Angle) (165, 515) (see Figure 6.1). The Feret’s Angle ranges from 0-180o and a reduced 
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variance of the Feret’s angle within an image of > 500 cells was indicative of a greater 
alignment with flow.  
Figure 6.1. The calculation of Feret’s Angle of HLMVEC. After the nucleus was stained with 0.125% crystal 
violet, the direction of alignment was quantified by identifying the angle formed by the longest axis of the 
nucleus (Feret’s Diameter) with the abscissa axis (Feret’s Angle). Each image contained > 500 cells and a mean 
of 3 images (> 1500 cells) were used for a single data point in statistical analyses. 
Crystal violet was subsequently extracted from the cells to estimate the number of cells 
remaining after treatments and exposures. Specifically, 2 mL ethanol/acetone (80/20%) 
was added to each well, and incubated for 5 mins at room temperature. Following this, 200 
μL was transferred from each well into a 96-well plate and absorbance was measured at 
wavelength 550 nm.  
6.3.4. Actin staining 
HLMVEC were washed with 2 mL/well of PBS (-Ca/-Mg; 2.7 mM KCl, 1.5 mM KH2PO4, 136.9 
mM NaCl, 8.9 mM Na2HPO47H2O; pH 7.1-7.5), and subsequently fixed with 2 mL/well of 
fresh 4% (w/v) paraformaldehyde (in PBS [-Ca/-Mg]) for 10 mins. The 4% (w/v) 
paraformaldehyde was then removed and cells were washed twice with 2 mL/well of PBS 
(-Ca/-Mg). Cells were then permeabilised with 2 mL/well of 0.1% Trition X-100 (in PBS [-
Ca/-Mg]) for 5 min. The 0.1% Triton X-100 was then removed and cells were washed twice 
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with 2 mL/well of PBS (-Ca/-Mg). Cells were then incubated at room temperature in 660 
μL/well of 100 nM of Rhodamine Phalloidin (ThermoFisher, MA, USA; prepared in PBS [-
Ca/-Mg] containing 1% BSA) for 20 mins, followed by an additional washing step. 
Subsequently, cells were co-stained with 1 mL/well of 5 μg/mL Hoechst 33342 (Molecular 
Probes, OR, USA) for 10 min. Data was collected from duplicate wells of 3 independent 
experiments at 16 h, 24 h and 48 h for the dose- and time-response analysis in static 
conditions. Data of singular wells of 3 independent experiments at the 24 h and 48 h time 
points were used for the shear stress manipulations. 
HLMVEC at the periphery of the well were imaged in triplicate at a magnification of 20x. 
ImageJ was also used to quantify Rhodamine Phalloidin and Hoechst 33342. Specifically, 
RGB colour images were converted to a RGB stack; with red fluorescence measured 
between 20-255 thresholds and blue fluorescence measured between 40-255 thresholds. 
RawIntDen of red was expressed relative to RawIntDen of blue to quantify total F-actin 
relative to the nuclei within the image.  
6.3.5. Measurement of [nitrite] and [ET-1]  
Supernatant (2 mL) was harvested from duplicate wells of 3 independent experiments, and 
centrifuged at 1500 x g for 10 mins at 4oC. Acellular supernatant was then frozen and stored 
at -80oC for future analysis.  
Supernatant [nitrite] was measured using Sievers NOA 280i (Analytix Ltd., East Boldon, UK), 
which is a chemiluminescence based NO analyser. Specifically, 4% (w/v) glacial acetic acid 
and sodium iodide solution reduced nitrite to NO, and 150 μL of the undiluted samples 
were injected into the analyser whereby nitrogen carried the sample through the reduction 
agent and cold trap to remove water. Samples were then carried into the reaction cells 
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where NO reacts with ozone to form nitrogen dioxide in the excited state. This 
electronically excited chemical was then relaxed into the ground state and emitted a 
photon that is detected by red-sensitive photomultiplier tube. 
Supernatant [ET-1] was measured by a commercially available Endothelin Pan Specific 
ELISA Kit (DY1160; Abcam, Cambridge, UK) with ET-1 standards. Samples were diluted 1:2 
before loading to the plates and data was transformed to concentration, according to a 
standard curve ranging from 3.91-250 pg/mL. The ELISA was performed as per the 
manufacturer’s instructions. 
6.3.6. Statistical analysis 
Data were presented as mean ± SEM, unless otherwise stated. Two-way ANOVA was used 
to determine exposure the effects of (static or orbital shaking) x condition (vehicle control, 
GlyH-101 or TNF-α) for cell viability, cellular alignment and F-actin formation. Two-way 
ANOVA was also used to determine the effect of time (8 h, 24 h, and 48 h) x exposure (static 
or orbital shaking) on supernatant [nitrite] and [ET-1] to determine the efficacy of our shear 
stress model. Whereas, 3-way ANOVA were used to determine the interaction effect of 
time (24 h and 48 h) x exposure (static or orbital shaking) x condition (vehicle control, GlyH-
101 and TNF-α) on supernatant [nitrite] and [ET-1]. Tukey HSD post-hoc t-tests were also 
used determine the effect of GlyH-101 upon outcomes during both static and orbital 
incubation.  
6.4. Results 
6.4.1. Cell viability 
Extraction of crystal violet demonstrated that the estimated cell count was significantly 
reduced after 48 h treatment with GlyH-101, compared to DMSO (n = 3, p < 0.01) and TNF-
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α (n = 3, p < 0.01). However, exposure to 24 h of either static or shear incubation did not 
significantly change estimated cell numbers in any condition (all p > 0.05).  
6.4.2. F-actin formation 
Representative images of F-actin following static or orbital incubation, and in response to 
GlyH-101, TNF-α or vehicle control treatments are presented in Figure 6.2A-L. In initial 
static experiments, there was a significant increase in F-actin formation in cells treated with 
GlyH-101 (20 μM) for 16 h (n = 3; 1.48 ± 0.29 RawIntDen F-actin/nuclei, p < 0.05) versus 
vehicle control (n = 3; 0.89 ± 0.07 RawIntDen F-actin/nuclei). However, there were no 
significant effect of  treatment with 5 μM (n = 3; 0.97 ± 0.04 RawIntDen F-actin/nuclei, p > 
0.05 vs. control) or 10 μM (n = 3; 1.19 ± 0.14 RawIntDen F-actin/nuclei, p > 0.05 vs. control) 
GlyH-101 for 16 h versus vehicle control. Therefore, treatment with 20 μM GlyH-101 was 
used in subsequent experiments. In cells treated with the vehicle control, F-actin was 
primarily distributed at the cortical rim with significantly increased in total F-actin with time 
(24 h vs. 48 h, p < 0.05) but not following shear stress (vs. static incubation, p > 0.05) (Figure 
6.2M and N). 
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Figure 6.2. HLMVEC F-actin formation in response to static or shear stress (11.1 dynes/cm2) incubation, and 
following treatment with vehicle control (0.1% [v/v] DMSO), GlyH-101 (20 μM) or TNF-α (10 ng/mL). The 
RawIntDen of F-actin (Red; 100 nM of Rhodamine Phalloidin) was expressed relative to nuclei (blue; 5 μg/mL 
Hoechst 33342). Images were captured at 20x magnification with 400 ms exposure to fluorescence, whereas 
images used for quantification were exposed to 200 ms of fluorescence. Triplicate images were captured for 
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singular wells of 3 independent experiments (n = 3). Data were expressed as mean ± SEM. Yellow arrows 
highlight paracellular gaps; white arrows highlight cortical rim F-actin; *, p < 0.05; **, p < 0.01. 
Under static conditions, there was a significant increase in F-actin formation between 
vehicle control and TNF-a treatment for 24 h (Figure 6.2M, p < 0.05), but not 48 h (Figure 
6.2N, p > 0.05). However, there were no significant differences in F-actin content between 
cells treated with the vehicle control or GlyH-101 under static conditions at either time 
point (Figure 6.2M and N, both p > 0.05). Under orbital conditions of shear stress, both 
GlyH-101 and TNF increased F-actin at 24 h compared to the vehicle control (Figure 6.2M, 
p < 0.05), but only GlyH-101 increased F-actin formation at 48 h (Figure 6.2N, p < 0.05). 
Therefore, the effect of GlyH-101, was dependant on shear stress (Figure 6.2M and N). 
Qualitative observations demonstrated a loss of cortical rim F-actin to form cytosolic F-
actin polymers in cells treated with GlyH-101 at 24 h and 48 h. Furthermore, the occurrence 
of paracellular gaps after 24 h of shear stress was observed in cells treated with GlyH-101 
but not control or TNF-α conditions (Figure 6.2E), suggesting the formation of stress fibres. 
6.4.3. Alignment with flow 
Representative images of HLMVEC morphology following static or orbital incubation, and 
in response to GlyH-101, TNF-α or vehicle control treatments are presented in Figure 6.3A-
L. Following 24 h of shear stress, cells treated with vehicle control or TNF-α (both p < 0.05), 
but not GlyH-101 (p > 0.05), aligned with flow as the variance in the Feret’s Angle was 
significantly reduced compared to static conditions (Figure 6.3M). After 48 h of shear stress, 
cells treated with vehicle control, GlyH-101 and TNF-α all significantly aligned in the 
direction of flow compared to static conditions (Figure 6.3N, all p < 0.05). However, there 
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was significantly greater variance in Feret’s Angle in cells treated GlyH-101 versus vehicle 
control and TNF-α conditions at 48 h (Figure 6.3N, both p < 0.05). 
Figure 6.3. HLMVEC alignment in response to static or shear stress (11.1 dynes/cm2) incubation, and following 
treatment with vehicle control (0.1% [v/v] DMSO), GlyH-101 (20 μM) or TNF-α (10 ng/mL). Nuclei were 
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stained with 0.125% (w/v) crystal violet and images were captured at 10x magnification. Uniformity of 
alignment was quantified by determining the SD of the Feret’s Angle for each cell within an image (> 500 cells 
per image). Duplicate images were captured for singular wells of 3 independent experiments (n = 3). Data 
were expressed as mean ± SEM. *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001. 
6.4.4. Supernatant [nitrite] and [ET-1] 
Cell culture supernatant [nitrite] significantly increased with time over 48 h, under both 
static and shear stress conditions (vs. 8 h static incubation, Figure 6.4A, p < 0.05). However, 
shear stress did not affect [nitrite] at any time point (Figure 6.4A, all p > 0.05). Post-hoc 
analysis revealed that neither treatment of HLMVEC with GlyH-101 had a significant effect 
on supernatant [nitrite] at any time point or exposure (Figure 6.4B, all p > 0.05). 
 
Figure 6.4. HLMVEC culture supernatant nitrite concentrations in response to static or shear stress (11.1 
dynes/cm2) incubation, and following treatment with vehicle control (0.1% [v/v] DMSO), GlyH-101 (20 μM) 
or TNF-α (10 ng/mL). Samples were collected from duplicate wells of 3 independent experiments (n = 3). Data 
were expressed as mean ± SEM. *, p < 0.05; **, p < 0.01. 
Cell culture supernatant [ET-1] was significantly greater following 48 h incubation under 
static conditions (vs. 8 h and 24 h static incubations, Figure 6.5A, both p < 0.05). 
Furthermore, shear stress significantly reduced [ET-1] compared with static incubation for 
48 h (Figure 6.5A, p < 0.05). Similarly to [nitrite], post-hoc analysis revealed that treatment 
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of HLMVEC with neither GlyH-101 had any significant effect on supernatant [ET-1] at any 
time point or exposure (Figure 6.5B, all p > 0.05). 
 
Figure 6.5. HLMVEC culture supernatant ET-1 concentrations in response to static or shear stress (11.1 
dynes/cm2) incubation, and following treatment with vehicle control (0.1% [v/v] DMSO), GlyH-101 (20 μM) 
or TNF-α (10 ng/mL). Samples were collected from duplicate wells of 3 independent experiments (n = 3). Data 
were expressed as mean ± SEM. *, p < 0.05; **, p < 0.01. 
6.5. Discussion 
This is the first study to investigate the role of functional CFTR in the regulation of the 
HLMVEC actin cytoskeleton and cellular alignment in response to flow. The present study 
identified three key findings: 1) pharmacological inhibition of endothelial CFTR significantly 
exacerbated F-actin formation in response to flow, through dismantling cortical rim F-actin 
to form cytosolic stress fibres; 2) pharmacological inhibition of endothelial CFTR 
significantly disturbed cellular alignment in response to flow; and, 3) CFTR-regulated 
adaptations to flow appeared to be independent of NO and ET-1, as pharmacological 
inhibition of endothelial CFTR did not significantly alter cell culture supernatant [nitrite] or 
[ET-1] during static or orbital incubation. These mechanistic findings are particularly 
important given the growing body of evidence to support endothelial vascular 
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perturbations in people with CF and should be considered within the development of 
future endothelial-targeted therapeutics in models of CF. 
Disruption of the actin cytoskeleton in CF epithelial cells has been documented (79). 
However, only a single study has reported actin stress fibre formation following CFTR 
inhibition using both GlyH-101 or CFTRinh-172 in rat lung microvascular endothelial cells 
(65). The present data is the first in human cells and demonstrates exacerbated actin 
polymerisation occurred in HLMVEC treated with GlyH-101 compared to vehicle control 
under shear stress conditions, and was characterised by a lack of cortical rim F-actin and 
the formation of cytosolic stress fibres (Figure 6.2B and H). However, TNF-α treatment 
induced F-actin formation in both static (24 h) and shear stress (24 h) conditions (Figure 
6.2C and F). This suggested that an exacerbated release of inflammatory cytokines 
following CFTR inhibition under shear stress conditions may have contributed to stress fibre 
formation through increasing cytosolic Ca2+, decreasing cyclic AMP and activating 
RhoA/Rho kinase (414). Interestingly, significantly increased F-actin formation in response 
to flow was only observed in circumstances of CFTR inhibition (Figure 6.2M and N). Given 
that the actin cytoskeleton is a first-responder to shear stress (312) and facilitates the 
reformation of cells to align in the direction of flow (386), a loss of CFTR activity could 
contribute to reduced endothelial barrier function observed in people with CF through 
altered actin dynamics and a loss of cellular alignment in response to flow. 
Disturbed flow-induced changes to endothelial cell morphology is an in vivo (134, 192) and 
in vitro (111) marker of endothelial dysfunction. Shear stress increases the expression of 
VEGF and VEGFR2 (124), which promotes actin polymerisation (436) and cell elongation 
through Rho/Rho-associated protein kinase (ROCK) signalling during angiogenesis (522). 
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Our laboratory has previously demonstrated that CFTR inhibition significantly increased 
VEGF expression in HLMVEC (Chapter 5). However, the present study demonstrated that 
GlyH-101 treatment significantly reduced HLMVEC alignment in the direction of flow and 
also promoted cellular retraction compared to both vehicle control and TNF-α. 
Furthermore, previous research has observed that CFTRinh-172 treatment caused HUVEC 
retraction and shrinkage, membrane bleb formation, and cellular vesicle release in 
response to low levels of shear stress (5 dynes/cm2) (518). Increased variability in cell 
morphology following CFTR blockade, despite elevated VEGF expression and unchanged 
[nitrite]/[ET-1], suggests that a factor downstream from VEGF is altered in models of the 
CF endothelium.  
Forkhead box protein O1 (Foxo1) is activated through VEGF-induced PI3K/Akt-signalling 
and modulates endothelial cell specification, growth and actin remodelling (522). 
Preliminary reports have suggested that a loss of CFTR reduces Foxo1 expression in CF 
epithelial cells, independent of PI3K/Akt expression, which was rescued following 
treatment with IGF-1 (481); however, no such data exists with regards to endothelial cell 
culture. Notably, in circumstances of increased VEGF, actin remodelling to form cytosolic 
stress fibres is prevented by the downregulation of mammalian target of rapamycin 
(mTOR) complex 2 (mTORC2) and its mTOR-independent companion of complex 2 (Rictor) 
(156). CF epithelial cells have an increased expression of both mTOR and Rictor (424), which 
could explain the disturbed morphology and loss of cortical rim F-actin in HLMVEC treated 
with GlyH-101 observed in the present study; however, this warrants further investigation. 
Furthermore, both the upregulation of Rictor in HUVEC (576) and inhibition of CFTR in 
HLMVEC (Chapter 5) is associated with supressed Nrf2 transcription and content. 
Suppression of Nrf2 is likely to contribute to the systemic pro-oxidant state people with 
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clinically-stable CF lung disease experience (Chapter 7), which may also be associated with 
oxidative damage to cytoskeleton components and disturbed cytoskeleton signalling (90). 
Importantly, clinically-approved CFTR modulator therapies restore Nrf2 transcription and 
activity in CF epithelial cells (49) and, reflecting on the present data in HLMVECs, these data 
provide an exciting rationale to investigate any potential effects of CFTR modulator therapy 
on the CF endothelium both in vivo and in vitro. 
There were several limitations worthy of note in the present study. Firstly, the specificity 
of the selected CFTR inhibitor (GlyH-101) has been questioned (267), due to reports that it 
may increase mitochondrial ROS production independent of changes in CFTR function. 
However, data from our laboratory has recently demonstrated that a mitochondrial specific 
antioxidant (MitoQ) had no effect on mitochondrial ROS generation following GlyH-101 
treatment (Chapter 5). Furthermore, following GlyH-101 treatment CFTR is still expressed 
at the apical membrane but is not functional (i.e. a class IV-V mutation) (547). However, a 
recent study has developed a long-term cell culture of CF (p.Phe508del) HPAEC (408); 
therefore, it would be useful to confirm the findings of the present study in cells that 
represent a loss of CFTR at the apical membrane (i.e. class I-III mutations). 
To conclude, the present study has demonstrated that endothelial CFTR regulates actin 
cytoskeleton remodelling and promotes morphological alignment with flow in HLMVEC, 
independently of nitrite and ET-1 pathways. Additionally, actin polymerisation following 
endothelial CFTR inhibition was characterised by a loss of cortical rim F-actin and the 
development of cytosolic stress fibres. Finally, HLMVEC exposed to flow following CFTR 
inhibition had a greater variability in cellular alignment, which could have implications for 
endothelial barrier permeability and function in vivo. 
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Circulating biomarkers of antioxidant status and oxidative stress in people 
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7.1. Abstract 
Introduction: Oxidative stress may play an important role in the pathophysiology of CF. 
This review aimed to quantify CF-related redox imbalances. Methods: Systematic searches 
of the Medline, CINAHL, CENTRAL and PsycINFO databases were conducted. Mean content 
of blood biomarkers from people with clinically-stable CF and non-CF controls were used 
to calculate the SMD and 95% CI. Results: Forty-nine studies were eligible for this review 
including a total of 1,792 people with CF and 1,675 controls. Meta-analysis revealed that 
protein carbonyls (SMD: 1.13, 95% CI: 0.48 to 1.77), total F2-isoprostane 8-iso-
prostaglandin F2α (8-iso-PGF2α; SMD: 0.64, 95% CI: 0.23 to 1.05) and malondialdehyde 
(MDA; SMD: 1.34, 95% CI: 0.30 to 2.39) were significantly higher, and vitamins A (SMD: -
0.66, 95% CI -1.14 to -0.17) and E (SMD: -0.74, 95% CI: -1.28 to -0.20), β-carotene (SMD: -
1.80, 95% CI: -2.92 to -0.67), lutein (SMD: -1.52, 95% CI: -1.83 to -1.20) and albumin (SMD: 
-0.98, 95% CI: -1.68 to -0.27) were significantly lower in the plasma or serum of people with 
CF versus controls. Conclusions: This systematic review and meta-analysis found good 
evidence for reduced antioxidant capacity and elevated oxidative stress in people with 
clinically-stable CF. 
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7.2. Introduction 
CF is a multi-system, life-shortening, autosomal recessive disease affecting more than 
70,000 people globally. The disease occurs as a result of mutations in the gene encoding 
for the CFTR, the primary function of which is the efflux of Cl- and HCO3- anions. CFTR is 
commonly expressed within the epithelial cells that line the mucous membrane and 
submucosal glands of the airway (152). Dysfunctional CFTR results in inflammation (345) 
and airway infection, a progressive decline in lung function (406) leading to respiratory 
failure and premature death (173). CFTR is also expressed within various other bodily 
systems, including the gastrointestinal tract, pancreas, sweat ducts, skeletal muscle, 
cardiovascular and reproductive organs (552). CF is, therefore, a complex multisystem 
condition requiring repeated comprehensive assessments to monitor for and treat disease 
complications. 
Transient increases in free radicals derived from oxygen (ROS) and nitrogen (RNS) activate 
various physiological signalling cascades that are beneficial for cellular function and 
communication (209). However, several CF co-morbidities, including lung disease (291), 
inflammation (299), systemic hypoxaemia (531, 580) and dysglycaemia (374) lead to the 
exacerbated production of ROS exceeding the levels required for optimal physiological 
function. CFTR has also been implicated in the efflux of the main non-enzymatic 
antioxidant, GSH (308). Therefore, a loss of CFTR function in vitro leads to an increased 
accumulation of intracellular GSH, which blunts the response to redox-sensitive signalling 
pathways that modulate adaptations to hypoxia (145) and cigarette smoke (193), and may 
render extracellular compartments more susceptible to oxidative stress (588). In addition 
to this, polymorphisms of the GST and the glutamate-cysteine ligase genes are likely to 
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further deplete extracellular synthesis and the detoxification potential of GSH (118, 308, 
321). Together, these factors in addition to the malabsorption of micronutrients with 
antioxidant properties in CF (479), causes an imbalance between oxidants and antioxidants 
in favour of oxidants (i.e. oxidative stress), the disruption of redox signalling and molecular 
damage (209). 
Whilst the study of CF-related redox imbalances dates back as far as 1967 (36) and has been 
the topic of several narrative reviews (181, 373, 588), a recent meta-analysis highlighted 
the potential significance of these imbalances when considering disease pathophysiology 
(537). Van t’ Erve et al. (537) observed that a biomarker of lipid peroxidation, 8-iso-PGF2α, 
was higher in CF compared to other diseases, including lifestyle factors and environmental 
exposures which are conventionally characterised by oxidative stress, such as tobacco 
smoking and cardiovascular disease (537). Whilst this review identified some evidence for 
increased oxidative stress in CF, the range of biomarkers considered was limited (96). 
Recent advances in analytical methodologies mean that previously inaccessible 
biomarkers, including those used to quantify oxidative damage in biological samples, are 
now more widely available for medical and physiological research purposes (176). Similarly 
to elevated 8-iso-PGF2α and MDA being indicative of lipid peroxidation, oxidative 
modifications to proteins and DNA can be investigated by quantifying protein carbonyl 
groups and 8-hydroxy-20-deoxyguanosine (8-OHdG), respectively (210). In addition to 
investigating the end-product of oxidative damage, it is also now possible to characterise 
antioxidant deficiencies that might be suitable therapeutic targets. It is recommended that 
vitamin and trace element concentrations are monitored in CF clinics (527); however, from 
an antioxidant-perspective it is also useful to quantify thiols, such as GSH and Cys, as these 
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molecules are essential to understanding the redox potential (Eh) of biological fluids (209). 
The content and activity of oxidoreductases, such as SOD, CAT and GPx, provide additional 
functional information regarding the maintenance of thiol:disulfide couples and are 
promising therapeutic targets (579). Despite the array of available biomarkers to study 
redox imbalances, there is no systematic evidence to suggest that oxidative stress occurs 
as a consequence of lowered antioxidants in the blood. 
Therefore, a systematic search of the existing evidence base from investigations of CF-
related redox imbalances is needed to provide comprehensive and contemporary 
recommendations for subsequent clinical practice and research trials. This review aimed to 
summarise the literature investigating whether redox abnormalities are present in the 
blood of people with clinically-stable CF. We hypothesised that: (1) blood markers of 
antioxidant status would be lowered in people with clinically-stable CF compared to non-
CF controls, and (2) blood markers of oxidative stress would be elevated in people with 
clinically-stable CF compared to non-CF controls. 
7.3. Methods 
7.3.1. Protocol registration 
The review protocol was registered on PROSPERO (Reference: CRD42018094241; 
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42018094241).  
7.3.2. Eligibility criteria 
Included studies reported blood biomarkers of oxidative stress and/or antioxidant status in 
humans with CF, and were compared to a non-CF control group. We included population-
based studies with a case-control comparison and intervention trials which had a case-
control comparison at baseline. A clinical diagnosis of CF must have been supported by an 
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abnormal sweat test, diagnostic genotyping and/or the participant being recruited through 
a CF clinic. Study participants must have been classed as clinically-stable and free from 
symptoms of an acute respiratory exacerbation at the time of testing, as this is a commonly 
accepted source of antioxidant deficiency and oxidative stress (326). Studies were excluded 
if they were review articles, case reports or letters to the editor. Studies which compared 
results from individuals with CF versus standard values derived from the literature were 
excluded. There was no restriction on the type of redox-related biomarker; however, it 
must have been analysed in blood as CF is associated with renal disease (360) and pelvic 
floor incontinence (362), both of which may mean local inflammation alters the redox state 
of urine. There were no restrictions on publication period. Studies were excluded if the full-
text was not available in English or French.  
7.3.3. Information sources 
Extensive searches of the Medline, CINAHL, CENTRAL and PsycINFO databases were 
conducted to identify eligible studies up to 9th October 2019. 
7.3.4. Searches 
In accordance with similar systematic reviews in this area (177), the current review utilised 
a three-part search process to identify studies matching the eligibility criteria. The first 
strategy used Medical Subject Heading (MeSH) or subject terms, as follows: “cystic 
fibrosis”[MeSH] AND (antioxidants[MeSH] OR oxidoreductase[MeSH] OR 
vitamins[Pharmacological Action] OR oxidants[MeSH] OR “oxidative stress”[MeSH] OR " 
lipid peroxidation”[MeSH]) AND blood[subheading]. When compared to the eligibility 
criteria, 11 independent and eligible studies provided a list of 16 common biomarkers in 
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plasma, serum, erythrocyte or whole blood samples. These data were then utilised to 
inform the second phase of the literature search. 
The second strategy identified references based on specific words found within the title 
and/or abstract (ti/ab). In this search, the biomarkers and biological substances identified 
in the MeSH search were AND-linked to “cystic fibrosis”, as follows: “cystic fibrosis”[tiab] 
AND (tocopherol[tiab] OR carotene[tiab] OR malondialdehyde[tiab] OR MDA[tiab] OR 
“thiobarbituric acid reactive substances”[tiab] OR TBARS[tiab] OR ascorb*[tiab] OR 
lycopene[tiab] OR “protein carbolyl”[tiab] OR copper[tiab] OR isoprostane[tiab] OR 
prostaglandin[tiab] OR glutathione[tiab] OR hydroperoxide[tiab] OR superoxide[tiab] OR 
SOD[tiab] OR vitamin[tiab] OR zinc[tiab]) AND (blood[tiab] OR plasma[tiab] OR serum[tiab] 
OR erythrocyte[tiab] OR “whole blood”[tiab]). The MeSH search was also repeated at this 
stage to ensure a broad, specific and sensitive search (529).  
The full search terms and strategies of the present review have been published on 
PROSPERO (Reference: CRD42018094241). Additionally, bibliographies of included studies 
and known review articles, clinical trial registers and conference proceedings were hand-
searched by authors. Experts in the field (identified by the lead authors in published 
studies) were contacted to find unpublished trials. 
7.3.5. Study selection 
The screening and selection process followed two steps and was completed independently 
by two authors (AJC and ZLS). After removing duplicate articles, the ti/ab of all references 
were screened to identify whether the study met the eligibility criteria, with exclusion of 
ineligible articles. Full-texts of the remaining references were subsequently retrieved and 
compared with eligibility criteria. All eligible references were included in the systematic 
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review (Table 7.1). Meta-analyses were only conducted on outcomes which were reported 
by a minimum of two independent studies. If a biomarker was the subject of two references 
by the same laboratory, only the most recent reference was included for meta-analysis. 
These methodologies have been used in similar meta-analyses (177, 357). 
7.3.6. Data collection process 
Two review authors (AJC and ZLS) used a review-specific form to independently extract 
relevant data on study design, study population, medications, eligibility criteria, biomarkers 
and biological fluids studied, and location. Details of the participants (both case and 
controls) were recorded where possible, such as information on age, sex, genotype, lung 
function, co-morbidities and treatments. When available, we extracted data on subgroups, 
including those stratified by severity, genotype or co-morbidities. Data was extracted from 
graphs using plot digitizer software. Where data and/or measures of variability were not 
available within a manuscript, this was either calculated or requested from the 
corresponding author. If data was not made available, the reference was included in the 
systematic review but excluded from the meta-analysis.  
7.3.7. Assessment of quality and risk of bias of included studies 
Two review authors (AJC and ZLS) independently assessed the quality of studies using the 
Newcastle-Ottawa Quality Assessment Scale for Case-Control Studies (560). To minimize 
bias in the interpretation of the scale, both authors independently assessed 10 unrelated 
studies not included in the present review, whereby disparities in judgements were 
discussed and a consensus was reached prior to the assessment of studies included in the 
present review. Each study was graded for selection, comparability and exposure, and 
could be awarded a maximum of 9 points. Studies scoring 0-2 were considered low quality, 
Redox abnormalities in clinically-stable CF 
Page 175 of 300 
 
studies scoring 3-5 were considered moderate quality and studies scoring 6-9 points were 
considered high quality (357). Risk of publication bias was assessed at the outcome level 
using a funnel plot (243), which was tested for asymmetry. These methodologies have been 
used in similar meta-analyses (177, 357). 
7.3.8. Measures of the group effect 
Measures of the group effect were calculated using the RevMan v5.3 (Cochrane, UK) 
software (225). For each study, SMD and 95% CI were calculated (225). Given that 
biomarkers were consistently expressed to different units or analysed using different 
methodologies, SMD were calculated. 
7.3.9. Assessment of heterogeneity in included studies 
Assessments of heterogeneity were calculated using the RevMan v5.3 (Cochrane, UK) 
software (225). In the present review, the I2 statistic was used to assess heterogeneity. The 
I2 statistic provides a percentage value that represents the variability in effect estimates 
that is due to heterogeneity. An I2 of ≥ 75% suggests considerable heterogeneity (225). In 
the presence of considerable heterogeneity, which could be explained by methodological 
or population-based considerations, a random-effects model was incorporated using The 
DerSimonian-Laird method (125). Data of considerable heterogeneity that could not be 
explained by methodological or population-based considerations were excluded from the 
meta-analysis. If heterogeneity could not be explained by methodological or clinical factors, 
data were not pooled but, instead, reported within the text. These techniques have been 
used in similar meta-analyses (177, 357). 
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7.3.10. Data synthesis 
Results of comparable studies were pooled using either fixed-effect or random-effects 
models, dependent upon the extent of heterogeneity. 
7.4. Results 
7.4.1. Study Selection  
A flow diagram of the screening process is presented in Figure 7.1. Briefly, after the removal 
of duplicate references, a total of 843 references were screened for their eligibility for the 
present systematic review. Of the 843 references, 660 were excluded during the ti/ab 
screen as they were outside of the scope of the present review. Following the screening of 
the full-texts (n = 183; n = 10 were excluded as the full-text was not available in English or 
French), a further  124 references were excluded because cases were not classified as 
clinically-stable (n = 89), there was no eligible control group (n = 21), the study did not 
include biomarkers which were within the scope of the present review (n = 13) or the study 
was not conducted in humans (n = 1). Consequently, 49 references were eligible for 
inclusion in the present review including a total of 1,792 people with CF and 1,675 controls, 
in which 25 biomarkers were eligible for meta-analysis (Table 7.1).  
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Figure 7.1. A CONSORT flow diagram of the study identification, screening and selection process. 1 Excluded 
studies either investigated participants who are not clinically-stable (n = 12) or does not mention the status 
of participants (n = 77). 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
AbdulWahab (1), 
cross-sectional 
Doha, Qatar 53 people with CF (M = 41.5%; 15.1 ± 9.1 y) from 
a kindred Arab tribe. 84.9% were I1234V 
homozygous and pancreatic sufficient (PS); 15.1% 
were non I1234V and PI; 35.8% had chronic P. 
aeruginosa colonisation; Mean ± SD FEV1 was 79.1 
± 22.2%. All those with PI were administered with 
pancreatic enzyme replacement and multivitamin 
supplements. 17.7% who were pancreatic 
sufficient were receiving multivitamins. 
45 healthy control participants (male 
(M) = not reported (NR); 20.4 ± 10.1 y) 
were recruited from the same kindred 
Arab tribe. 
Plasma albumin (CF 
group only) and zinc. 
Olveira (380), 
cross-sectional 
Malaga, Spain 36 people with CF (M = 56.3%; 27.2 ± 8.9 y).  In 
those with frequent exacerbations, bacterial 
colonization and/or FEV1 ≤ 50% predicted, 500 
mg/day of azithromycin was administered 
(63.9%). Of those administered with azithromycin, 
mean ± SD FEV1 was 47.1 ± 21.3% and FVC was 
60.1 ± 21.8%; 69.6% were PI; 30.4% had CFRD. Of 
those who were not administered with 
azithromycin, mean ± SD FEV1 was 77.1 ± 20.9% 
and FVC was 82.9 ± 17.1%; 61.5% were PI; 38.5% 
had CFRD. None were receiving dietary 
supplements with Omega-3 fatty acids. 
41 healthy control participants (M = 
41.5%; 29.0 ± 9.6) matched for 
nutritional status, sex and age. 
Plasma GPx, total 
antioxidant capacity 
(TAC), CAT and SOD. 
Plasma or serum 8-
iso-PG2α, 
Thiobarbituric acid 
reactive substances 
(TBARS), vitamins A, 
D and E, and zinc.  
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
Konstantinidis 
(285), 
cross-sectional 
Thessaloniki, 
Greece 
58 people with CF; 27 with (M = 48.1%; 28.5 ± 6.1 
y) and 31 without (M = 54.8%; 28.1 ± 6.5 y) nasal 
polyposis; 25.9% were p.Phe508del homozygous; 
50.0% were P.Phe508del heterozygous; 24.1% 
were non-P.Phe508del. 32.8% had P. aeruginosa 
colonisation. All CF participants were 
supplemented with 3,000 IU/day of Vitamin D3. 
62 people with chronic rhinosinusitis; 
32 with (M = 53.1%; 29.3 ± 8.4 y) and 30 
without (M = 46.7%; 29.5 ± 5.9 y) nasal 
polyposis. 32 healthy control 
participants (M = 53.0%; 28.2 ± 7.9 y) 
from an outpatient clinic for elective 
nasal or oral surgery. 
Serum 25(OH) VD3. 
Antus (12), 
cross-sectional 
Budapest, 
Hungary 
40 people with CF (M = 60.0%; 25.0 ± 0.9 y); 50% 
were P.Phe508del homozygous. Mean ± SD FEV1 
was 54.4 ± 4.0% and FVC was 73.5 ± 3.4%; 52.5% 
had P. aeruginosa colonisation. All were taking 
vitamin supplements, pancreatic enzyme 
supplements, inhaled/nebulised β2-agonists. 
31.1% were receiving inhaled corticosteroid and 
75.6% were receiving nebulised DNase. 31.1% 
were receiving inhaled antibiotics at the time of 
sample collection. 
25 healthy control participants (M = 
52.0%; 35.8 ± 2.4 y) with no evidence of 
pulmonary disease. 
 
 
 
Plasma MDA. 
Lee (300), 
cross-sectional 
Atlanta, USA 25 people with CF (M = 56.0%; 18.5 ± 14.0 y); 88% 
were PI; 48.0% were administered with vitamin D 
supplements. 
28 healthy control participants (M = 
21.0%; 29.0 ± 6.0 y) on no medications 
which affect vitamin D concentration 
and metabolism. Vitamin D intake was 
limited to < 1,000 IU/day. 
Serum albumin, total 
and free 25(OH)D and 
vitamin D binding 
protein. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
Turowski (528), 
flaxseed 
supplement non-
randomized and 
non-controlled trial 
 
Philadelphia 
and 
Pennsylvania, 
USA 
10 people with CF (M = 30.0%; 31.9 ± 10.8 y; FEV1 
76.8 ± 16.8% predicted; BMI 22.0 ± 1.8 kg/m2); 
70.0% were PI, 80.0% taking pancrealipase.   
5 healthy control participants 
(comparable in age). 
Plasma enterodiol 
and enterolactone. 
Yadav (575), 
cross-sectional 
Chandigarh, 
India 
21 people with CF (M = 81.5%; 5.7 ± 2.5 y; this 
includes those with an acute respiratory 
exacerbation); 22.2% were receiving pancreatic 
enzyme supplementation.  
27 healthy control participants (M = 
70.4%; 7.4 ± 2.7 y) who were matched 
for age and sex. 
Plasma 25(OH)D, and 
vitamins A and E. 
Serum copper, iron 
and zinc. 
Sadowska-Bartosz 
(444), 
cross-sectional 
Rzeszow, 
Poland 
22 people with CF; 12 with chronic P. aeruginosa 
(M = 30.0%; 12.8 ± 7.6 y; BMI 18.7 ± 2.9 kg/m2) 
and 10 with chronic S. aureus (M = 30.0%; 10.2 ± 
3.6 y; BMI 18.6 ± 3.8 kg/m2) infections; 40.1% for 
P.Phe508del homozygous. Of those with P. 
aeruginosa colonization, mean ± SD FEV1 was 71.0 
± 8.7% predicted and FEV1/FVC ratio was 79.7 ± 
20.0%. Of those with S. aureus colonisation, mean 
± SD FEV1 was 94.2 ± 11.4%, and FEV1/FVC ratio 
was 89.6 ± 17.8%. All were PI and receiving 
pancreatic replacement therapy and nebulized 
DNase. All were receiving multivitamin 
11 healthy control participants (M = 
45.5%; 11.3 ± 4.5 y; BMI 16.7 ± 1.5 
kg/m2) who were recruited as 
outpatients without chronic disease. 
FEV1 was 96.5 ± 12.1% predicted and 
FEV1/FVC ratio was 107.5 ± 5.9%.  
Plasma advances 
glycation end-
products, amadori 
products,  advanced 
oxidation protein 
products, dityrosine, 
formylkynurenine, 
kynurenine, protein 
carbonyls, thiol 
groups and 
tryptophan. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
supplements, nutritional drinks, inhaled sodium 
chloride. Those with P. aeruginosa were receiving 
250 mg azithromycin 3 d per week. 
Erythrocyte CAT, GST, 
SOD and TAC. 
Ambroszkiewicz (7), 
cross-sectional 
Warsaw, 
Poland 
35 people with CF (M = 48.6%; median (range), 7.0 
(5-9) y); 60.0% were P.Phe508del homozygous; 
29.0% were P.Phe508del heterozygous; 11.0% 
were non-P.Phe508del. Mean ± SD FEV1 was 89.6 
± 12.2% predicted. No participants had CFRD and 
2.9% had hepatic insufficiency; 94.3% of 
participants were PI, and were receiving 
pancreatic enzyme replacement supplements 
(6,000 U lipase/kg/day).  No participants received 
inhaled or systemic corticosteroids 1 month prior 
to sample collection. All participants were 
supplemented with Vitamins A (2,000 IU/day), E 
(200 IU/day) and D3 (400 IU/day) 
35 healthy control participants (M = 
48.6%; median (range), 7.0 (5-9) y) who 
were matched for age and sex. healthy 
control participants were recruited 
from an outpatient clinic and presented 
with minor problems other than 
infections and diseases which may 
influence bone status. 
Serum 25(OH)D, and 
vitamins A and E. 
Olveira (381), 
cross-sectional 
Malaga, Spain 36 people with CF (M = 50.0%; 27.2 ± 8.9 y). Mean 
± SD FEV1 was 57.8 ± 25.4% and FVC was 68.2 ± 
22.8%; 86.1 were colonized with P. aeruginosa 
and mean ± SD exacerbations for the past year 
was 2.4 ± 2.0. None were receiving Omega-3 fatty 
acid supplements.  
50 healthy control participants (M = 
25.0%; 12.8 ± 7.6 y); 54 non-CF 
bronchiectasis (M = 29.7%; 47.4 ± 18.9 
y). 
Plasma or serum 
copper, selenium and 
vitamin C. Plasma 8-
iso-PG2α, CAT, GPx, 
SOD, total 
antioxidant capacity 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
(TAC) and TBARS. 
Serum vitamins A, D, 
E:cholerterol and 
zinc. Neutrophil, 
lymphocyte, 
monocyte and total 
leukocyte peroxide, 
O₂̇‾and GSH. 
Bernardi (38), 
cross-sectional 
Sao Paulo, 
Brazil 
44 people with CF (M = 50.0%; 8.4 ± 3.2 y); 31.8% 
were P.Phe508del homozygous; 68.2% for 
P.Phe508del heterozygous; 100% were PI; 6.8% 
had CFRD; 38.6% had hepatic disease. 
Furthermore, 25.0% were colonized with S. aureus 
and 6.8% were colonized with P. aeruginosa. 
16 healthy control participants (M = 
25.0%; 8.3 ± 2.6 y).  
Erythrocyte GSH. 
Sadowska-Woda 
(445), 
AquADEK 
supplementation 
non-randomized 
controlled trial 
Rzeszow, 
Poland 
50 people with CF (M = 60.0%; 9.6 ± 3.7 y; BMI 
19.3 ± 2.8 kg/m2). Mean ± SD FEV1 was 57.8 ± 
25.4% predicted and FVC was 68.2 ± 22.8%; 
100.0% were PI and receiving pancreatic enzyme 
replacement supplements (Creon or Lapancrea). 
Children were receiving daily inhaled DNase. 
21 healthy control participants (m = 
66.7%; 9.6 ± 3.1 y; bmi 20.1 ± 5.2 kg/m2) 
who were not receiving multivitamin 
supplementation.  Mean ± SD FEV1 
104.2 ± 12.3% predicted and FEV1/FVC 
was 90.0 ± 12.7%. 
Plasma 
hydroperoxides, 
MDA, thiol groups 
and TAC. Erythrocyte 
CAT, SOD and thiol 
groups. 
Cobanoglu (95), 
cross-sectional 
Ankara, 
Turkey 
16 people with CF (M = 50.0%; 6.1 ± 1.5 y and pre-
pubertal); 6.3% were P.Phe508del homozygous; 
16 healthy control participants (M = 
50.0%; 6.1 ± 1.4 y) admitted to hospital 
Serum 25(OH)D. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
43.8% were P.Phe508del heterozygous; 50.0% 
were non-P.Phe508del; 100.0% were PI and 
receiving pancreatic enzyme replacement 
supplements and 800 IU/day of vitamin D. Non-
had CFRD or liver disease. None were receiving 
anti-epileptic drugs, calcium supplements, 
systemic or inhaled steroids. 
for minor issues other than infection 
and were pre-pubertal.  
Durieu (146),  
intravenous fish oil 
n-3 emulsion open-
pilot observation 
Lyon, France 13 people with CF (M = NR; 19.4 ± 11.1 y) prior to 
treatment with intravenous n-3 fatty acids. Mean 
± SD FEV1 was 81.5 ± 12.8% and 51.0 ± 15.6% for 
children and adults, respectively. 
 
21 healthy control participants (M = NR; 
age range, 20-55 y) from a related study 
(13). 
Plasma 
hydroperoxides.  
Plasma vitamins A 
and E, carotenoids 
and MDA in CF group 
only. 
van Biervliet (539), 
cross-sectional 
Ghent, 
Belgium 
104 people with CF; separated into two groups, 
(A) class I, II, III (M = 50.6%; median (interquartile 
range, IQR), 15.0 (13.4) y), and (B) class IV, V or 
unknown CFTR genotypes (M = 56.0%; median 
(IQR), 16.0 (20.0) y). Group A: median (IQR) FEV1 
was 80.4 (40.4)% predicted and FVC 89.7 (21.3)% 
predicted; 100% were PI; 11.4% had CFRD; 16.5% 
had liver disease. Group B:  median (IQR) FEV1 
was 75.0 (41.4)% and FVC 86.7 (21.3)% predicted; 
44 healthy control participants (M = NR; 
median (range), 18.0 (1-47) y). 
Serum α-linolenic 
acid, arachidonic 
acid, 
docosahexaenoic 
acid, linoleic acid and 
oleic acid. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
32.0% were PI; 19.0% had CFRD; 8.0% had liver 
disease. None received polyunsaturated fat 
supplements. PI participants received pancreatic 
enzyme replacement and multivitamin 
supplements (1000 IU cholecalciferol, 100 mg α-
tocopherolacetate, 1 mg phytoimenadion and 
10000 IU retionolacetate).  
Rovner (437), 
cross-sectional 
Pennsylvania, 
USA 
101 people with CF (M = 50.0%; 14.8 ± 4.2 y). FEV1 
was 84 ± 19% predicted. None had CFRD. All 
participants were receiving vitamin D and 
pancreatic enzyme supplements. 
177 healthy control participants (M = 
42.0; 12.5 ± 3.5 y). 
Serum 1,25(OH)2D  
and 25(OH)D. 
Oudshoorn (387), 
cross-sectional 
Utrecht, The 
Netherland 
30 people with CF (M = 53.3; 11.9 ± 2.6 y, range 8-
18 y). FEV1 was 88.5 ± 18.7% predicted. All 
received a mean ± SD 120 ± 75 mg/day α-
tocopherol supplementation. 
30 outpatients (M = 43.3; 11.3 ± 2.9 y) 
who underwent ear, nose or throat 
surgery. 
Plasma α-tocopherol, 
coenzyme 
Q10:cholesterol ratio, 
total, oxidized, 
reduced coenzyme 
Q10. 
Tirouvanziam (517),   
non-randomized 
trial of NAC 
Stanford, USA 18 people with CF (sex and age NR) prior to 
treatment with NAC. 
9 healthy control participants (sex and 
age NR). 
Neutrophil GSH. 
Nicolaidou (369), 
cross-sectional 
Athens, 
Greece 
25 people with CF (M = 50.0; range 6-17 y, median 
(p25, p75), M = 15.0 (14.0, 16.0), F = 14.5 (11.0, 
25 healthy control participants (M = 
52.0; range 8-17 y, median (p25, p75), 
Serum 25(OH)D  and 
vitamin K. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
15.0) y) without a vitamin K intervention.  Median 
(p25, p75) FEV1 was 71.5 (45, 85)% predicted for 
males and 75.5 (62, 104)% predicted for females. 
No group specific genotype data was available. 
100.0% were PI and receiving pancreatic enzyme 
replacement supplements. None were receiving 
antibiotics or had ever received corticosteroids. 
All were receiving 800 IU/day vitamin D 
M = 14.0 (12.0, 16.0), F = 11.0 (9.0, 14.0) 
y). 
Back (23), 
cross-sectional 
Tubingen, 
Germany 
22 people with CF (M = 40.9%); separated into 3 
groups for analysis: those who are 7 6-11 y 
(median (IQR), 9.4 (7.7-11.1) y), 7 12-17 y (median 
(IQR), 15.0 (14.0-16.7) y) or 7 ≥18 y (median (IQR), 
23.6 (19.7-29.0) y); 27.3% were P.Phe508del 
homozygous; 45.5% were P.Phe508del 
heterozygous; 13.6% were non-P.Phe508del. 
86.4% were PI and 18.2% had CFRD. Median (IQR) 
FEV1 was 90.0 (84.5-102.0)% predicted in those 6-
11 y, 80.0 (63.0-82.0)% predicted in those 12-17 y 
and 65.0 (42.0-84.0)% predicted in those ≥18 y.  
FVC was 92.0 (87.0-95.0)% predicted in those 6-11 
y, 81.0 (71.0-86.0)% predicted in those 12-17 y 
and 6588 (65.0-95.0)% predicted in those ≥18 y. 
30 healthy control participants (M = 
53.3); separated into 3 groups for 
analysis: 9 6-11 y (median (IQR), 8.4 
(7.4-10.3) y), 5 12-17 y (median (IQR), 
13.3 (12.6-16.4) y) and 16 ≥18 y 
(median (IQR), 27.6 (24.5-30.2) y). 
 
Plasma vitamin E, β-
carotene, β-
cryptoxanthin, 
lycopene, protein 
carbonyls, TBARS and 
vitamin C. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
Best (39),   
randomized 
controlled trial of 
copper 
supplementation 
Columbus, 
USA 
38 people with CF (M = NR; 24.8 ± 8.0 y, range 12-
48 y) before supplementation with copper and 
zinc; 100% had PI and were receiving pancreatic 
enzyme replacement and multivitamin 
supplements (ADEK). None had CFRD, renal failure 
or advanced lung disease.   
30 healthy control participants (age and 
sex NR). 
Erythrocyte SOD. 
Plasma ceruloplasmin 
and diamine oxidase 
Lagrange-Puget 
(291), 
cross-sectional 
Lyon, France Up to 232 people (depending on biomarker 
studied) with CF (M = NR; mean (range), 13.0 (0.5-
45.0) y). All had PI and were receiving pancreatic 
enzyme replacement supplements. Those with 
vitamin A and E deficiency received retinol or 
tocopherol supplements.   
53 healthy control participants (M = NR; 
mean (range), 22.0 (1.0-40.0) y); 
including, 21 children admitted for 
orthopedic surgery (before treatment) 
and 32 healthy individuals attending a 
phase I clinical trial center.  
Plasma α-carotene, β-
carotene, GSH, tGSH, 
lipid peroxides, 
lutein, lycopene, 
MDA, TBARS, 
vitamins A and E, and 
zeaxanthin. 
Schupp (459), 
cross-sectional 
California, USA 10 people with CF (M = 90.0; 31.2 ± 10.0 y, range 
21-47 y). Mean ± SD FEV1 was 45.0 ± 25.4% 
predicted. 100% were PI and receiving pancreatic 
enzyme replacement supplements. 30% had 
CFRD. All were receiving nutritional supplements, 
however, 10% were receiving multivitamin 
supplements containing lutein.  
10 healthy control participants (age 
range 20-51 y) matched for age, sex and 
ethnicity.  
Plasma lutein and 
zeaxanthin. 
Sidlova (478), 
cross-sectional 
Prague, Czech 
Republic 
37 people with CF (M = 64.9; mean (range), 10.4 
(1-28) y); 10.8% had hepatobiliary abnormalities. 
27 controls (M = 66.7; mean (range), 
8.5 (2-17) y). 
Serum GSTα 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
Aris (15), 
cross-sectional 
North 
Carolina, USA 
50 people with CF (M = 46.0; 28.3 ± 7.8 y); 56% 
were P.Phe508del homozygous; 28% were 
P.Phe508del heterozygous; 16% were non-
P.Phe508del. Mean ± SD FEV1 was 46.1 ± 18.6% 
predicted and FVC was 67.5 ± 17.9% predicted. 
94% were PI and were receiving pancreatic 
enzyme replacement supplements; All were 
receiving multivitamin supplementation.  
53 healthy control participants (M = 
50.9; 28.9 ± 7.8 y) who were matched 
for age and sex.  
Serum 1,25(OH)2D 
and  25(OH)D. 
McGrath (327), 
cross-sectional 
Belfast, UK 11 people with CF (M = 72.7%; range, 18-37 y). All 
were receiving vitamin E supplementation (200 
mg/day). None receiving any other antioxidants 
and all non-smokers.  
11 healthy control participants (M = 
72.7%; range, 20-35 y). All non-
smokers.  
Plasma vitamin 
E:cholesterol, 
MDA:cholesterol, 
protein carbonyls and 
protein thiols.  
Wood (571), 
cross-sectional 
Newcastle, 
Australia 
21 people with CF (M = 61.9; 14.8 ± 1.1 y); 57% 
were P.Phe508del homozygous; 38% were 
P.Phe508del heterozygous; 5% were non 
P.Phe508del.  Mean ± SEM FEV1 was 85.3 ± 6.2% 
predicted and FVC was 90.1 ± 4.7% predicted. 91% 
were PI; 71% were receiving aerosol β2-agonists; 
33% were receiving inhaled corticosteroids; 14% 
were receiving cromoglycate; 24% were receiving 
ipratropium; 19% were receiving DNase; 19% 
21 healthy control participants (M = 
61.9; 14.2 ± 1.1 y) matched for age and 
sex. 
Erythrocyte SOD. 
Plasma 8-iso-PGF2α, 
β-carotene, GPx, 
selenium, zinc, 
copper, vitamins A, C 
and E. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
were receiving antibiotics. None received vitamin 
supplementation in the previous 4 wk.  
Madarasi (314), 
cross-sectional 
Budapest, 
Hungary 
21 people with CF (M = 57.1; mean (range), 8.7 (6-
12) y). None had liver manifestations; 100.0% 
received pancreatic enzyme replacement and 
multivitamin supplements. 
24 healthy control participants (M = 
45.8; mean (range), 8.3 (6-12) y) 
matched for age. HEALTHY CONTROL 
PARTICIPANTS were formally 
hospitalised children with minor 
ailments who were attending clinic for 
follow-up blood testing.  
Erythrocyte CAT and 
SOD. Serum α-
tocopherol, ascorbic 
acid, MDA, TAC, uric 
acid and vitamin A. 
Whole blood GPx. 
Lands (295), 
cross-sectional 
Montreal, 
Canada 
24 people with CF (M = 62.5; 11.4 ± 3.4 y), who 
were not hospitalised for an acute respiratory 
exacerbation. Mean ± SD FEV1 was 77.6 ± 17.4% 
predicted and RV/TLV was 31.1 ± 10.3%. 
17 healthy control participants (M = 
58.8; 23.8 ± 3.9 y) who were recruited 
as part of a study investigating 
oxidative stress and exercise. 
Plasma trolox 
equivalent 
antioxidant capacity 
(TEAC). 
Percival (395), 
cross-sectional 
Florida, USA 7 people with CF (M = 100.0; 24.5 ± 3.5 y, range 
19-32 y). Mean ± SD FEV1 was 55.0 ± 28.8% (range 
25-99%) and FVC was 75.8 ± 20.2% (51-105%) 
predicted. 85.7% were PI and receiving pancreatic 
enzyme replacement supplements. All were 
receiving multivitamin supplements. 
 
6 healthy control participants (M = 
100.0; 24.5 ± 5.5 y, range 20-30 y) who 
were matched for age.  
Plasma, 
polymorphonuclear 
cell and mononuclear 
cell copper. 
Polymorphonuclear 
cell and mononuclear 
cell Copper-Zinc SOD. 
Plasma 
ceruloplasmin. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
Tauber (510), 
cross-sectional 
Vienna, 
Austria 
28 people with CF (M = 51.1; 10.8 ± 6.5 y; this 
includes those with an acute respiratory 
exacerbation (n = 17)) who did not have an acute 
respiratory exacerbation; 4.4% of all (including 
those with an acute respiratory exacerbation) had 
chronic P. aeruginosa infections.  
175 children with bronchial asthma 
(BA) (M = 55.4; 9.8 ± 3.8 y); 87 HEALTHY 
CONTROL PARTICIPANTS (M = 29.9; 
10.2 ± 4.5 y); 23 non-asthmatic children 
with bacterial lower respiratory tract 
infection (LRTI) (M = 39.1; 8.6 ± 2.5 y). 
Serum  
myeloperoxidase  
(MPO). 
Collins (97), 
cross-sectional 
New South 
Wales, 
Australia 
10 people with CF (sex NR; mean (range), 17.4 
(5.8-37.8) y; this includes those with an acute 
respiratory exacerbation (n = 12)), who are not 
undergoing treatment for an acute respiratory 
exacerbation.  
9 healthy control participants (sex NR; 
mean (range), 29.8 (22.8-46.1) y). 
Plasma 8-iso-PGF2α. 
Eichler (151), 
cross-sectional 
Vienna, 
Austria 
23 people with CF (M = 57.1; median (range), 14.5 
(8-17) y; this includes those with an acute 
respiratory exacerbation (n = 19)). In those who 
were clinically-stable, median (IQR) FEV1 was 
81.2% (72.4-98.4) and FVC was 87.8% (79.6-
102.3%) predicted. 
25 healthy control participants (M = 
56.0; median (range), 13.4 (3-16) y). 
Serum lactoferrin and 
MPO. 
Dominguez (136), 
cross-sectional 
Barcelona, 
Spain 
101 people with CF (M = 54.5%; 11.5 ± 6.9 y). 43-95 healthy control participants 
(varies between biomarkers) of a 
similar age to the CF group (age and sex 
NR). 
Erythrocyte SOD. 
Plasma α-tocopherol, 
glutathione 
reductase (GR), 
hydroperoxides, MDA 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
and protein 
carbonyls. 
Koller (284), 
cross-sectional 
Vienna, 
Austria 
23 people with CF (M = 57.1; median (range), 14.5 
(8-17) y; this includes those with an acute 
respiratory exacerbation (n = 19)), without an 
acute respiratory exacerbation. Median (quartile 
1-3) FEV1 was 81.2 (72.4-98.4)% and FVC was 87.8 
(79.6-102.3)%. 
25 healthy control participants (M = 
56.0; median (range), 13.4 (3-16) y). 
Serum eosinophil 
peroxidase. 
Hung (238), 
cross-sectional 
Edinburgh, UK 63 people with CF (M = 49.2; mean (range) 7.9 
(0.5-16) y). All participants were receiving 
pancreatic enzyme replacement and multivitamin 
supplements; all participants were receiving 
flucloxacillin, inhaled steroids and/or inhaled 
steroid and bronchodilators. 
59 healthy control participants (M = 
62.7; mean (range), 7.2 (1-16) y). 96.6% 
were screened for CF and fragile X 
syndrome but had normal genotypes; 
1.7% had bronchiolitis; 1.7% had an 
inguinal hernia. 
Serum GSTα1. 
Kearns (261), 
cross-sectional 
Arkansas, USA 15 people with CF (M = 46.7%; 13.1 ± 2.7 y, range 
8.7-19.3 y); 7/15 had genotype analysis; 100% 
were P.Phe508del homozygous; 13.3% were 
receiving pancreatic enzyme replacement and 
multivitamin supplements.  
15 healthy control participants (M = 
46.7%; 14.5 ± 3.1 y, range 8.9-18.9 y). 
Serum albumin and  
γ-glutamyl 
transpeptidase. 
Koller (283), 
cross-sectional 
Vienna, 
Austria 
59 people with CF (M = 45.9%; 11.0 ± 7.7 y; this 
includes those with an acute respiratory 
85 healthy control participants (M = NR; 
10.8 ± 5.7 y). 
Serum MPO. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
exacerbation (n = 39)) without an acute 
respiratory exacerbation. 
Winklehofer-Roob 
(569),   
pre-β-alanine 
intervention 
Zurich, 
Switzerland 
Up to 32 people with CF (M = 48.6%; 10.8 ± 7.6 y); 
100.0 were PI and receiving pancreatic enzyme 
replacement and multivitamin supplements. 
Up to 40 healthy control participants 
(M = 35.7%; 31.5 ± 8.0 y). 
Low-density 
lipoprotein, α-
tocopherol and β-
carotene. Plasma α-
tocopherol, β-
carotene and MDA. 
Mocchegiani (341), 
cross-sectional 
Ancona, Italy 15 people with CF (M = 46.7%; mean (range), 6.7 
(2-13) y); 90% were colonized with P. aeruginosa. 
All were receiving pancreatic enzyme 
replacement and vitamin supplementation. No 
individuals with signs of diabetes or heart failure 
were included. All were receiving antibiotics and 
bronchodilators. 
15 healthy control participants (M = 
60.0%; mean (range), NR (2-13) y) who 
were admitted to hospital for minor 
surgery. 
Serum albumin. 
Plasma Zinc. 
Koller (282), 
cross-sectional 
Vienna, 
Austria 
42 people with CF (M = 47.6%; mean (range), 14.5 
(0.8-28) y). Mean ± SD FEV1 was 67.8 ± 32.4% 
predicted (range 17.1-125.5% predicted), MEF50 
was 52.0 (42.5)% predicted (range 4.4-130.2% 
predicted). 73.3% were colonized with P. 
aeruginosa. 
30 healthy control participants (M = 
53.3%; mean (range), 13.4 (4-32) y). 
Serum MPO. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
Mangione (318), 
cross-sectional 
Pennsylvania, 
USA 
32 people with CF (age and sex NR). 8 healthy control participants who 
were healthy, active, non-smokers and 
age-matched to their CF-counterparts.  
Erythrocyte GSH. 
Vaisman (533), 
cross-sectional 
Rehovot, 
Israel 
11 people with CF (mean (range), NR (4-14) y). 
“Most” were colonized with P. aeruginosa. All 
were receiving vitamin A and E supplements (100 
IU) and multivitamin preparations. 
 
 
10 age-matched healthy control 
participants (age and sex NR). Not 
receiving any vitamin supplementation.  
Plasma tocopherol 
vitamin A. Blood 
neutrophil 
tocopherol. 
James (245), 
cross-sectional 
Cardiff, UK 22 people with CF (M = 45.5%; median (range), 8.3 
(1.6-16.5) y). 
9 healthy control participants (M = 
22.2%; median (range), 10.9 (4.7-16.4) 
y). 
Plasma and 
erythrocyte α-
tocopherol. Serum 
selenium. 
Stead (487), 
cross-sectional 
London, UK 31 people with CF (24.5 y (range, 17-52 y)); 93.5% 
receiving pancreatic enzyme replacement and no 
evidence of liver disease. FEV1 was 41.5 ± 11.4% 
predicted.  96.8% taking vitamin D supplements 
(daily intake range: 0.6-54.3 µg [24-2,172 IU)]. 
28 healthy control participants (M = NR; 
age = NR). 
Serum 25(OH)D,  and 
1,25(OH)2D. Plasma 
albumin. 
Reiter (425), 
cross-sectional 
Massachusett
s and Arizona, 
USA 
20 people with CF (M = 50.0%; range, 12-25 y); 
50% in Massachusetts and 50% in Arizona. All 
were receiving pancreatic enzyme replacement, 
8 healthy control participants (M = 
40.0%; 18.6 ± 8.1 y). 
Serum carotene, 
albumin and 
1,25(OH)2D. 
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First author 
[reference],  
study design 
Location Cases; n and characteristics Controls; n and characteristics Biomarker of interest 
           
 
 
 
 
 
 
 
 
 
 
 
Data is expressed as mean ± SD unless otherwise stated.
vitamin supplementation and intermittent 
antibiotic therapy.   
Hahn (207), 
cross-sectional 
St. Louis, USA 21 people with CF (M = 57.1%; mean (range), 20.9 
(12-36) y). All were PI. All were receiving 
pancreatic enzyme replacement (given as 
Cotazyme) and multivitamin supplements 
(containing 400 units of vitamin D/tablet).  One 
patient had diabetes and was receiving oral 
hypoglycaemic agents.  
21 age- and sex-matched healthy 
control participants (M = 57.1%; mean 
(range), 20.3 (12-34) y). 
Serum 25(OH)D, 
albumin and 
carotene. 
Jacob (244), 
cross-sectional 
Chicago, USA 18 people with CF (range, 6-17 y). All were 
receiving daily multivitamin supplements (Poly-vi-
sol) containing 2,500 IU of water miscible vitamin 
A per tablet.  
40 adolescent healthy control 
participants (range, 11-17 y). 
Plasma vitamin A, 
zinc and albumin.   
Hubbard (235), 
cross-sectional 
Tennessee, 
USA 
16 people with CF (M = 43.8%; range, 13-47 y); 
68.8% were PI. Those with PI were receiving 
pancreatic enzyme replacement and multivitamin 
supplements.  
8 healthy control participants (M = 
50.0%; range, 19-32 y). 
Serum vitamin A and 
carotene. Plasma 
vitamin E. 
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7.4.2. Study Characteristics 
A summary of the included references are presented in Table 7.1. The included studies 
were published between 1977 and 2017, and data were collected from 28 centres in 
Europe, 15 centres in North America, 3 centres in Asia, 2 centres in Oceania and 1 centre 
in South America. The majority of studies were of cross-sectional study design (n = 43; 
87.8%), along with data collected at baseline in 2 non-randomized controlled trials (4.1%), 
2 non-randomized and non-controlled trials (4.1%), 1 randomized controlled trial (2.0%), 
and 1 open-pilot observation (2.0%; Table 7.1). The sample sizes of included studies were 
generally modest, with the number of cases and controls ranging from 7 to 232 and 6 to 
177, respectively. 
7.4.3. Risk of bias and quality of studies 
A summary of the risk of bias assessments is presented in Table 7.2. Briefly, the quality of 
the studies was generally moderate (n = 31; 63.3%), with 14 high (28.6%) and 4 low (8.2%) 
quality studies included.  
7.4.5. Missing data 
Missing data was requested for 7 studies as the mean and/or SD were not computable (23, 
38, 146, 245, 369, 517, 571); however, no authors provided additional data.  
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Table 7.2. Summary of the quality ratings for the eligible studies using the Newcastle-Ottawa Quality 
Assessment Scale for case-control studies.   
First author [reference] Selection Comparability Exposure Total points Rating1 
AbdulWahab (1) 2 1 3 6 High 
Ambroszkiewicz (7) 3 2 2 7 High 
Antus (12) 3 0 1 4 Moderate 
Aris (15) 2 1 3 6 High 
Back (23) 1 1 2 4 Moderate 
Bernardi (38) 2 1 2 5 Moderate 
Best (39) 1 1 3 5 Moderate 
Cobanoglu (95) 2 2 3 7 High 
Collins (97) 3 0 3 6 High 
Dominguez (136) 1 1 1 3 Moderate 
Durieu (146) 0 0 2 2 Low 
Eichler (151) 2 0 1 3 Moderate 
Hahn (207) 2 2 3 7 High 
Hubbard (235) 2 0 1 3 Moderate 
Hung (238) 3 0 1 4 Moderate 
Jacob (244) 2 0 2 4 Moderate 
James (245) 0 0 2 2 Low 
Kearns (261) 1 1 2 4 Moderate 
Koller (284) 1 0 2 3 Moderate 
Koller (283) 0 0 2 2 Low 
Koller (282) 1 0 2 3 Moderate 
Konstantinidis (285) 1 1 3 5 Moderate 
Lagrange-Puget (291) 2 0 2 4 Moderate 
Lands (295) 1 0 2 3 Moderate 
Lee (300) 2 0 1 3 Moderate 
Madarasi (314) 1 1 2 4 Moderate 
Mangione (318) 0 1 3 4 Moderate 
McGrath (327) 3 2 3 8 High 
Mocchegiani (341) 1 1 3 5 Moderate 
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Table 7.2. Continued.    
First author [reference] Selection Comparability Exposure Total points Rating1 
Nicolaidou (369) 2 0 3 5 Moderate 
Olveira (380) 1 2 3 6 High 
Olveira (381) 0 1 3 4 Moderate 
Oudshoorn (387) 0 1 3 4 Moderate 
Percival (395) 3 1 3 7 High 
Reiter (425) 3 2 3 8 High 
Rovner (437) 3 0 3 6 High 
Sadowska-Bartosz (444) 1 0 3 4 Moderate 
Sadowska-Woda (445) 0 1 3 4 Moderate 
Schupp (459) 2 2 3 7 High 
Sidlova (478) 2 0 3 5 Moderate 
Stead (487) 2 1 2 5 Moderate 
Tauber (510) 0 1 2 3 Moderate 
Tirouvanziam (517) 1 0 3 4 Moderate 
Turowski (528) 2 0 3 5 Moderate 
Vaisman (533) 0 1 3 4 Moderate 
Van Biervliet (539) 2 0 3 5 Moderate 
Winklhofer-Roob (569) 2 0 2 4 Moderate 
Wood (571) 4 2 3 9 High 
Yadav (575) 2 1 3 6 High 
1 Studies scoring 0-2 were considered low quality, studies scoring 3-5 were considered moderate quality and 
studies scoring 6-8 points were considered high quality. 
7.4.6. Synthesis of results 
7.4.6.1. Thiols 
Twelve eligible studies assayed the content of thiols within the erythrocytes, blood 
neutrophils, plasma or serum of people in clinically-stable CF versus non-CF controls. The 
biomarkers studied were plasma or serum albumin (n = 6) (207, 244, 261, 300, 341, 487), 
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erythrocyte GSH (n = 2) (38, 318), blood neutrophil GSH (n = 2) (381, 517) and plasma or 
serum protein thiol groups (n = 2) (327, 444). 
Whilst GSH was studied in blood neutrophils (n = 2) (381, 517) and erythrocytes (n = 2) (38, 
318) by 4 eligible trials, a meta-analysis was not possible for either biomarker as mean ± SD 
was not computable for 2 trials as medians and interquartile ranges were reported (38, 
517). The concentration of albumin in the plasma or serum was significantly lower in people 
with clinically-stable CF compared to the non-CF controls (SMD -0.98, 95% CI -1.68 to -0.27, 
p < 0.01, I2 86%, 6 trials) (207, 244, 261, 300, 341, 487). The concentration of protein thiol 
groups in plasma or serum were not significantly different between people with clinically-
stable CF and non-CF controls (SMD -0.35, 95% CI -0.90 to 0.20, p = 0.22, I2 0%, 2 trials) 
(327, 444). 
7.4.6.2. Vitamins 
Twenty-two studies were eligible and studied the levels of vitamins within the plasma or 
serum of people with clinically-stable CF versus non-CF controls. The most studied 
biomarkers were related to the fat-soluble vitamins A (inclusive of ‘vitamin A’, ‘retinol’, 
carotene, β-carotene, lutein and lycopene; n = 13) (7, 23, 569, 571, 575, 207, 235, 244, 291, 
314, 380, 459, 533), E (inclusive of ‘vitamin E’, ‘vitamin E:cholesterol’, tocopherol and α-
tocopherol; n = 13) (7, 23, 533, 569, 571, 575, 136, 235, 245, 291, 314, 327, 381, 387), D 
(inclusive of ‘vitamin D, ‘25(OH)D’ and ‘1,25(OH)2D’; n = 11) (7, 15, 575, 95, 207, 300, 369, 
380, 425, 437, 487) and C (inclusive of ‘vitamin C’, ‘ascorbic acid’ and ‘zeaxanthin’; n = 5) 
(23, 291, 314, 459, 571). 
The concentration of vitamin A (inclusive of ‘retinol’; SMD -0.66, 95% CI -1.14 to -0.17, p = 
0.02, I2 83%, 8 trials; Figure 7.2) (7, 235, 244, 291, 314, 380, 533, 571, 575) and β-carotene 
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(inclusive of ‘carotene’; SMD -2.17, 95% CI -3.30 to -1.03, p = < 0.01, I2 91%, 4 trials) (207, 
235, 291, 569) were significantly lower in the plasma or serum of people with CF compared 
to the non-CF controls. The non-provitamin A carotenoids, lutein (SMD -1.52, 95% CI -1.83 
to -1.20, p < 0.01, I2 0%, 2 trials) (291, 459), lycopene (2 trials; mean ± SD not computable 
for 1 trial (23), therefore, meta-analysis was not complete) (23, 291) and zeaxanthin (SMD 
1.48, 95% CI -5.87 to 8.83, p = 0.69, I2 99%, 2 trials) (291, 459) were also studied in plasma 
or serum samples. The concentration of vitamin C (inclusive of ‘ascorbic acid’) in the plasma 
or serum were not significantly different between people with clinically-stable CF and non-
CF controls (SMD -0.05, 95% CI -1.83 to 1.72, p 0.95, I2 93%, 2 trials) (314, 571). The 
concentration of 25(OH)D (inclusive of ‘vitamin D’) in the plasma or serum were not 
significantly different between people with clinically-stable CF and non-CF controls (SMD -
0.23, 95% CI -0.79 to 0.33, p = 0.42, I2 92%, 9 trials; Figure 7.2) (7, 15, 95, 207, 300, 380, 
437, 487, 575). A metabolite of 25(OH)D, 1,25(OH)2D, has also been studied, however 
concentrations in plasma or serum were not different between people with CF and non-CF 
controls (SMD -0.46, 95% CI -1.12 to 0.20, p =0.17, I2 90%, 4 trials) (15, 425, 437, 487). Data 
were taken from samples collected during winter months where possible. The 
concentration of vitamin E (inclusive of ‘tocopherol’ and ‘α-tocopherol’) in the plasma or 
serum were significantly lowered in people with CF compared to their non-CF controls 
(SMD -0.67, 95% CI -1.13 to -0.21, p < 0.01, I2 87%, 11 trials; Figure 7.2) (7, 136, 575, 235, 
291, 314, 327, 387, 533, 569, 571). However, plasma or serum vitamin E:cholesterol was 
not significantly different between people with CF and their non-CF controls (SMD -0.35, 
95% CI -0.03 to 0.74, p = 0.07, I2 0%, 2 trials) (327, 381). 
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7.4.6.3. Trace elements 
Eight studies were eligible and studied the levels of trace elements within the plasma or 
serum of people with CF versus non-CF controls. The trace elements studied were zinc (n = 
6) (1, 244, 341, 380, 571, 575), copper (n = 3) (395, 571, 575) and selenium (n = 2) (245, 
571). 
The concentrations of copper in the plasma or serum were not significantly different 
between people with clinically-stable CF and non-CF controls (SMD 0.53, 95% CI -0.25 to 
1.30, p = 0.53, I2 67%, 3 trials) (395, 571, 575). The concentration of selenium in the plasma 
or serum were significantly lower in people with CF versus the non-CF controls in 1 trial 
(571), however, a meta-analysis was not conducted in this biomarker as mean ± SD was not 
computable for the second trial (245). The concentration of zinc in the plasma or serum 
was not significantly different between people with CF and non-CF controls (SMD -0.50, 
95% CI -1.21 to 0.20, p = 0.16, I2 89%, 6 trials) (1, 244, 341, 380, 571, 575).  
7.4.6.4. Oxidoreductases 
Five studies were eligible and studied oxidoreductases within the erythrocytes, plasma or 
serum of people with CF versus non-CF controls. The oxidoreductases studied were 
erythrocyte SOD activity (n = 5) (39, 136, 314, 444, 571), erythrocyte CAT activity (n = 2) 
(314, 444) and plasma or serum ceruloplasmin (n = 2) content (39, 395). 
CAT activity in the erythrocytes were not significantly different between people with CF 
and non-CF controls (SMD -0.40, 95% CI -1.51 to 0.72, p = 0.49, I2 78%, 2 trials) (314, 444). 
Ceruloplasmin content of the plasma or serum were not significantly different between 
people with CF and non-CF controls (SMD 0.60, 95% CI -0.38 to 1.58, p = 0.23, I2 58%, 2 
trials) (39, 395). SOD activity in the erythrocytes were not significantly different between 
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people with CF and non-CF controls (SMD 0.02, 95% CI -1.16 to 1.20, p = 0.97, I2 96%, 5 
trials) (39, 136, 314, 444, 571).  
7.4.6.5. Total antioxidant capacity 
Four studies were eligible and studied the TAC (inclusive of total antioxidant status and 
TEAS) of plasma or serum in people with CF versus non-CF controls. TAC of the plasma or 
serum was not significantly different between people with CF compared and the non-CF 
controls (SMD -0.82, 95% CI -2.02 to 0.37, p = 0.18, I2 94%, 4 trials) (295, 314, 380, 445). 
7.4.6.6. Lipid peroxidation 
Eleven studies were eligible and studied the levels of lipid peroxidation within the plasma 
or serum of people with CF versus non-CF controls. The biomarkers studied were MDA 
(inclusive of the TBARS assay) (n = 7) (12, 23, 136, 291, 314, 327, 380, 445, 569), 
hydroperoxides (n = 3) (136, 146, 445) and total 8-iso-PGF2α (n = 3) (97, 380, 571).  
The concentration of MDA (SMD 1.33, 95% CI 0.43 to 2.24, p < 0.01, I2 96%, 8 trials; Figure 
7.3) (12, 136, 291, 314, 327, 380, 445, 569) and total 8-iso-PGF2α (SMD 0.64, 95% CI 0.23 to 
1.05, p < 0.01, I2 0%, 2 trials; Figure 7.3) (97, 380) in the plasma or serum were significantly 
higher in people with clinically-stable CF compared to the non-CF controls (Figure 7.3). The 
concentration of hydroperoxides (SMD 2.80, 95% CI -2.71 to 8.31, p = 0.26, I2 99%, 2 trials; 
Figure 7.3) (136, 445) in the plasma or serum were not significantly different between 
people with CF and non-CF controls.  
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7.4.6.7. Protein carbonylation 
The only biomarker of protein carbonylation studied was plasma or serum protein 
carbonyls (n = 4) (23, 136, 327, 444). The concentration of protein carbonyls in the plasma 
or serum were significantly higher in people with CF compared to the non-CF controls (SMD 
1.13, 95% CI 0.48 to 1.77, p < 0.01, I2 61%, 3 trials; Figure 7.3) (136, 327, 444). 
Table 7.3. Statistically significant correlation coefficients for biomarkers of antioxidant status, oxidative 
damage and clinical outcomes. 
First author 
[reference] 
Biomarker Sample Clinical outcome r 
Vitamins    
Lagrange-Puget 
(291) 
Vitamin A P/S 
BMI 
FEV1 
+NR 
+NR 
Madarasi (314) Vitamin A P/S Shwachman-Kulzycki score +0.75 
Lagrange-Puget 
(291) 
β-carotene P/S 
BMI 
FEV1 
+NR 
+NR 
Wood (571) β-carotene P/S 
Monocyte count 
Neutrophil count 
White cell count 
-0.311 
-0.461 
-0.421 
Lagrange-Puget 
(291) 
Lutein P/S BMI +NR 
Schupp (459) Lutein P/S Macular pigment optical density +0.76 
Lagrange-Puget 
(291) 
Lycopene P/S 
BMI 
FEV1 
+NR 
+NR 
Lagrange-Puget 
(291) 
Zeaxanthin P/S FEV1 +NR 
Schupp (459) Zeaxanthin P/S Macular pigment optical density +0.80 
Madarasi (314) Vitamin C P/S Shwachman-Kulzycki score +0.49 
Back (23) Vitamin C P/S 
Age 
FEV1 
-0.77 
+0.50 
Aris (15) Vitamin D P/S 
Serum intact parathyroid 
hormone 
Serum osteocalcin 
Urinary free deoxypyridinoline 
-NR 
+NR 
-NR 
Hahn (207) Vitamin D P/S 
Serum calcium 
Diaphyseal bone mass 
+0.54 
+0.42 
Aris (15) 1,25(OH)2D P/S 
Serum intact parathyroid 
hormone 
Serum osteocalcin 
Urinary free deoxypyridinoline 
-NR 
+NR 
-NR 
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Table 7.3. Continued.    
First author 
[reference] 
Biomarker Sample Clinical outcome r 
Back (23) Vitamin E P/S 
Age 
FEV1 
-0.47 
+0.46 
Lagrange-Puget 
(291) 
Vitamin E P/S FEV1 +NR 
Oudshoorn (387) Vitamin E P/S Coenzyme Q10 +0.40 
Wood (571) Vitamin E P/S 
Monocyte count 
Neutrophil count 
-0.341 
-0.341 
Trace elements     
AbdulWahab (1) Zinc P/S 
BMI 
FEV1 
FEV1/FVC 
FVC 
+NR 
+NR 
+NR 
+NR 
Jacob (244) Zinc P/S 
Age 
Retinol binding protein 
Vitamin A 
-0.63 
+0.64 
+0.51 
Mocchegiani (341) Zinc P/S 
Interleukin-2 
Weight/age (percentile) 
Weight/height deficits (%) 
+0.791 
+0.861 
+0.941 
Thiols    
Mangione (318) Glutathione Erythrocyte 
FEV1 
FVC 
-0.30 
+0.35 
Other antioxidants     
Lands (295) TEAC P/S 
BMI 
FEV1 
Uric acid 
Height 
Weight 
RV/TLC 
+0.472 
+0.432 
+0.492 
+0.392 
+0.502 
-0.422 
Lipid peroxidation     
Wood (571) 8-iso-PGF2α P/S 
P/S β-carotene 
P/S vitamin C 
P/S vitamin E 
Monocyte count 
Neutrophil count 
White cell count 
-0.421 
-0.431 
-0.371 
+0.371 
+0.311 
+0.311 
Lagrange-Puget 
(291) 
MDA P/S Age +NR 
Lagrange-Puget 
(291) 
TBARS P/S 
Age 
BMI 
+NR 
-NR 
1 Denotes that both case and control participants were included in the correlation analysis; 2 Denotes that 
both non-hospitalized and hospitalized participants were included in the correlation analysis. +, statistically 
significant positive correlation (p ≤ 0.05); -, denotes statistically significant negative correlation (p ≤ 0.05). 
P/S, plasma or serum samples. 
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7.5. Discussion 
This systematic review and meta-analysis is the first to investigate whether circulating 
biomarkers of antioxidant status and oxidative stress are abnormal in people with clinically-
stable CF versus non-CF controls. Forty-nine eligible studies were identified, including a 
total of 1,792 people with CF and 1,675 controls, in which 25 biomarkers were eligible for 
meta-analysis. Two principal findings were observed: (1) vitamins A and E, β-carotene, 
lutein and albumin were significantly lowered in the plasma or serum of people with 
clinically-stable CF versus non-CF control participants, and (2) protein carbonyls, total 8-
iso-PG2α and MDA were significantly higher in the plasma or serum of people with 
clinically-stable CF versus non-CF control participants. These data provide systematic 
evidence that oxidative stress may be implicated in the pathophysiology of CF even in those 
who are clinically-stable and free from a pulmonary exacerbation at the time of sampling. 
7.5.1. Thiols 
GSH is a tripeptide compound which plays a major role in regulating intracellular redox 
balances. In the present review, 4 eligible studies quantified GSH in the erythrocytes (38, 
318) and blood neutrophils (381, 517) of people with CF versus controls, however meta-
analyses were not possible due to appropriate data not being reported in 2 of these trials 
(38, 517). Notably, neither trial included in the present review reported significant 
differences in erythrocyte GSH in people with CF compared to controls (38, 318); however, 
a significant negative correlation between erythrocyte GSH and FEV1 was reported in adults 
with mild-to-very severe CF lung disease (318) (Table 7.3). Mangione et al. (318) speculated 
that these observations reflected the mobilisation of GSH into circulation to neutralize 
pulmonary ROS in advanced lung disease. Therefore, it could be suggested that elevated 
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erythrocyte GSH is a bookmark for historical incidences of oxidative damage in the CF lung 
(318). It is unknown whether other causes of oxidative stress in CF (e.g. CFRD) contribute 
to altered erythrocyte GSH concentrations. 
Functional CFTR is permeable to GSH, and defective or deficient CFTR may contribute to 
oxidative stress, due to insufficient concentrations of extracellular GSH (308). No studies 
were eligible for the present review that quantified plasma GSH, as GSH is rapidly oxidized 
in plasma to form glutathione disulphide (GSSG) (253). Two studies demonstrated that 
there were no differences between plasma protein thiol groups, which are rich in Cys, in 
people with CF compared to controls (327, 444). Conversely, plasma or serum albumin, a 
protein which constitutes the majority of the plasma protein thiol pool, was significantly 
lower in people with CF compared to controls (207, 244, 261, 300, 341, 487). Notably, 
serum albumin may also be affected in CF by various co-morbidities including liver disease 
(495) and malnutrition (485). Importantly, only 2 trials that studied circulating thiols 
reported the genotype of participants (38) and no trials reported results from a group with 
a single homozygous genotype. Previous reports from cell culture have shown that GSH 
efflux is lowered even in genotypes with residual CFTR function (classes IV-VI) (321); 
however, no studies to date have investigated whether higher concentrations of 
extracellular thiols contribute to the improved phenotype often observed in class IV-VI 
genotypes. It is, therefore, important for future studies to control for the genotype of 
participants and also investigate differences in thiol concentrations between subgroups 
classified by genotype. 
An important area for future research is to investigate the thiol:disulphide couples in the 
blood of individuals with clinically-stable CF. For instance, Roum et al. (435) demonstrated 
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that total plasma GSH was ~ 40% lower in people with CF versus healthy controls, however 
this study was excluded from the present review as it was unclear whether included cases 
were clinically-stable. In a later review, Ziady & Hansen (588) suggested that whilst the GSH 
Eh was not significantly different between people with CF and their healthy counterparts 
in the study by Roum et al. (435) (-139 mV vs. -138 mV, respectively), the lower 
concentration of GSH meant that an acute oxidative pertubation would affect GSH Eh to a 
greater degree in those with CF versus healthy controls (588). However, to fully understand 
the redox potential of thiols within plasma of people with CF, other thiol:dilsufide couples 
must be considered, including Cys (254) and thioredoxin (87). No studies to date have 
investigated the Cys:Cystine (Cyss) in people with CF. Importantly, whilst extracellular Cys 
pools are a key regulator of GSH synthesis, GSH:GSSG and Cys:cystine may have 
independent functions. For instance, a lowered Cys:Cyss ratio causes mitochondria-derived 
ROS generation, which subsequently activates the key antioxidant transcriptional factor, 
Nrf2 (239). Interestingly, pharmacological inhibition of CFTR in cellular models causes 
lowered expression of Nrf2 in the lung epithelium (86); therefore, thiol perturbations could 
contribute to the accumulation of cytotoxic ROS in CF. 
7.5.2. Micronutrients 
Important sources of exogenous antioxidants are the consumption of water- and fat-
soluble vitamins. In terms of water-soluble micronutrients, vitamin C content was not 
significantly different between people with CF and controls; however, this was only 
addressed by 2 trials of moderate-to-high quality (314, 571). Importantly, Madarasi et al. 
(314) reported significantly elevated vitamin C in children with CF compared to age-
matched healthy controls; however, participants enrolled on this study were administered 
100-200 mg/d of ascorbic acid. Conversely, Wood et al. (571) reported significantly lowered 
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concentrations of vitamin C in adolescents with CF who refrained from multivitamin 
supplementation for 4 weeks prior to sampling versus age- and sex-matched healthy 
controls. Fat-soluble micronutrients, vitamin A (7, 235, 244, 291, 314, 380, 533, 571, 575), 
β-carotene (207, 235, 291, 569), lutein (291, 459) and vitamin E (7, 136, 235, 291, 314, 387, 
533, 569, 571, 575) were significantly lowered in the plasma or serum of people with CF 
versus controls, whilst 25(OH)D (7, 15, 95, 207, 300, 380, 437, 487, 575), 1,25(OH)2D (15, 
425, 437, 487) and vitamin E:cholesterol (327, 381) were not significantly different. 
Importantly, there was a considerable degree of heterogeneity in the analysis of both 
water- and fat-soluble micronutrients, likely caused by differences in the studied 
population (i.e. age, sex and genotype), differences in measurement units and 
supplementation protocols (in addition to adherence variability (479)).  
Interestingly, Wood et al. (571) found significant negative correlations between lipid 
peroxidation biomarkers and vitamins C, E, and β-carotene (Table 7.3). It was speculated 
that the intensified inflammatory-induced free radical production may result in a depletion 
of antioxidant defences in non-supplemented CF participants (571). Furthermore, vitamins 
C and E were positively correlated with prognostically relevant clinical outcomes, such as 
FEV1 and the Shwachman-Kulzycki score (Table 7.3). Multivitamin supplementation is a 
logical strategy to increase antioxidant pools in the blood of people with CF and is 
recommended by The European Society for Clinical Nutrition and Metabolism (527). 
However, increasing the concentrations of antioxidant vitamins is challenging in this 
population due to suboptimal dosing, poor adherence to treatment or nutrient 
malabsorption (479). The high treatment burden of CF, and the subsequent poor 
adherence to oral supplements, is a considerable challenge when developing interventions 
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to mitigate oxidative stress, which is evidenced by the conflicting evidence regarding 
micronutrient supplementation for the management of CF lung disease (92).  
 
Figure 7.2. Forest plot demonstrating the differences in fat-soluble vitamin concentrations in clinically-stable 
people with CF versus non-CF controls. N.B. ‘vitamin A’ is inclusive of ‘retinol’, ‘25(OH)D’ is inclusive of 
‘vitamin D’ and ‘vitamin E’ is inclusive of ‘tocopherol’ and ‘α-tocopherol’. N.B. a negative SMD represents a 
lower vitamin concentration in CF versus controls, whereas a positive SMD represents a higher vitamin 
concentration in CF versus controls.   
In addition to water- and fat-soluble vitamins, various trace elements in blood have direct 
antioxidant abilities as well as mediating the activity of oxidoreductases. Only 8 included 
studies investigated trace element levels in the blood of people with clinically-stable CF. 
The concentrations of plasma or serum copper (395, 571, 575) and zinc (1, 244, 341, 380, 
571, 575) were not different between people with CF and controls. Furthermore, whilst it 
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was not possible to conduct meta-analysis on selenium, neither of the included trials 
reported a significant difference between the CF and control groups (245, 571). Two trials 
reported correlations between zinc and clinically relevant outcomes, including positive 
relationships with lung function, nutritional status and IL-2 (Table 7.3) (1, 341). These data 
suggest that suboptimal zinc content may be observed in those with more severe lung 
disease and/or malnutrition. However, whether this contributes to cases of oxidative stress 
is currently unknown and warrants further investigation.  
7.5.3. Oxidoreductases 
In addition to thiol groups and the exogenous micronutrients, blood also contains 
antioxidant defence enzymes that have direct antioxidant effects as well as catalysing 
reactions which maintain thiol:disulfide ratios, which limits the development of oxidative 
stress (209). The most studied of these enzymes, SOD, was investigated in 5 trials included 
in the present systematic review (39, 136, 314, 444, 571). However, meta-analysis 
demonstrated that there were no significant differences in erythrocyte SOD activity 
between those with CF and controls (39, 136, 314, 444, 571). Notably, there was a large 
variability in the results of the included trials, with 2 demonstrating lowered (39, 315), 2 
indifferent (444, 571) and 1 elevated (136) erythrocyte SOD activity in the CF group versus 
controls. Whilst the cause for such variable results is unknown, the only trial showing 
elevated erythrocyte SOD activity in CF did not use a methodology that expressed data 
relative to haemoglobin or red blood cell count (361). While it was not possible to quantify 
iron deficiencies in the present review, iron deficiency is reported in 64% of clinically-stable 
adults with CF (183) and iron supplementation is recommended in those with persistent 
inflammation (527). Therefore, it is possible that the inconsistent result of elevated 
erythrocyte SOD activity in people with CF is due to haemoglobin abnormalities and/or iron 
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supplementation (data regarding nutritional intake/supplementation was not reported) 
(136). It is important to note, however, that no correlations were observed between 
erythrocyte SOD activity and a biomarker of lipid peroxidation in children with CF (315). 
Therefore, given these results, it remains unclear whether circulatory SOD activity has a 
role in the pathophysiology of CF. 
Other oxidoreductases included in the present review’s meta-analyses were erythrocyte 
CAT activity and plasma/serum ceruloplasmin content. Notably, there were no differences 
in erythrocyte CAT activity (314, 444) or plasma/serum ceruloplasmin content (39, 395) in 
people with clinically-stable CF compared to controls. However, both of these biomarkers 
were studied by only 2 trials that were of moderate-to-high quality, but contained modest 
sample sizes. Furthermore, trials have documented normal plasma and whole blood GPx 
activity (315, 380, 381), lowered plasma diamine oxidase activity (39), elevated serum αGST 
content (478), elevated serum αGST subunit 1 content (238), elevated erythrocyte GR 
activity (136), and normal serum GGT content (261). However, these biomarkers were not 
the subject of meta-analysis either due to being studied by only a single trial or by two or 
more trials from the same laboratory. Further research is required to understand whether, 
or not, circulating oxidoreductases are suitable therapeutic targets.  
7.5.4. Lipid peroxidation 
A vulnerability to lipid peroxidation has been associated with reduced longevity of life in 
non-CF populations (413). Despite the suggested clinical importance of lipid peroxidation 
in the pathophysiology of various chronic diseases, the poor specificity of biomarkers is 
often described as a limiting factor in the study of oxidative stress (337). However, the 
Redox abnormalities in clinically-stable cystic fibrosis 
Page 210 of 300 
 
emergence of 8-iso-PGF2α, a lipid peroxidation product of arachidonic acid, as a biomarker 
of oxidative stress has vastly improved the progression of the field (338). 
Despite a wealth of research investigating 8-iso-PGF2α levels in human disease (537), the 
present review revealed only 2 independent studies eligible for meta-analysis (97, 380), 
both of which were of high quality (Table 7.2). Whilst total 8-iso-PGF2α was significantly 
increased in people with CF versus controls (Figure 7.3), neither study reported 
concentrations of free 8-iso-PGF2α, which would allow the conclusion of increased lipid 
peroxidation as opposed to the simultaneous activity of the inflammatory-induced 
prostaglandin-endoperoxide synthases (536). This is important, as a recent meta-analysis 
summarizing the levels of total and free 8-iso-PGF2α in human disease demonstrated a 
greater response of free 8-iso-PGF2α in CF (including those who are classified as unstable) 
versus controls, suggesting that the increased concentrations of 8-iso-PGF2α may be a result 
of non-specific production (537). 
The most studied biomarker of lipid peroxidation in CF was MDA in plasma or serum, which 
was the topic of 8 trials eligible for meta-analysis (12, 136, 291, 314, 327, 380, 445, 569). 
Meta-analysis observed significantly elevated concentrations of MDA in the plasma or 
serum of people with CF versus controls, albeit with a large degree of heterogeneity (Figure 
7.3). Notably, 5/8 of the trials measured MDA using thiobarbituric acid based assays (136, 
315, 380, 445, 569); however, the use of these assays in complex biological samples is 
cautioned against as many compounds within blood react with thiobarbituric acid to 
produce coloured adducts that could be mistaken for elevated lipid peroxidation (169). In 
contrast, the present review demonstrated that concentrations of lipid hydroperoxides in 
the plasma or serum of people with CF versus controls were not different; however, meta-
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analysis was only conducted on 2 trials and a large degree of heterogeneity limited the 
results (Figure 7.3). 
 
Figure 7.3. Forest plot demonstrating the differences in biomarkers of oxidative damage in clinically-stable 
people with CF versus non-CF controls. N.B. a negative SMD represents a lower vitamin concentration in CF 
versus controls, whereas a positive SMD represents a higher vitamin concentration in CF versus controls.   
Interestingly, lipid peroxidation biomarkers were positively correlated to blood monocyte, 
neutrophil and white cell counts (Table 7.3). These correlations suggest that elevated total 
8-iso-PGF2α is associated with exacerbated immune stresses and inflammation that 
characterises CF-lung disease. Indeed, chronic bacterial colonization of the CF airway leads 
to a dysregulated cycle of inflammation and redox dysregulation (108), which subsequently 
leads to cases of oxidative stress (444). There was not sufficient data to conduct subgroup 
analysis of 8-iso-PGF2α content in participants with varying degrees of lung disease. 
However, it must be noted that there was no significant correlations between total 8-iso-
PGF2α and FEV1 in people with mild-to-moderate CF lung disease (97, 571). Importantly, 
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authors state that whilst spirometry assesses previous lung damage from infection, 
transient increases in 8-iso-PGF2α may reflect the current pathophysiological state of the 
lung (346). Therefore, future trials investigating longitudinal changes in blood 8-iso-PGF2α 
alongside spirometry may be of interest to determine whether this biomarker is a suitable 
target for redox-based therapeutics. 
Various non-pulmonary consequences of CF have also been suggested to contribute to lipid 
peroxidation, such as CF-related dysglycaemia (374). Specifically, exocrine pancreatic 
insufficiency and variable insulin resistance lead to the development of CFRD in ~35% of 
adults with CF (173), which is associated with greater declines in lung function (298), 
nutritional status (280), exercise capacity (Chapter 4) and prognosis (349). It was not 
possible to conduct sub-group analysis on lipid peroxidation biomarkers in people along 
the dysglycaemic spectrum of CF, and no correlations between lipid peroxidation and 
glycaemic control were reported by included studies. No studies to date have investigated 
the content of 8-iso-PGF2α in CFRD. Instead, Ntimbane et al. (374) described significantly 
increased concentrations (+109%) of 4-hydroxynonenal-protein adducts in people with 
CFRD vs. their CF-counterparts with normal glucose tolerance. Oxidative stress, in vitro, is 
also implicated in pancreatic β-cell dysregulation, and thus, reduced insulin secretion (375). 
Therefore, whilst defective CFTR contributes to oxidative stress in CF, it is likely that the 
dysregulation of various inflammatory-redox cycles also exacerbates cellular damage and 
contributes to a worsened phenotype (e.g. the progression from impaired glucose 
tolerance to CFRD) (375). 
Whilst the present meta-analysis does provide preliminary evidence that lipid peroxidation 
is elevated in the blood of clinically-stable people with CF, further high-quality research is 
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required to improve the clarity of our understanding. Prospective observational trials 
should quantify free and total 8-iso-PGF2α in CF versus healthy control participants. Such 
data would further the rationale to investigate redox-based therapeutics in CF. In other 
chronic health conditions, non-pharmaceutical interventions to inhibit lipid peroxidation 
include dietary and lifestyle modifications (e.g. physical activity promotion), and 
supplementation of various extracts, oils and juices (e.g. green tea extract); however, such 
strategies are yet to be investigated in people with CF (538). 
7.5.5. Protein carbonylation 
Oxidative damage of proteins has been linked with the pathophysiology of many diseases 
and is most commonly quantified by the determination of protein carbonyls (209). A 
number of radical species, including H2O2 and peroxynitrous acid, readily oxidize amino acid 
residues to form carbonyl groups. The present review observed significantly elevated 
concentrations of protein carbonyls in the plasma or serum of people with CF versus 
controls (Figure 7.3). However, included studies did not report correlation coefficients 
between protein carbonyls and clinically relevant outcomes. In other chronic health 
conditions, oxidative damage to proteins is a significant contributor to skeletal muscle 
dysfunction (32), with reports showing elevated concentrations of protein carbonylation 
and nitration in the blood and skeletal muscle of people with COPD (431). Such associations 
could have implications in the skeletal muscle dysfunction which characterise CF (203). 
It has been suggested that peripheral skeletal muscle dysfunction in CF may be a 
consequence of reduced skeletal muscle mass due to nutrient malabsorption, physical 
inactivity and inflammation, but also a defect in skeletal muscle oxidative metabolism (237, 
429). More recently, redox disturbances have been suggested to contribute to exercise 
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intolerance in CF (524). Tucker et al. (524) used electron paramagnetic resonance 
spectroscopy to determine alkoxyl radical formation during a single bout of submaximal 
cycling in adolescents with CF (FEV1 93 ± 16% predicted) versus age- and sex-matched 
healthy controls. It was discovered that whilst circulating protein carbonyls and total 8-iso-
PGF2α were not significantly different at baseline or during exercise (notably, in a small 
sample of adolescents with only mild CF lung disease), there was a significant increase in 
alkoxyl radical production during exercise in the CF group only (524). However, the sources 
for an exacerbated production of ROS during exercise in people with CF are unknown. 
Defective CFTR has been associated with mitochondrial defects (535), whereby several 
studies have reported a reduced activity of the mitochondrial complex I in CF cells (471, 
472, 534), potentially due to mitochondrial GSH depletion (265), and complex V in CF mice 
(P.Phe508del) (292). However, a marker of mitochondrial oxidative stress, aconitase, was 
not different in skeletal muscle subsarcolemmal or interfibrillar mitochondria between CF 
and control mice (292). Other key non-mitochondrial sources of ROS that could contribute 
to the oxidative modification of protein during exercise are NADPH oxidase, xanthine 
oxidase and phospholipase A2 (412). However, these enzyme complexes are yet to be 
studied in models of CF skeletal muscle. It is, therefore, not clear whether redox imbalances 
are a suitable therapeutic target to improve mitochondrial function and/or skeletal muscle 
oxidative capacity in CF. This represents an important avenue for future research. 
Whilst the present meta-analysis does provide preliminary evidence that protein 
carbonylation is elevated in the blood of clinically-stable people with CF, further research 
is required to improve the clarity of our understanding. Prospective observational trials 
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should identify relationships between protein carbonylation biomarkers and clinically 
relevant outcomes. 
7.5.6. Limitations 
The present systematic review and meta-analysis had several inherent limitations. At 
present, there are significant gaps in the literature investigating whether age, sex and 
genotype affect redox biomarkers. From the correlations reported by the studies included 
in this review, it appears that antioxidants have a negative, but oxidative stress biomarkers 
have a positive relationship with age. However, longitudinal studies are required to confirm 
these associations. A limiting factor of the present review was a high degree of 
heterogeneity in the majority of biomarkers, which might be explained by only 10/49 
studies having matched cases and controls by age and one other factor (Table 7.2). We, 
therefore, recommend that future trials must match controls and cases by at least age and, 
preferably, sex. Other sources of heterogeneity include variations in the methodology of 
the assays and units of measure. 
Another important limitation is the age of some of the included studies. Due to advances 
in medicine, the survival age of people with CF has substantially increased since the oldest 
included study in 1977. Furthermore, ground breaking treatments, such as CFTR 
modulators that alter the negative consequences of CFTR mutations at a molecular level, 
are becoming mainstream treatment options. It is unknown whether the redox imbalances 
observed in the present review would persist following CFTR modulator treatment, and this 
is also an important area for future research. 
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7.5.7. Future research directions 
The present review focussed upon antioxidant and oxidative stress biomarkers that were 
sampled whilst the cases with CF had clinically-stable lung disease (i.e. not hospitalised). In 
addition to increased lung infection and inflammation (583), CF-related pulmonary 
exacerbations are also associated with the development of acute dysglycaemia even in 
cases with normal glucose tolerance (364), increased muscle weakness and weight loss in 
bedbound patients (72, 359), and hypovitaminosis of antioxidant micronutrients (326)  - all 
of which may increase biomarkers of oxidative damage (209). Furthermore, whilst the 
treatment of pulmonary exacerbations may lead to increased antioxidant vitamin content 
of the blood plasma (423), evidence of elevated lipid peroxidation and protein 
carbonylation persist despite significant improvements in lung function (423, 572). 
Therefore, it would be of interest for future trials to investigate whether such redox 
imbalances following the treatment of acute pulmonary exacerbations are associated with 
clinically relevant outcomes, such as time until the next hospitalization.  
Various biomarkers which are important to understand oxidative stress in vivo have not yet 
been studied on a case-control basis in the blood of people with clinically-stable CF. DNA 
oxidation can be quantified by circulating 8-OHdG. Systematic evidence suggests blood 8-
OHdG is elevated in cardiovascular disease (126). Furthermore, elevated blood 8-OHdG is 
associated with poorer prognosis in people with metabolic (448), cardiovascular (503, 574) 
and neurodegenerative (187) diseases. Elevated urinary 8-OHdG has been documented in 
adolescents with mild to severe CF lung disease versus age-matched controls (66). 
Additionally, urinary 8-OHdG was positively associated with plasma α-tocopherol, but a 
significant correlation was not observed with FEV1 (66). However, various co-morbidities of 
CF, such as renal disease, are becoming increasingly common (360). These co-morbidities 
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may cause local inflammation that could reduce the ability of urinary samples to provide 
systemic indices of oxidative stress. Therefore, it would be useful to confirm these findings 
in blood samples. 
Another increasingly recognised co-morbidity of CF is micro- (430) and macrovascular (411) 
endothelial dysfunction (121), which may be accentuated by the development of 
dysglycaemia (541). Cell culture studies have demonstrated that CFTR is expressed in 
endothelial cells from the human pulmonary artery (408, 518), lung microvasculature (519) 
and umbilical vein (519), which normally limits, but in CF may exacerbate, the production 
of pro-inflammatory and pro-oxidant pathways (121). Previous research has demonstrated 
that acute treatment of CF participants with antioxidants (1,000 mg vitamin C, 600 IU 
vitamin E, and 600 mg α-lipoic acid) (525) or BH4 (20 mg/kg) (248) improved endothelial 
function measured by FMD. These data implicate both oxidative stress and a reduced 
bioavailability of the potent vasodilator, NO, in CF-related endothelial dysfunction. 
Notably, in circumstances of oxidative stress, O₂̇‾readily oxidises NO to form ONOO–. 
Therefore, it would be useful for future studies to quantify levels of nitrotyrosine (a 
biomarker of nitrosative stress by RNS, including ONOO-) in the blood of clinically-stable 
people with CF versus controls. Notably, previous trials have reported elevated 
concentrations of nitrotyrosine in the exhaled breath condensate (26) and sputum (54) of 
people with CF. 
7.6. Conclusion 
This review is the first to systematically demonstrate that some, but not all, circulating 
biomarkers of antioxidant capacity are lowered and oxidative stress are increased in people 
with clinically-stable CF compared to controls. Further research is required to understand 
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the consequences of oxidative stress upon the pathophysiology of CF-related disorders, 
such as lung disease, diabetes mellitus and skeletal muscle abnormalities. 
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Chapter 8 
 
General Discussion 
8.1. Summary of the Key Findings 
The primary hypothesis of this thesis was that dysglycaemia impairs aerobic exercise 
function and this may be associated with the microvascular endothelial perturbation and 
oxidative stress that are often observed in people with CF. Specifically, the key findings 
from the data presented within this thesis are: 
Chapter 3: CPET with Smax was safe and feasible in children, adolescents and adults 
with mild to severe CF lung disease, and a valid measurement of V̇O2max was 
achieved by 85.7% of paediatric and 96.4% of adult CPET; 
Chapter 4: CFRD and IGT resulted in a significantly lower V̇O2max compared to age- 
and sex-matched controls with CF and NGT, due to a greater severity of lung disease 
in adults with CFRD and IGT. However, evidence of V̇/Q̇-mismatches were observed 
in all groups with CF and exacerbated by CFRD, independent of lung function; 
Chapter 5: CFTR is expressed and constitutively active in HLMVEC, where it acts as 
a promoter of Nrf2 signalling, thereby downregulating endothelial oxidative stress 
(H2O2 generation) and inflammation (IL-8 expression); 
Chapter 6: Endothelial CFTR promoted actin cytoskeleton localisation at the cortical 
rim and morphological alignment in response to 24 h and 48 h of shear stress, 
independent of the NO or ET-1 pathways;  
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Chapter 7: Various circulating biomarkers of antioxidant status were lower and 
those of oxidative stress were higher in people with clinically-stable CF versus non-
CF controls, and several biomarkers were associated with clinically relevant 
outcomes. 
Data presented within the experimental chapters of this thesis have made important 
contributions to the literature, by improving the understanding of the implications of 
dysglycaemia upon aerobic exercise dysfunction in people with CF. Additionally, this 
research presents novel mechanisms of microvascular endothelial perturbation that may 
mediate such implications. The present chapter summarises the primary findings of each 
experimental chapter and highlights their significance to the field in the context of the 
previously existing evidence base. 
8.1.1. %̇O2max was safely achieved during CPET with Smax in people with mild to severe CF 
lung disease  
CPET is now recommended as an annual clinical assessment by both the ECFS and ERS (217, 
389, 419). This is primarily because people with CF who have a higher V̇O2peak are likely to 
have a better quality of life (221) and at a lower risk of being hospitalised due to a 
respiratory exacerbation (397). Furthermore, various ‘maximal’ parameters from CPET hold 
prognostic value, including V̇O2peak, Wpeak, V̇E/V̇O2peak, V̇E/V̇CO2peak and V̇E/MVV (220, 371, 
402). However, in the absence of a V̇O2 plateau, secondary verification criteria must be 
achieved in order to confirm a maximal effort has been provided by the participant (217). 
Such criteria, however, are too liberal and result in submaximal tests being classified as 
maximal in children and adolescents with mild to moderate CF lung disease when 
compared to the utility of Smax (453, 564). Whilst Smax is a useful tool to verify that a maximal 
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effort has been provided by the participant (409), various concerns regarding the safety 
and feasibility of Smax in adults with more severe CF lung disease have been raised (218). 
This is the first study to demonstrate that CPET with Smax is feasible and safe in an adult CF 
outpatient CPET clinic. Out of the 45 children, adolescents and adults with CF who 
underwent CPET in the studied period, only 2 paediatric participants did not complete Smax 
due to parental time restrictions and the unwillingness of 1 adolescent to exercise further 
following their ramp incremental test. All adult participants who underwent CPET were 
willing and able to successfully complete Smax testing. This builds on previous pilot data, 
whereby our research group demonstrated that the majority of young people with CF (75%; 
n = 9/12) enjoyed CPET with Smax, and completing the test empowered 50% (n = 6/12) of 
them to seek advice regarding physical activity (263). From a safety perspective, there were 
no significant adverse events, however 9 (20.0%) adult participants did experience a ≥ 5% 
drop in SpO2 during combined ramp incremental and Smax CPET. The frequency of a drop in 
SpO2 of ≥ 5% during CPET with Smax was, however, no greater than CPET without Smax 
(22.7%) (441). Importantly, the present findings suggest that including Smax does not 
increase the risk of hypoxemia during CPET in people with CF, even those with more severe 
lung disease (FEV1: 29.9-102.3%). Collectively, this data suggests that CPET with Smax is safe 
and feasible for people with mild to severe CF lung disease. 
The primary criterion to confirm V̇O2max was considered to be a plateau in V̇O2 despite an 
increasing work-rate (511). However, a V̇O2 plateau is uncommon (434), especially in 
paediatric and clinical populations (453). Our paediatric CF group experienced a V̇O2 
plateau frequency of only 23.5%, which is in keeping with previous literature that have 
reported frequencies of 7.1% (453) and 31.3% (564). This study was the first to report the 
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V̇O2 plateau frequency of adults with CF and more severe lung disease (10.7%), which was 
considerably lower than that observed in the paediatric group. Furthermore, whilst V̇O2max 
was only reported in 15.6% of participants the utility of secondary criteria observed that all 
45 (100.0%) of CPET were maximal, which suggests a valid measure of V̇O2peak was achieved 
in all of the included participants. This research demonstrated that these criteria have a 
mean bias of up to -0.20 Lmin-1 (95% CI: -0.25-0.70 Lmin-1), compared to the groups’ 
highest V̇O2 achieved during either the ramp incremental or Smax tests (i.e. V̇O2max). These 
findings also demonstrate that Smax identified 21.4% of both paediatric and adult ‘maximal’ 
ramp incremental exercise tests as submaximal, which supports previous evidence in 
children and adolescents with mild to moderate CF from the UK and The Netherlands (16.6-
28.4%) (453, 564). 
These findings have important clinical implications for the interpretation of CPET when 
secondary verification criteria are utilised instead of Smax. Firstly, if CPET is used to assess 
the individual’s functional capacity during their annual review, a falsely low V̇O2peak could 
demotivate the individual when undertaking exercise training and also suggest a false 
deterioration in health during the previous year. For instance, this research observed a case 
whereby an increase in V̇O2peak (+ 24.4%) with Smax was reported in a female (26.1 y; 1.57 
m; 48.2 kg; FEV1 80.7% predicted), despite her ramp incremental test being deemed 
maximal based upon achieving a RER of 1.10 and a RPE of 19 at exhaustion. Such a falsely 
low score would mean her prognostic stratification is incorrect (402). In light of this, data 
from Chapter 3 have recently been recognised in the ERS statement regarding 
standardising CPET in respiratory clinics (419). Given that CPET with Smax produced a safe, 
feasible and valid measure of V̇O2max in people with mild to severe CF lung disease, it was 
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possible to utilise this protocol to investigate the implications of various non-pulmonary CF 
co-morbidities upon aerobic exercise and ventilatory function.  
8.1.2. Dysglycaemia caused aerobic exercise and ventilatory dysfunction in adults with 
mild to severe CF lung disease  
Data presented within Chapter 4 utilised this CPET with Smax protocol to determine how the 
presence of CF-related dysglycaemia affected parameters of aerobic exercise and 
ventilatory function. CFRD is the most common non-respiratory consequence of CF 
affecting 30.5% of adults with CF in the UK (530) and is associated with a greater decline in 
lung function (298), worsened nutritional status (280) and poorer prognosis (349). Children 
and adolescents with CFRD have a reduced V̇O2peak (172) and Wpeak (256) compared to those 
with CF and NGT or IGT, whereas adults with CF plus IGT have significantly greater 
reductions in SpO2 during exercise compared to their NGT counterparts (590). However, 
prior to this study it was unknown whether the development of CF-related dysglycaemia 
worsened aerobic exercise and ventilatory function during CPET.  
The results of the experiments described in Chapter 4 demonstrated that V̇O2max (as a 
percent predicted) was reduced in people with CFRD and IGT compared to their age- and 
sex-matched counterparts with CF and NGT. However, no statistical significance remained 
once parameters of lung function (FEV1 and FVC) were included as covariates, suggesting 
that advanced lung disease in the CFRD and IGT groups modulated exercise capacity. 
Previous research has also demonstrated a significant difference in V̇O2peak between 
paediatric participants with CFRD and NGT, despite no significant difference in FEV1 
amongst their paediatric NGT, IGT and CFRD groups (172). Therefore, it is possible that 
subclinical consequences of CF-related dysglycaemia may mediate reductions in exercise 
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capacity seen in paediatric groups, whereas significantly advanced lung disease in adults 
with CFRD and IGT becomes the principle cause of exercise intolerance during adulthood. 
This notion is substantiated by the observation that insulin and glucose values during OGTT 
predictors of V̇O2peak in paediatric patients with CF, even after accounting for the covariance 
of age and FEV1 (172). However, parameters of glycaemic control were not significant 
predictors of V̇O2max in adults with CF. Notably, the regression model in Chapter 4 was 
limited by the inclusion of 9 covariates; therefore, future analyses should utilise a theory-
driven model of 4-5 covariates for a similar sample size of 46. 
Previous research has demonstrated that changes in parameters of ventilatory limitation 
and efficiency occur prior to changes in FEV1 and V̇O2peak in people with CF (526). Therefore, 
it may be plausible to observe changes in V̇E/MVV, V̇E/V̇O2peak, V̇E/V̇CO2peak, or ∆V̇E/∆V̇CO2 
in the absence of a reduced V̇O2max. Despite no significant differences in ∆SpO2 being 
observed amongst the adult NGT, IGT and CFRD groups following CPET, there was a 
significantly greater frequency of ventilatory limitation (i.e. V̇E/MVV ≥ 85%) in participants 
with CFRD (84% were ventilatory limited) versus their age- and sex-matched counterparts 
with CF and NGT (37% were ventilatory limited). After FEV1 and FVC were included as 
covariates, there were no significant differences amongst groups in terms of V̇E/MVV, 
V̇E/V̇O2peak or V̇E/V̇CO2peak – despite the mean values for these outcomes being comparable 
to the clusters at greatest risk of mortality (220). If a healthy control group had been 
included in this study, it is likely that aerobic exercise and ventilatory dysfunction may have 
been present in adults with CF; but, not significantly different amongst groups with NGT, 
IGT or CFRD once FEV1 and FVC were included as covariates. 
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An important finding, was that a medium effect size (n2 = 0.11) suggested that ∆V̇E/∆V̇CO2 
may be elevated in those with CF-related dysglycaemia compared to their age- and sex-
matched controls with CF and NGT, even after accounting for the influence of FEV1 and 
FVC. A ∆V̇E/∆V̇CO2 that is ≥ 34 is indicative of a V̇/Q̇-mismatch (499). According to this non-
invasive measure, 32% of adults with mild to severe CF lung disease experienced a V̇/Q̇-
mismatch during submaximal exercise. The genesis of such mismatching in CF is possibly 
due to a greater VD/VT and, to a lesser extent, a reduced PaCO2 set-point (127). However, 
vasoconstriction of the lung microvasculature may also be a contributing factor (400). 
Indeed, CFTR is expressed in HLMVEC (519) and pharmacological CFTR inhibition is 
suggested to exacerbate inflammation (518), oxidative stress (159), ET-1 mediated 
vasoconstriction (223), and reduce the bioavailability of the vasodilator, NO (223, 518). 
However, the role of CFTR in regulating inflammation and oxidative stress in the 
microvascular endothelium was poorly understood prior to the collection of the data 
presented in Chapter 5. 
8.1.3. Endothelial CFTR activity appears to play a role in the regulation of inflammation, 
oxidative stress and cell signalling 
Given the above, data presented within Chapter 5 aimed to determine whether a loss of 
CFTR function in the lung microvascular endothelium could contribute to vascular 
dysfunction and exercise intolerance, via exacerbated inflammation, oxidative stress and 
cell signalling. Notably, epithelial CFTR activity was previously shown to regulate 
inflammation and oxidative stress through increasing Nrf2 expression (86) and, suppressing 
NF-κB and EGFR tyrosine kinase activity (322, 396). Therefore, a loss of epithelial CFTR leads 
to a sterile increase in IL-8 (396) and VEGF (322) release, in addition to reduced GSH that is 
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associated with oxidative stress (116). However, signalling pathways within epithelial and 
endothelial cells may differ, and it is important to characterise the inflammatory and redox 
signalling pathways associated with a loss of endothelial CFTR. 
The data presented in Chapter 5 demonstrated that CFTR is expressed, albeit at lower levels 
than previously reported (519), and is also constitutively active in HLMVEC. Indeed, 
depolarisation of HLMVEC, 16HBE and HEK293 was achieved through increased cAMP 
synthesis (treatment with Fk) and PDE inhibition (treatment with IBMX); whilst co-
treatment with the CFTR inhibitor, GlyH-101, prevented the subsequent depolarisation in 
HLMVEC and 16HBE, but not HEK293 cells as these cells do not express CFTR. Furthermore, 
GlyH-101 caused hyperpolarisation of inactivated HLMVEC and 16HBE (0.1% DMSO), which 
suggests that CFTR is constitutively active in the human lung microvascular endothelium 
and may play an important role in trafficking anions, ATP and antioxidants (308, 309, 476). 
HLMVEC treated with GlyH-101 resulted in a significantly greater production of ROS than 
HLMVEC treated with a positive control, TNF-α. Sources of ROS in the endothelium 
following CFTR inhibition are unknown, but ROS derived from the mitochondria and NOX 
are unlikely candidates given that MitoQ (a mitochondrial targeted antioxidant) and DPI (a 
NOX targeted antioxidant) failed to suppress the ROS and H2O2 generation associated with 
HLMVEC CFTR inhibition, respectively. Conversely, the co-treatment of cells with NAC, a 
pre-cursor in the synthesis of intracellular GSH, significantly reduced ROS formation in 
HLMVEC exposed to GlyH-101 for 30 mins. Previous research has noted suppression of 
intracellular GSH in epithelial cells following CFTR inhibition (CFTRinh-172) (116); therefore, 
it may be plausible that increased ROS generation in HLMVEC exposed to GlyH-101 is a 
result of depleted intracellular GSH. Notably, if the observed elevation of ∆V̇E/∆V̇CO2 in CF 
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is partially a result of endothelial dysfunction, then antioxidant therapy may improve 
ventilatory efficiency in vivo. 
Reduced intracellular GSH in response to CFTR inhibition could be a direct result of losing 
CFTR trafficking of GSH (308); or conversely, studies from epithelial cells have 
demonstrated that functional CFTR has an important role in upregulating the antioxidant 
transcriptional factor, Nrf2 (86). The increased ROS generation by HLMVEC as a result of 
CFTR inhibition could contribute to the degradation of cytosolic Nrf2 released from Keap-1 
(562). In epithelial cells, inflammation and oxidative stress in response to a loss of CFTR is 
associated with the activation of various inflammatory pathways, including TNF-R adaptor 
molecule, TRADD and NF-κB (550). However, CFTR inhibition in HLMVEC did not result in 
NF-κB activation. Furthermore, whilst EGFR tyrosine kinase inhibitors (AG1478) limit the 
formation of VEGF in epithelial cells treated with CFTR inhibitors (322), both CFTR inhibition 
and AG1478 significantly increased VEGF expression in HLMVEC. Increased expression of 
VEGF in HLMVEC are likely to promote angiogenesis and increase vascular permeability, 
enhance inflammation and increase plasma exudation.  
The resultant inflammation (increased IL-8 expression) and oxidative stress (increased ROS 
generation) experienced by HLMVEC following CFTR inhibition are likely to activate various 
redox sensitive pathways. For instance, similarly to epithelial cells (86), CFTR inhibition in 
HLMVEC resulted in a significantly increased expression of the oxidoreductase, SOD2. 
Furthermore, various signalling pathways that regulate NO and ET-1 expression, and actin 
cytoskeleton re-formation in response to shear stress are sensitive to increased VEGF 
expression, inflammation and oxidative stress (89, 233). Therefore, CFTR inhibition of the 
lung microvasculature may result in increased vascular permeability and vasoconstriction 
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through exacerbated VEGF expression. There was a need for further research to investigate 
the role of CFTR in regulating various adaptations to shear stress, such as the actin 
cytoskeleton remodelling and changes to cellular morphology, which was the topic of 
investigation in Chapter 6. 
8.1.4. CFTR regulates the endothelial cytoskeleton and promotes alignment with flow in 
response to shear stress 
The actin cytoskeleton is the first responder to changes in shear stress and modulates the 
subsequent cellular alignment with flow (312, 384). Inflammation, as experienced during 
CFTR inhibition, causes the re-distribution of cortical F-actin to form ventral cytosolic stress 
fibres (549), which is associated with cellular junction retraction and increased barrier 
permeability (473). CFTR is anchored to cortical F-actin (84) and a functioning cytoskeleton 
regulates CFTR activity (74); whilst a loss of CFTR function was associated with reduced 
sphingosine-1-phosphate (55), which reduces endothelial barrier function through 
dismantling F-actin at the cortical rim (65). However, prior to this research it was not 
understood whether inhibition of CFTR activity induced disturbances of the actin 
cytoskeleton contributing to reductions in morphological alignment with flow in HLMVEC. 
Data reported in Chapter 6 were the first to demonstrate that CFTR inhibition in human 
endothelial cells exacerbates actin polymerisation, which was characterised by a lack of 
cortical rim F-actin and the formation of cytosolic stress fibres. Notably, previous research 
has demonstrated that the formation of actin stress fibres increases cellular stiffness and 
limits NO release (162). Whilst paracellular gaps were observed following CFTR inhibition 
in HLMVEC following shear stress, which is indicative of increased cellular stiffness and may 
contribute to increased endothelial permeability in vivo, no differences were observed in 
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cell supernatant [nitrite] or [ET-1], irrespective of static or orbital culture conditions. 
Together, these data suggest that NO producing and ET-1 supressing pathways are not 
regulated by CFTR in HLMVEC exposed to flow. However, given that antioxidant 
supplementation improves vascular function through increasing NO bioavailability in 
people with CF (525), the exacerbated oxidative stress observed as a consequence of CF 
lung infection (Chapter 7) may cause a reduced NO bioavailability in vivo. 
The data presented in Chapter 6 demonstrated that CFTR inhibition prevented cellular 
alignment following both 24 h and 48 h of shear stress, compared to both the vehicle 
control and TNF-α conditions. Furthermore, previous research has observed that CFTR 
inhibition in HUVEC caused cellular retraction and shrinkage, membrane bleb formation, 
and cellular vesicle release in response to low levels of shear stress (5 dynes/cm2) (518). 
These findings are particularly important, given that disturbed flow-induced changes to 
endothelial cell morphology is an in vitro (111) marker of endothelial dysfunction, which is 
also observed in vivo (134, 192). The mechanisms promoting actin polymerisation and 
preventing cellular alignment with flow following CFTR inhibition are presently unknown. 
Shear stress induced upregulation of VEGF promotes actin remodelling and cell elongation 
through Rho/ROCK-signalling (522). Given that CFTR inhibition significantly increased the 
expression of VEGF in HLMVEC cultured in static conditions (Chapter 5), factors 
downstream of VEGF may modulate the actin cytoskeleton and cellular alignment. 
Foxo1 is activated through VEGF-induced PI3K/Akt-signalling and is an important 
modulator of endothelial cell specification and actin remodelling (522). Preliminary reports 
have suggested that Foxo1 expression is reduced in CF epithelial cells, independent of 
PI3K/Akt expression (481). Furthermore, mTORC2 and Rictor downregulate cytosolic stress 
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fibre formation in circumstances of increased VEGF expression (156) (such as those 
observed in Chapter 5); whereas, CF epithelial cells have an increased expression of both 
mTOR and Rictor (424). Interestingly, both the upregulation of Rictor in HUVEC (576) and 
inhibition of CFTR in HLMVEC (Chapter 5) is associated with suppressed Nrf2 transcription 
and content. Oxidative stress may cause oxidative damage to cytoskeleton components 
and disturbed cytoskeleton signalling (90). However, the role of oxidative stress in the 
pathophysiology of CF is not fully understood and often thought of as a consequence of the 
lung infection and inflammation observed in people with CF (181). Therefore, there was a 
need to quantify whether systemic redox abnormalities were observed in people with CF, 
especially when lung disease was stable.  
8.1.5. Circulating antioxidants and biomarkers of oxidative stress were abnormal in 
people with clinically-stable CF 
A common pathophysiological pathway referred to in the present thesis is the development 
of oxidative stress in people with CF, due to: 1) malabsorption of fat-soluble micronutrients 
resulting in hypovitaminosis (479); 2) reduced CFTR GSH and SCN- trafficking (308, 309); a 
genetic predisposition limiting GSH synthesis (118, 321); and, 3) lung disease (291), 
inflammation (299), systemic hypoxaemia (531, 580) and dysglycaemia (374) causing an 
exacerbated production of ROS. CF-related redox imbalances have been documented since 
1967 (36) and have been the topic of several narrative reviews (181, 373, 588). Recent data 
has demonstrated that lipid peroxidation is higher in the blood of people with CF compared 
to other diseases, including lifestyle factors and environmental exposures which are 
conventionally characterised by oxidative stress, such as tobacco smoking and 
cardiovascular disease (537). However, only a single biomarker (8-iso-PGF2α) was the topic 
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of this meta-analysis and a range of biomarkers are required to adequately characterise 
redox disturbances in vivo (96). 
Prior to the collection of the data presented in Chapter 7, there was a lack of consensus 
regarding the existence of circulating oxidative stress when CF lung disease was clinically 
stable, and also debate regarding the most appropriate biomarkers to be used when 
studying CF-related redox abnormalities. In agreement with previous narrative reviews 
(181, 373, 588) and meta-analyses (537), it was discovered that protein carbonyls, total 8-
iso-PGF2α and MDA were significantly higher in the plasma or serum of people with 
clinically-stable CF versus non-CF controls. Biomarkers of lipid peroxidation were positively 
related to markers of inflammation and immune activation, suggesting that progressive 
lung disease contributed to redox disturbances even in people with clinically stable CF lung 
disease. However, no trials were available for inclusion in Chapter 7 that linked diabetes or 
vascular endothelial function to oxidative stress in CF. Additionally, vitamins A and E, β-
carotene, lutein and albumin were significantly lower in the plasma or serum of people 
with CF versus controls. Negative correlations between lipid peroxidation biomarkers and 
vitamins C, E, and β-carotene were observed (571). This data suggests that nutritional 
insufficiencies contribute to micronutrient malabsorption and a reduced antioxidant 
defence system in people with CF (571). Furthermore, intensified free radical production 
may also further deplete an already weakened antioxidant defence system in non-
supplemented CF participants (571). Importantly, this is the first systematic data to 
demonstrate that redox abnormalities are present in the blood of people with CF; a notion 
that has previously been debated (291, 327). A considerable strength of this study was that 
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it included data from 49 studies, including a total of 1,792 people with CF and 1,675 
controls. 
Despite the scale of the studied population in Chapter 7, various biomarkers of interest 
with regards to CF were not studied sufficiently to warrant inclusion in the meta-analysis. 
For instance, circulating GSH was only the topic of 4 investigations (38, 318, 381, 517) 
However, the mean ± SD were not available for 2 trials (38, 517) and, as such, GSH was not 
the topic of meta-analysis. A lack of evidence with respect to GSH is somewhat surprising, 
given that reduced GSH trafficking and synthesis may be a central factor contributing to 
oxidative stress in CF (118, 308, 321). Nonetheless, the data analysed in Chapter 7 provides 
good evidence that oxidative stress exists in CF and may contribute to a worsening 
phenotype. Furthermore, moderate evidence exists demonstrating that antioxidant 
therapy can improve lung disease in CF (92). Together, such systematic evidence provide 
an exciting rationale to further study redox disturbances in CF in the context of lung 
disease, dysglycaemia and microvascular endothelial dysfunction.  
8.2. Directions for Future Research 
The pathophysiology of CF is continually evolving due to the constantly increasing median 
survival age (530), with various non-pulmonary co-morbidities now modulating the quality 
and longevity of life of people with CF. Data from this thesis has provided an understanding 
of the implications of CF-related dysglycaemia, CFTR-mediated endothelial perturbation 
and systemic oxidative stress that are likely to be important outcomes to consider when 
studying therapeutic interventions, including the ground-breaking CFTR modulators.  
This thesis supports existing evidence (172, 256, 590) that  CF-related dysglycaemia is 
associated with a reduced exercise capacity, and previous research has demonstrated that 
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exercise training can improve glycaemic control in adults with CF (34). However, the 
relationship between habitual physical activity and free living glycaemic control has never 
been studied. This is an important avenue for future research for 2 primary reasons: 1) it is 
important to understand whether the abnormalities that we have observed in aerobic 
exercise and ventilatory function of people with CF-related dysglycaemia is an artefact of 
this population being more physically inactive; and, 2) physical activity interventions are a 
potential therapeutic strategy in groups with CF (101) and may be especially important to 
manage CF-related dysglycaemia given the poor adherence to insulin therapies (266, 350). 
The recommended mode to quantify habitual physical activity in CF is via accelerometry 
(57). Furthermore, the alignment of accelerometry data with CGM is becoming increasingly 
common in groups with non-CF related diabetes (328). In type II diabetes mellitus, 
accelerometer-derived sedentary time was negatively associated with time spent in 
euglycaemia (3.9–7.8 mmol·L-1), and breaks in sedentary time were positively associated 
with time spent in euglycaemia (388). The quantification of such associations in people with 
CF along the spectrum of dysglycaemia would be of utmost interest to the CF community, 
given that the prevention of CFRD is the 5th most important research priority (246) and 
physical activity promotion may be a realistic preventative strategy. 
This thesis has also developed a comprehensive foundation to study the effectiveness of 
therapeutic interventions, both in vivo and in vitro. For instance, despite exercise being a 
hallmark treatment for non-CF forms of diabetes mellitus (e.g. type II diabetes mellitus), 
only a single trial has reported the effectiveness of combined exercise training upon CF-
related dysglycaemia (34). Beaudoin et al. (34) demonstrated that combined aerobic and 
resistance training 3 days per week for 12 weeks significantly improved 2 h plasma 
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[glucose], potentially through insulin sensitisation, in adults with mild to moderate CF lung 
disease and CF-related dysglycaemia (i.e. IGT or CFRD). However, outcomes from OGTT 
may underestimate dysglycaemia in people with CF (132) and also lack sensitivity in 
predicting early dysglycaemia-induced lung damage (298). Given the outcomes reported in 
Chapter 4 are prognostically relevant in groups with CF (220) and influenced by 
dysglycaemia, it would be of interest for future exercise interventions to include aerobic 
exercise and ventilatory function as an outcome measure.  
Moderate evidence also exists demonstrating that antioxidant therapy improves FEV1 in 
people with CF (92); however, findings are inconsistent (91, 92) and, as such, antioxidant 
therapies are not often considered in the clinical management of CF (152). Future research 
investigating the effectiveness of antioxidant therapy in CF should consider including CPET 
alongside spirometry. CPET is becoming a more widely used clinical tool (217, 419), 
therefore further clinical trials should also use outcomes from CPET as an outcome. This 
would provide researchers and clinicians with a more sensitive array of outcome measures 
(V̇O2max, V̇E/MVV, V̇E/V̇O2peak, V̇E/V̇CO2peak, and ∆V̇E/∆V̇CO2) (526), compared to those that 
are traditionally reported (FEV1, FVC and BMI) (91, 92). Furthermore, the results presented 
in Chapter 7 demonstrated that some biomarkers of antioxidant status were lower, 
whereas various biomarkers of lipid peroxidation and protein carbonylation were elevated 
in clinically-stable CF. Circulating redox abnormalities were consistently associated with 
lower values for FEV1 and FVC. Therefore, future research should also consider using 
circulating biomarkers of antioxidant status on a case-control basis. This would allow 
researchers to quantify whether, or not, the antioxidant regimen has overcome the genetic 
predisposition to antioxidant deficiency due to reduced CFTR GSH and SCN- trafficking (308, 
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309), and a genetic predisposition to reduced GSH recycling (118, 321). This could be an 
important source of the variation in results observed in recent systematic reviews of 
antioxidant therapies (91, 92), as residual GSH conductance is observed in class IV-V CFTR 
mutations and may render this sub-population more appropriate for antioxidant 
interventions. 
In addition to antioxidant therapy targeting GSH, various pharmacological approaches that 
target Nrf2 may have therapeutic benefits in CF. In the epithelium, treatment with CDDO 
increased Nrf2 activity whilst reducing NF-κB in preclinical models of CF (368). In humans 
with CF, 5 d consumption of sulforaphane (100 g raw broccoli sprouts; a supplement to 
increase Nrf2 activity) was less convincing (ClinicalTrials.gov registration number: 
NCT01315665). However, this pilot study contained only 5 participants with CF. We 
demonstrated that Nrf2 expression was reduced in endothelial cells treated with GlyH-101. 
Therefore, interventions to increase Nrf2 expression may improve the efficacy of Nrf2 
activators in vivo. One such intervention, dimethyl fumarate (DMF), is already approved in 
the treatment of multiple sclerosis and psoriasis (211, 301, 353); therefore, repurposing 
DMF for the treatment of CF is plausible. DMF downregulates inflammation and oxidative 
stress through increasing Keap-1 and Nrf2 expression at the mRNA and protein level, whilst 
also increasing levels of the Nrf2 target genes, NQO1 and AKR1C1 (211). Furthermore, 
ground-breaking CFTR potentiators that restore p.Phe508del in epithelial cells also induced 
Nrf2 nuclear translocation, Nrf2-dependent luciferase activity, and transcriptional 
activation of target genes (49). Such CFTR potentiators (e.g. Elexacaftor-Tezacaftor-
Ivacaftor), are reported to result in a 10-14% greater increase in FEV1 (as a percent 
predicted) in patients with one or two p.Phe508del allelles than Tezacaftor and Ivacaftor 
General discussion 
Page 236 of 300 
 
alone (222, 335). However, no studies to date have investigated whether triple-therapy 
improves dysglycaemia, vascular endothelial function or functional outcomes, such as 
those from CPET. This remains an important area for future research. 
8.3. Conclusions 
This thesis presents a series of novel studies demonstrating the complex relationships 
between a loss of CFTR, dysglycaemia, vascular perturbation and altered exercise 
physiology in people with CF. It has presented the first data to demonstrate that CF-related 
dysglycaemia is associated with aerobic exercise and ventilatory dysfunction (Chapter 4), 
measured by a valid maximal CPET protocol (Chapter 3). In vitro experiments have further 
confirmed that the microvascular endothelium of the CF lung may contribute to the 
observed in vivo ventilatory dysfunction during CPET, through promoting a pro-
inflammatory and pro-oxidant environment within the endothelium that may lead to 
vasoconstriction and a reduced endothelial barrier integrity (Chapters 5 and 6). Lastly, this 
thesis has also demonstrated that antioxidant deficiency and oxidative stress is present 
even in people with clinically-stable CF lung disease (Chapter 7). Many of the associations 
observed in the present thesis are subclinical, yet may have significant prognostic 
implications independent of lung disease (220). Furthermore, due to a lack of efficacy for 
many anti-inflammatory and antioxidant interventions many of these consequences 
remain untreated (75, 92, 152) and, as such, this programme of research has identified 
potential viable targets for intervention in this patient group. 
This thesis is particularly timely, given that CFTR modulators are becoming available in the 
UK and elsewhere. Limited evidence exists demonstrating whether CFTR modulator 
therapy can improve dysglycaemia and exercise intolerance in CF. The present thesis 
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provides the foundations for further research to be conducted in this area by highlighting 
various CPET outcomes, cellular processes and biomarkers that have the potential to be 
prognostically-driven outcomes in such trials. Furthermore, the next decade of research is 
likely to be integral when considering the future outlook of people with CF, given that the 
initial insights into the longitudinal efficacy of CFTR modulator treatments will be 
published.  
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Cysteine Cys 
Cystine Cyss 
Cystic fibrosis CF 
Cystic fibrosis-related diabetes CFRD 
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Cystic fibrosis transmembrane conductance regulator CFTR 
Cytochrome P450 monooxygenase CYP450 
Deoxyribonucleic acid DNA 
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Human embryonic kidney cell line HEK293 
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Human epidermal growth factor hEGF 
Human fibroblast growth factor hFGF-B 
Human lung microvascular endothelial cells HLMVEC 
Human pulmonary artery endothelial cells HPAEC 
Human umbilical vein endothelial cells HUVEC 
Hydrogen peroxide H2O2 
Impaired glucose tolerance IGT 
Inducible nitric oxide synthase iNOS 
Insulin-like growth factor IGF 
Interleukin IL 
Interquartile range IQR 
Intravenous antiobiotics IVAB 
Kelch-like ECH associated protein Keap 
Krüppel-like factor 2 KLF2 
L-arginine L-arg 
Malondialdehyde  MDA  
Mammalian target of rapamycin mTOR 
Mammalian target of rapamycin-independent companion of complex 2 Rictor 
Maximal oxygen uptake V̇O2max 
Maximal voluntary ventilation MVV 
Medical subject headings MeSH 
Membrane spanning domain MSD 
Microsomal epoxide hydrolase 1 EPHX1 
Minimum essential medium eagle MEM 
Minute ventilation V̇E 
Mitogen-activated protein kinase MAPK 
Mitogen-activated protein kinase kinase 5 MKK5 
Molecular oxygen O2 
Muscle carbon dioxide consumption #̇CO2 
Muscle oxygen consumption #̇O2 
Myeloperoxidase  MPO  
Myocyte enhancer factor-2 MEF2 
N-acetylcysteine NAC 
Nicotinamide adenine dinucleotide phosphate NADPH 
Nicotinamide adenine dinucleotide phosphate oxidase NOX 
Nicotinamide adenine dinucleotide phosphate quinone NQO1 
Nitric oxide NO 
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Nitric oxide synthase NOS 
Normal glucose tolerance NGT 
Nuclear factor erythroid-derived-like 2 Nrf2 
Nuclear factor kappa-light-chain-enhancer of activated B cells NF-κB 
Nucleotide binding domain NBD 
Oral glucose tolerance testing OGTT 
Outwardly rectifying chloride channel ORCC 
Pancreatic insufficiency PI 
Partial eta squared n2 
Partial pressure of arterial carbon dioxide PaCO2 
Peak heart rate HRpeak 
Peak oxygen uptake V̇O2peak 
Peak work rate Wpeak 
Peroxynitrite ONOO– 
Phosphate-buffered saline PBS 
Phosphatidylinositol-3-kinase PI3K 
Phosphocreatine PCr 
Phospholipase C PLC 
Plasminogen activator inhibitor-1 PAI-1 
Platelet endothelial cell adhesion molecule 1 PECAM-1 
Post-reactive hypoglycaemia PRH 
Potassium K+ 
Prostacyclin PGI2 
Protease-activated receptor 3 PAR3 
Protein kinase C PKC 
Quantitative real-time polymerase chain reaction qRT-PCR 
RAC-α serine/threonine protein kinase Akt 
Ras-related C3 botulinum toxin substrate 1 Rac1 
Rating of perceived dyspnoea RPD 
Rating of perceived exhaustion RPE 
Reactive nitrogen species RNS 
Reactive oxygen species ROS 
Redox potential Eh 
Regulatory domain R domain 
Respiratory exchange ratio RER 
Ribonucleic acid RNA 
Rho-associated protein kinase ROCK 
Semaphorin-3F SEMA3F 
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Sequestosome 1 SQSTM1 
Silencing of CFTR siCFTR 
Sodium Na+ 
Standard deviation SD 
Standard error of the mean SEM 
Stress-activated protein kinase SAPK 
Stroke volume SV 
Superoxide dismutase SOD 
Superoxide radical O₂̇‾ 
Supramaximal verification Smax 
T-cell lymphoma invasion and metastasis-inducing protein 1 TIAM1 
Tetrahydrobiopterin BH4 
Tidal volume VT 
Tissue factor TF 
Tissue plasminogen activator t-PA 
Title and abstract Ti/ab 
Thiobarbituric acid reactive substances TBARS 
Thiocyanate SCN- 
Thioredoxin 1 TRX1 
Thrombomodulin TM 
Total antioxidant capacity TAC 
Transfer ribonucleic acid tRNA 
Trolox equivalent antioxidant capacity TEAC 
Tumour necrosis factor TNF 
Tumour necrosis factor receptor 1-associated death domain protein TRADD 
Vascular cell adhesion molecule 1 VCAM1 
Vascular endothelial cadherin VE-cadherin 
Vascular endothelial growth factor VEGF 
Vascular endothelial growth factor receptor 2 VEGFR2 
Ventilation/perfusion V̇/Q̇ 
Ventilatory dead space to tidal volume ration VD/VT 
Ventilatory drive ∆V̇E/∆V̇CO2 
Ventilatory equivalent of carbon dioxide V̇E/V̇CO2peak 
Ventilatory equivalent of oxygen V̇E/V̇O2peak 
Volume-regulated anion channel VRAC 
Xanthine oxidase XO 
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